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Introduction and outline of this thesis 9
iNTRoduCTioN ANd ouTLiNe of ThiS TheSiS
The most severe, but least common skin cancer is melanoma, a malignant tumor 
of melanocytes. In 1787, Hunter was the first to perform surgery on a patient with 
melanoma.1 In 1812, Laennec described melanoma as “cancer noire” when he found 
metastatic deposits in distant sites. He named the disease melanosis.1 Norris was, 
in 1857, the first to suggest wide excision for a primary melanoma to prevent lo-
coregional recurrence, which was the beginning of clinicians realizing the regional 
lymph nodes were at risk. A pioneer in melanoma surgery, Dr. Snow, subsequently 
suggested that the proper management of melanoma of the skin was removal of all 
regional lymph nodes in 1892.1 For nearly a century, this approach remained to be 
routine management.2
Worldwide, the incidence and mortality of melanoma is still on the rise. In the 
Netherlands, the incidence rate of melanoma increased with an average of 4.1% 
annually in the last two decades.3 This increase is much larger than the increase in 
mortality, although there have been no major improvements in melanoma therapy 
during this period. It is thought to be caused by early awareness in patients and 
doctors, an increase in excision of pigmented lesions cautious diagnosis by patholo-
gists which upstages patients and, most importantly, due to earlier detection.3 The 
rise of incidence and mortality of melanoma has also been demonstrated across 
Europe, however, with considerably variation.4 Trends recently seem to decrease in 
northern Europe, stabilize in Western Europe, but are still increasing in eastern and 
southern Europe.5 Both Australian and New Zealand cancer registries have mela-
noma incidence rates that were substantially above those from all other reporting 
registries worldwide.6 The increased incidence worldwide is mainly caused by earlier 
detection due to more campaigns and prevention programs detecting more thin 
primary tumors.7
Prognosis of melanoma patients is accurately defined by the American Joint Com-
mittee on Cancer (AJCC), which determines the TNM melanoma staging system.8, 9 
The 7th edition, published in 2009, analyzed almost 60.000 patients from 17 cancer 
centers. Stage I – II patients (T1-4) have non-metastatic disease confined to the skin. 
Stage III melanoma patients (N1-3) have metastatic disease limited to the lymph 
nodes and stage IV patients (M1a-c) have disseminated disease distant sites and 
especially to the organs. The latter group (M1a-c) will not be discussed in the present 
thesis. The management and prognosis of stage I, II and III patients will be discussed.
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PART i: STAge i – ii MeLANoMA
Prognosis for stage I - II patients has a large spread. Five-year estimated survival 
rates differ from 95% for T1 (≤ 1.00 mm thick melanoma) patients to 50% for T4 
(> 4.00 mm thick melanoma) patients.9 For primary melanoma patients, melanoma 
thickness and tumor ulceration define the T category strata. Primary tumor mitotic 
rate, defined as mitoses/mm², is an important independent adverse predictor of 
survival as well.9, 10
elective lymph node dissection
The most frequent first apparent site of melanoma spread is to the regional lymph 
node fields. Therefore, it was very common to perform an elective lymph node 
dissection (ELND) in stage I – II melanoma patients. ELND is prophylactic removal 
of all regional lymph nodes. Approximately 20% of patients who underwent ELND 
turned out to have metastatic disease in their resection specimen. Four randomized 
controlled trials (RCT) evaluated stage I and II primary melanoma patients random-
ized for either wide local excision (WLE) and ELND or WLE and delayed lymph node 
dissection (DLND) when regional metastatic melanoma was diagnosed.11-16 All four 
RCTs and two meta-analyses could not demonstrate a survival benefit for patients 
who underwent ELND.11-18 However, analyses of subgroups revealed that selected 
subgroups, such as intermediate thickness melanoma patients (1.0 – 2.0 mm and 0.76 
– 3.99 mm), non-ulcerated or extremity melanomas, might have had a therapeutic 
benefit from undergoing prophylactic lymphadenectomy.16, 18 The high morbidity and 
unknown therapeutic benefit of ELND made clinicians search for alternatives.
Sentinel node biopsy
Earlier developed in 1977 for penile carcinoma by Dr. Cabanas, Dr. Morton and 
colleagues introduced sentinel node (SN) biopsy (SNB) for patients with early stage 
melanoma disease in the early 1990s.19-21 This new procedure was developed to 
intraoperatively identify the SN, which is the first lymph node to receive afferent 
lymphatic drainage from the primary.21, 22 Lymph node metastases from melanoma 
can be detected early by SNB with less morbidity than a lymph node dissection.23 
Only patients with proven melanoma metastases in one or more SNs undergo an 
“early” completion lymph node dissection (CLND), sparing the patients without SN 
metastases the additional surgery. Twenty years after its introduction, SNB for stage 
I and II melanoma is standard staging in most cancer centers worldwide. SNB is still, 
however, subject of extensive debate and ongoing controversy.24 Many have raised 
questions on, amongst others, the false negative rate and the therapeutic value of 
SNB. These issues are addressed in chapter 2 of part I of this thesis, evaluating nearly 
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6000 melanoma patients, who underwent SNB or were observed after undergo-
ing wide local excision of their primary at the Melanoma Institute Australia (MIA), 
Sydney, Australia.
In brief, the procedure of SNB consists of three steps; (1) identification of the SN 
field and site with pre-operative lymphoscintigraphy using radio-labelled colloid, 
undertaken within 24 hours of the operation being performed, (2) perioperative use 
of patent blue dye and (3) a handheld gamma detection probe to detect the SN(s). 
A lymph node is identified as SN if stained blue, if it is located in the expected 
site and/or has a high in situ or ex vivo radioactivity count. With experience in 
this procedure, the SN(s) can be identified in nearly 100% of the patients.25, 26 Most 
difficulties are present in the head and neck region, compared to the axilla or groin 
regions, due to the unpredictable lymphatic drainage and the anatomical difficul-
ties.27, 28 Pre-operative lymphoscintigraphy is of great value in the head and neck 
region to determine the lymphatic drainage pattern and the locations of the SNs.29 
Ear melanomas represent approximately 10% of head and neck melanomas.30 In 
chapter 3, the lymphatic drainage patterns of ear melanomas are determined in 111 
patients treated at the MIA, Sydney, Australia. The precise location on the ear was 
correlated with the location of the SNs identified by lymphoscintigraphy.
histo-Pathologic work-up
After the surgical procedure, the SNs are sent to the pathology department for patho-
logical examination. Pathology work-up protocols are different worldwide and no 
standard approach for the SNs has been adopted. In general, three protocols are 
being assessed. The European Organisation for Research and Treatment of Can-
cer (EORTC) Melanoma Group uses the protocol developed by Cook et al.31 The 
Melanoma Institute Australia handles a protocol formed by Scolyer et al.32 The John 
Wayne Cancer Institute uses the protocol developed by Cochran et al.33
The differences between protocols are where the sections in the SN are cut, 
how many sections are cut and how large the interval between sections is. These 
differences, amongst others, lead to different percentages of SN positive cases. SN 
positivity rates show a spread from approximately 14% to nearly 30% in literature 
for different patient cohorts, with other baseline prognostic values regarding the 
Breslow thickness and ulceration rates.34-36 Studies have shown that the use of im-
munohistochemistry, an increased number of sections cut from the SN and RT-PCR 
increases the detection rate of melanoma cells.31, 37-40
histo-pathologic analysis
As above mentioned, approximately 20% of SNB patients are diagnosed with SN 
tumor burden by the pathologist. Different parameters as the size, location and 
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penetrative depth of SN metastases provide important prognostic information.41-47 
The maximum size of largest SN tumor deposit could be categorized in different 
classification schemes, i.e. the Rotterdam criteria (≤ 0.1, 0.1 – 1.0, > 1.0 mm) or 
the Gershenwald criteria (≤ 0.5, > 0.5 – ≤ 2.0, > 2.0 – ≤ 10.0, > 10.0 mm).43, 48 The 
location is originally classified by the Dewar criteria into the following categories: 
subcapsular, parenchymal, combined (subcapsular and parenchymal), multifocal 
and extensive.45 The tumor penetrative depth is classified according to the Starz 
S-classification (≤ 0.3 (S1), > 0.3 – ≤ 1.0 (S2), > 1.0 (S3) mm).46, 49
PART ii: STAge iii MeLANoMA, MiCRoMeTASTASeS
In the 6th, and subsequently in the 7th TNM staging category created by the AJCC, 
stage III melanoma patients are divided in two different groups with lymph node 
metastases by the mode of detection.8, 9 Patients with clinically occult micrometastases 
are diagnosed by SNB, while patients with macrometastases are defined as clinically 
detectable nodal metastases confirmed pathologically.41 Patients with micrometasta-
ses are discussed in part II of this thesis, while patients with macrometastases are 
discussed in part III.
Management and prognosis
Outcome of SN positive patients is determined by the predictive value for non-
sentinel node (NSN) status in the CLND specimen and the prognostic value for 
survival. The group of SN positive patients is a heterogeneous group of patients with 
survival rates ranging from approximately 20% to over 90% in various subgroups.41 
Patients with high volume SN tumor burden have significant worse outcome than 
patients with low volume tumor burden.41-47
In chapter 4 of this thesis, management and prognosis of 421 SNB patients from 
the Erasmus University Medical Center – Daniel den Hoed Cancer center, Rotterdam, 
the Netherlands, are evaluated. SN positive patients are compared to SN negative 
patients. To identify low-risk and high-risk patients, 121 SN positive patients are 
stratified for the maximum SN tumor size classified according to the Rotterdam 
criteria. In chapter 5, management and prognosis of a large group of SN positive 
patients is evaluated. Nine cancer centers collaborating in the EORTC Melanoma 
Group combined their data. The outcome of more than 1000 SN positive patients in 
a multicenter setting was evaluated. The predictive and prognostic values of two SN 
tumor burden parameters are evaluated: the maximum size classified according to 
the Rotterdam criteria and the intranodal location classified according to the Dewar 
criteria. In chapter 6, the cohort is extended with data from one European and one 
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Australian melanoma treatment center to the largest group of SN positive patients 
in the world. The prognostic significance of the Rotterdam and Dewar criteria and 
S-classification is evaluated in the total group of 1539 patients and, for the first time, 
in each individual melanoma treatment center.
Completion lymph node dissection
In most cancer centers, standard treatment for all SN positive patients is CLND. The 
therapeutic benefit of CLND is unknown and it attends with high morbidity.23, 50-52 
Some have hypothesized that not all SN positive patients might be indicated for 
immediate “early” CLND.43, 44, 50, 53, 54 Others have reported that all SN positive patients 
should undergo CLND.55-57 In chapter 7, the European cohort of over 1000 SN posi-
tive patients are evaluated in light of this issue. SN positive patients who did not 
undergo CLND are evaluated and compared with patients who underwent CLND. 
Again, patients were stratified for the above mentioned different SN tumor burden 
parameters.
PART iii: STAge iii MeLANoMA, MACRoMeTASTASeS
Approximately 4 to 9% of all patients presenting with melanoma are diagnosed 
with clinically detectable nodal disease, i.e. macrometastases.35, 58 Patients with nodal 
macrometastases have 5-year survival rates ranging from 30% to 50%.41 Important 
prognostic factors are the number of metastatic nodes, the presence or absence of 
extracapsular extension, the presence or absence of ulceration and tumor thick-
ness.41 After excluding stage IV disease using appropriate investigations, a therapeu-
tic lymph node dissection (TLND) is indicated. The AJCC staging system classifies 
melanoma patients with macroscopic metastases as stage IIIB or IIIC by considering 
the number of invaded nodes, presence of ulceration in the primary tumor and pres-
ence of satellitosis or in-transit metastases. Other factors of prognostic significance 
in stage III patients that have been described such as age or site of invasion have 
not been considered in current staging criteria. In chapter 8 all prognostic factors 
were assessed in a cohort with patients who underwent TLND for palpable disease 
from Brisbane, Australia and validated in a cohort from Rotterdam. Nomograms are 
created to accurately predict recurrence and survival patterns in these patients.
groin surgery
In general, palpable melanoma disease can be detected in three different lymph 
node fields followed by three different TLNDs, i.e. a neck dissection, an axillary 
dissection or a groin dissection. The appropriate management of palpable groin 
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metastases is very frequently discussed.59-63 According to most publications in the 
literature, an ilioinguinal or combined superficial and deep groin lymph node dis-
section (CGD) should be performed. In practice, an inguinal or superficial groin 
dissection (SGD) is still performed in some patients. In chapter 9, the experience 
in patients with clinically detectable disease of the groin treated with TLND at the 
Erasmus University Medical Center – Daniel den Hoed Cancer Center is evaluated. 
The outcome of 121 patients treated with CGD is compared with the outcome of 48 
patients who underwent SGD.
unknown primary
Of all melanoma patients presenting with clinically detectable nodal disease, 13 to 
17% has melanoma with an unknown primary site (MUP).64-66 MUP has been defined 
as histologically confirmed subcutaneous, nodal or visceral metastatic melanoma with 
no evidence of a cutaneous or non-cutaneous primary melanoma.67 The outcome of 
MUP in relation to patients with a known primary melanoma (MKP) is unknown as 
well as the origin of MUP. Chapter 10 describes a retrospective study performed at 
the Erasmus University Medical Center – Daniel den Hoed Cancer Center regarding 
the outcome of 47 MUP patients and 292 MKP patients who were all treated with 
TLND for palpable disease. The total patient population was assessed for analyses. 
To validate the results of chapter 9, an equivalent study has been performed at the 
MIA, Sydney, Australia. In chapter 11, the outcome of 287 MUP patients is compared 
with the outcome of a uniformly selected group of 264 MKP patients treated with 
TLND.
To conclude, chapter 12, and chapter 13 in Dutch, provides a general summary 
and conclusion of the entire thesis. In chapter 14, a general discussion is presented 
together with future perspectives in the field of the management and prognosis of 
early-stage melanoma.
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AbSTRACT
Worldwide, sentinel node biopsy (SNB) is now a standard staging procedure for 
most patients with melanomas ≥1mm in thickness, but its therapeutic benefit is not 
clear, pending randomized trial results. This study sought to assess the therapeutic 
benefit of SNB in a large, non-randomized patient cohort.
Patients with primary melanomas ≥1.00mm thick or with adverse prognostic 
features treated with wide local excision (WLE) at a single institution between 1992 
and 2008 were identified. The outcomes for those who underwent WLE plus SNB 
(n=2909) were compared with the outcomes for patients in an observation (OBS) 
group who had WLE only (n=2931). Median follow-up was 42 months.
Melanoma-specific survival (MSS) was not significantly different for patients in the 
SNB and OBS groups. However, a stratified univariate analysis of MSS for different 
thickness subgroups indicated a significantly better MSS for SNB patients with T2 
and T3 melanomas (>1.0-4.0mm thick) (p=0.011), but this was not independently 
significant in multivariate analysis. Compared with OBS patients, SNB patients dem-
onstrated improved disease-free survival (DFS) (p<0.001) and regional recurrence-
free survival (p<0.001). There was also an improvement in distant metastasis-free 
survival for SNB patients with T2 and T3 melanomas (p=0.041).
In this study, the outcome for the overall cohort after WLE alone did not differ 
significantly from the outcome after additional SNB. However, the outcome for the 
sub-group of patients with melanomas >1.0-4.0mm in thickness was improved if 
they had a SNB, with significantly improved disease-free and distant metastasis-free 
survival.
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iNTRoduCTioN
Worldwide, sentinel node (SN) biopsy (SNB) is now a standard staging procedure 
for most patients with melanomas ≥1.0mm in thickness.1-4 The American Joint Com-
mittee on Cancer (AJCC) included micrometastasis diagnosed by SNB in the two 
latest (6th and 7th) editions of its TNM staging system.5, 6 Survival in patients with SN 
metastases is considerably better than in patients with clinically-evident metastases,7 
and SN status is the most important prognostic factor for survival in patients with 
early stage melanoma.1, 8, 9
Nevertheless, the role of SNB is still being defined, and an overall survival benefit 
in patients having SNB, with immediate completion lymph node dissection (CNLD) 
if found to be SN-positive, has yet to be demonstrated in a randomized clinical trial 
(RCT).2, 10, 11 In the third interim analysis of the first Multicenter Selective Lymph-
adenectomy Trial (MSLT-I), which compared patients who had SNB and patients 
who had nodal observation (OBS), no overall survival benefit for SNB patients was 
demonstrated but disease-free survival (DFS) was improved.1 However, there was 
substantially improved 5-year survival (72.3% vs 52.4%, p=0.004) in patients with 
intermediate-thickness melanomas (1.2-3.5mm) with nodal metastases who had an 
immediate CLND.1
Most retrospective studies comparing outcome between SNB and OBS patients 
have also shown a DFS benefit in favor of SNB, with no overall survival benefit.12-17 
However, a survival benefit has been reported in specific groups stratified by thick-
ness.14, 17 Several investigators have analyzed the group of patients with nodal me-
tastases only, comparing SN-positive patients undergoing CLND with OBS patients 
undergoing therapeutic lymph node dissection (TLND) when regional lymph node 
metastasis was diagnosed clinically.16-22 Results have been conflicting, with four stud-
ies showing a survival benefit for CLND patients and three reporting no statistical dif-
ference. Meta-analysis of six of these studies, however, did show an overall survival 
benefit for SNB patients undergoing immediate CLND compared with patients having 
a TLND for clinically evident lymph node disease.22
The criteria for recommending SNB are not similar in melanoma management guide-
lines. The most recent guideline of the American Society of Clinical Oncology (ASCO) 
and Society of Surgical Oncology (SSO) advocate offering SNB to patients with mela-
noma ≥1.0mm to 4mm. SNB may be recommended to patients with thick melanomas 
(> 4 mm) for staging purposes and to facilitate regional disease control. The European 
and Australian guidelines encourage to discuss SNB in patients with melanoma > 1.0 
mm and > 1.2 mm, respectively, or when one or more adverse prognostic features is 
present.23-25 Such features may be ulceration or mitotic rate ≥ 1/mm2, especially in the 
subgroup of patients with melanomas 0.75 to 0.99 mm in Breslow thickness
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The aims of the present study were to compare regional recurrence-free survival, 
distant metastasis-free survival (DMFS) and melanoma-specific survival (MSS) of SNB 
patients with OBS patients in a large patient cohort treated at a single institution, as 
well as comparing the outcomes for SNB patients undergoing early CLND with those 
of OBS patients undergoing a delayed TLND for recurrence.
PATieNTS ANd MeThodS
Patients
Prospectively-collected data were extracted from the Melanoma Institute Australia 
(MIA) database. Patient selection for this retrospective assessment was based on 
eligibility for SNB at the MIA. Between 1992 and 2008, wide local excision (WLE) 
was performed in 5840 patients with a single primary melanoma ≥1.0 mm in thick-
ness or when ulceration, Clark level IV or V invasion or a tumor mitotic rate ≥1/
mm2 was recorded. SNB was discussed with nearly every patient in this study, but 
some chose not to have the additional procedure or were advised against SNB 
for reasons including medical co-morbidities and advanced age. After WLE, 2909 
(49.8%) patients underwent SNB and 2931 (50.2%) did not (OBS). Of the 5840 
patients, 803 (13.7%) were enrolled in the randomized first Multicenter Selective 
Lymphadenectomy Trial (MSLT-I)1 and those randomized to WLE only did not have 
a SNB. Patients were excluded from the present study if they had multiple primary 
melanomas, extra-cutaneous melanoma, melanoma of the ear, incomplete follow-up, 
a SNB for recurrent melanoma, an elective lymph node dissection or no immediate 
CLND when found to be SN-positive.
Methods
WLE was performed in all patients, with surgical clearance margins based on the 
Australian clinical practice guidelines.23, 26 These recommend margins of 1cm for 
melanomas <1.0mm thick, 1-2cm for melanomas 1.0-4.0mm thick and 2cm for mela-
nomas > 4.0mm thick. After WLE, 49.8% of patients underwent SNB, using a standard 
protocol that has been described in detail previously27. After removal, the SNs were 
examined histopathologically as previously described.28 In patients found to be SN-
positive, CLND was performed. Follow-up surveillance of melanoma patients at MIA 
has varied over time and by clinician preference.
Statistics
Statistical analyses were performed with IBM SPSS Statistic 19.0. Variables were 
coded and included in statistical analyses as reported in Table 1. Survival time was 
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Table 1 – Baseline characteristics of patients in the sentinel node biopsy (SNB) and observation 
(OBS) groups and of patients with nodal metastases
All Patients Patients with Nodal Metastases
SN
B
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er
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ti
on
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B 
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si
ti
ve
††
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ls
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e‡
‡
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‡‡
n (%) n (%) P-value n (%) n (%) n (%) P-value
Total 2909 (49.8) 2931 (50.2%) 394 (13.5)† 89 (18.4) ‡ 417 (14.2) ∫
Follow-up (months)
Median (IQR) 44 (20-76) 40 (18-81) 0.190 43 (22-73) 42 (25-81) 51 (27-97) 0.003
Mean±SE 53.4±0.8 54.2±0.8 0.500 52.0±1.8 59.2±4.6 64.4±2.2 <0.001
Gender
Female 1167 (40.1) 1253 (42.7)
0.041
147 (37.3) 38 (42.7) 160 (38.4)
Male 1742 (59.9) 1678 (57.3) 247 (62.7) 51 (57.3) 257 (61.6) 0.640
Age (yr)
Mean±SE 56.1±0.3 60.2±0.3 <0.001 53.0±0.9 57.3±1.7 57.7±0.9 <0.001
≤ 50 1015 (34.9) 880 (30.0)
<0.001
170 (43.1) 32 (36.0) 148 (35.5)
0.069
> 50 1894 (65.1) 2051 (70.0) 224 (56.9) 57 (64.0) 269 (64.5)
Site
Extremity 1319 (45.5) 1157 (39.7)
<0.001
165 (42.0) 41 (46.1) 171 (41.0)
0.059Trunk 1133 (39.1) 1025 (35.2) 169 (43.0) 29 (32.6) 154 (36.9)
Head & Neck 445 (15.4) 731 (25.1) 59 (15.0) 19 (21.3) 92 (22.1)
Thickness (mm)
Median 1.8 1.5 <0.001 3 2.4 2.2 <0.001
Mean±SE 2.47±0.03 2.33±0.04 0.015 3.41±0.11 3.00±0.22 2.94±0.13 0.016
≤ 1.00 / T1 328 (11.3) 811 (27.7)
<0.001
20 (5.1) 5 (5.6) 53 (12.7)
<0.001
> 1.00 – ≤ 2.00 / T2 1328 (45.7) 1055 (36.0) 107 (27.2) 31 (34.8) 134 (32.1)
> 2.00 – ≤ 4.00 / T3 840 (28.9) 671 (22.9) 149 (37.8) 36 (40.4) 156 (37.4)
> 4.00 / T4 413 (14.2) 394 (13.4) 118 (29.9) 17 (19.1) 74 (17.7)
Mitotic Rate (/mm2)
Median (IQR) 3 (2-7) 2 (1-6) <0.001 5 (3-9) 6 (3-12) 5 (2-9) 0.037
Mean±SD 5.18±0.11 4.67±0.12 0.003 6.74±0.30 8.16±0.74 6.60±0.33 0.120
Clark level
II-III 791 (27.7) 833 (29.2)
0.161
72 (18.5) 20 (22.7) 95 (23.2)
0.503IV 1825 (64.0) 1759 (61.6) 265 (68.1) 58 (65.9) 270 (65.9)
V 237 (8.3) 263 (9.2) 52 (13.4) 10 (11.4) 45 (11.0)
Ulceration
Absent 1863 (71.2) 1734 (71.0)
0.922
217 (59.0) 46 (56.8) 210 (57.4)
0.883
Present 755 (28.8) 707 (29.0) 151 (41.0) 35 (43.2) 156 (42.6)
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measured from date of definitive primary melanoma surgery to first disease recur-
rence for disease-free survival (DFS), to first recurrence in the regional lymph node 
field for regional lymph node recurrence, to first relapse at a distant site for DMFS, 
and to last follow-up (censored) or death from melanoma for MSS. P-values <0.05 
were considered statistically significant.
Fisher’s exact test, Chi-square test, independent groups’ t-test, Kruskal-Wallis test 
and one-way ANOVA test were performed to determine differences between the 
OBS and SNB groups, and the differences between the groups with nodal metasta-
ses, (SN-positive patients and SN-false-negative patients, with first recurrence in the 
biopsied regional lymph node field) and OBS patients with regional lymph node 
recurrence. Kaplan-Meier curves together with the log rank (Mantel-Cox) test were 
used to assess univariate survival. The Cox proportional hazards model was used for 
multivariate survival analysis. The proportionality assumption was inspected visually 
for each categorical covariate.
Table 1 (continued)
Melanoma subtype
SSM 863 (39.4) 879 (43.1)
<0.001
102 (32.4) 16 (21.3) 116 (38.4)
0.002NM 800 (36.5) 595 (29.2) 147 (46.7) 29 (38.7) 118 (39.1)
Other 529 (24.1) 567 (27.8) 66 (21.0) 30 (40.0) 68 (22.5)
Positive nodes
Mean±SE 1.69±0.06 2.57±0.32 2.92±0.17 <0.001
1 243 (61.7) 51 (57.3) 181 (47.0)
<0.0012-3 91 (23.1) 12 (13.5) 79 (20.5)
>3 60 (15.2) 26 (29.2) 125 (32.5)
First recurrence type
Local 116 (20.9) 86 (12.7)
<0.001
Intransit 95 (17.1) 51 (7.5)
Nodal 111 (20.0) 367 (54.3)
Distant 234 (42.1) 172 (25.4)
SNB = Sentinel Node Biopsy; OBS=Observation; IQR = InterQuartile Range; SE = Standard Error of the 
Mean; SSM = Superficial Spreading Melanoma; NM = Nodular Melanoma
† 394 of 2909 (13.5%) of SNB patients had positive SNs.
‡ 89 of 2515 (3.5%) patients with a negative SNB had their first recurrence in a lymph node in the 
SNB field. False negativity rate = false-negative SNB / (false-negative SNB + true positive SNB) = 89/483 
= 18.4%
∫ 417 of 2931 patients (12.5%) with nodal observation had regional lymph node recurrence.
†† Early completion lymphadenectomy (CLND) was performed in 393 sentinel node-positive patients.
‡‡ Delayed lymphadenectomy (DLND) was performed in 89 false-negative SNB patients and 389 
patients with nodal observation.
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ReSuLTS
SNb vs. obS groups – Characteristics and Recurrence Rates
The mean and median follow-up times for the 2931 OBS patients (57.2% men) were 
54.2 and 40 (interquartile range (IQR) 18-81) months, respectively. The mean and 
median follow-up times for the 2909 SNB patients (59.9% men) were 53.4 and 44 
(IQR 20-76) months, respectively. There were significant differences in baseline char-
acteristics between the SNB and OBS groups (see Table 1). The SNB group contained 
more young patients and more melanomas of nodular subtype, while the OBS group 
contained more melanomas <1mm in thickness, with a lower mitotic rate and located 
in head/neck sites (p<0.05). The site of first recurrence in the SNB group differed sig-
nificantly from the OBS group (p<0.001). In the SNB group, a distant metastasis (DM) 
was the most common first recurrence (42.1%) while in the OBS group a regional node 
metastasis was most common (54.3%). The median time to first recurrence was 38 
(range 1-215) months for SNB patients and 31 (range 1-223) months for OBS patients.
Recurrence rates for the OBS and SNB groups stratified by three different primary 
tumor thickness criteria are presented in Table 2 for patients having a minimum of 
five years follow-up or recurrence within five years (n=2918). The three separate cri-
teria for SNB assessed in these analyses were (1) tumors <1mm thick with ulceration, 
Clark level IV or V invasion, or a mitotic rate ≥1/mm2; (2) tumors =1.0mm thick and 
(3) tumors with >1mm thick.
Table 2 – First recurrence data in the sentinel node biopsy (SNB) and observation (OBS) groups 
according to primary tumor thickness criteria for SNB*
Group
None Local In-transit
Regional 
Node
Distant Total
N % N % N % N % N % N %
OBS (n=1471)
< 1 mm** 152 76.4% 6 3.0% 0 0.0% 29 14.6% 12 6.0% 199 13.5%
1 mm 107 78.7% 4 2.9% 0 0.0% 18 13.2% 7 5.1% 136 9.2%
> 1 mm 536 47.2% 76 6.7% 51 4.5% 320 28.2% 153 13.5% 1136 77.2%
SNB (n=1447)
< 1 mm** 40 81.6% 3 6.1% 0 0.0% 2 4.1% 4 8.2% 49 3.4%
1 mm 56 83.6% 3 4.5% 0 0.0% 3 4.5% 5 7.5% 67 4.6%
> 1 mm 795 59.7% 110 8.3% 95 7.1% 106 8.0% 225 16.9% 1331 92.0%
*Including patients with at least five years of follow-up or a recurrence event within five years. In this 
sub-group of patients, the median Breslow thickness in the OBS group (1.7 mm) was significantly 
lower than the SNB group (2.0 mm) p<0.001). Similarly, the median mitotic rate in the OBS group (3/
mm2) was significantly lower than that of the SNB group (4/mm2) (p<0.001). Percentage of ulcerated 
cases did not differ significantly between the OBS and SNB groups (31% and 30%, respectively).
**Clark IV/V or ulceration or mitoses present
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There were significantly fewer regional node recurrences in the SNB group com-
pared with the OBS group for the SNB criteria <1mm (p=0.047) and >1mm (p<0.001) 
groups, but not for the 1mm group (p=0.054; Table 2). However, the proportion of 
patients in the SNB and OBS groups that developed a regional node metastasis, when 
including positive SNs at primary presentation, was statistically the same for each 
primary tumor thickness criterion (<1mm, p=0.959; 1mm, p=0.743; >1mm, p=0.406).
There was no difference between the SNB and OBS groups in the proportion 
of DM as first recurrences for the SNB criteria of <1mm and 1mm. However, in the 
group of patients with melanomas >1mm thick, there were significantly more DMs 
as first recurrences in the SNB group (16.9%) compared with the OBS group (13.5%, 
p=0.018). Similarly, when considering SN-positive patients as first recurring in the 
regional nodes there was no difference in the proportion of DMs as first recurrences 
between the SNB and OBS groups for each of the SNB criteria (<1mm, p=0.586; 
1mm, p=0.511; >1mm, p=0.058).
For patients with melanomas >1mm thick, there were significantly fewer experi-
enced a recurrence of any type in the SNB group (40.3%) compared with the OBS 
group (52.8%, p<0.001); this was not significantly different for patients in the <1mm 
and 1mm SNB groups.
SNb vs. obS groups – disease-free and distant Metastasis-free Survival
In univariate analysis, SNB patients showed improved DFS (p<0.001) and regional 
lymph node control (p<0.001) but no difference in DMFS (p=0.974) (Figure 1A-B). 
However, in the subgroup of patients with T2 and T3 melanomas (>1.0–4.0mm in 
thickness), SNB patients demonstrated improved DMFS compared to the OBS group 
(p=0.021) (Figure 1C).
After adjusting for all major prognostic factors in multivariate analysis, SNB pa-
tients continued to have significantly improved DFS compared with OBS patients 
(HR=1.40; 95%CI 1.23 - 1.58; p<0.001) (Table 3A). The same associations were 
observed with respect to regional lymph node control in the overall cohort (OBS 
HR=3.23, 95% CI: 2.66-3.94, p<0.001) and DMFS for T2 and T3 melanoma sub-groups 
(OBS HR=1.23, 95% CI: 1.01-1.50, p=0.041) as in the univariate analyses (Table S1).
SNb vs. obS group – Melanoma-specific Survival
Univariate analysis of MSS demonstrated no significant difference when compar-
ing all patients in the SNB and OBS groups (p=0.560). The five-year Kaplan-Meier 
estimates of MSS were 85.0% for SNB patients and 85.8% for OBS patients. However, 
a stratified analysis of MSS for different tumor thickness subgroups demonstrated 
a better prognosis for all patients in the SNB group with melanomas >1mm thick 
(p=0.012) and in those with T2 and T3 melanomas (>1.0-4.0mm thick, p=0.011) 
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(Figure 1D). For the patients with T2 and T3 melanomas, 5-year MSS rates were 
86.8% for the SNB group and 85.3% for the OBS group (Figure 3B). However, after 
adjusting for known prognostic factors in multivariate MSS analysis, no signifi cant 
benefi t for SNB patients was demonstrated overall (Table 3A) or for any of the tumor 
thickness subgroups.
SN-positive vs. SN-negative groups
In multivariate analysis of the SNB group, SN status was an independent prognostic 
factor for DFS (HR= 3.04; 95%CI: 2.50-3.70; p<0.001) and MSS (HR=2.97; 95%CI: 
2.34-3.77; p<0.001) (Table 3B). SN-negative and SN-positive patients had estimated 
5-year DFS rates of 81.4% and 51.2%, respectively and estimated 5-year MSS rates of 
88.9% and 63.8% (p<0.001).
SNb with early CLNd group vs. obS with late TLNd group
Of the 2909 SNB patients, 394 (13.5%) were SN-positive, and these patients subse-
quently received CLND. There were positive non-SNs (NSNs) in the CLND specimen 
figuur 1 - A) Disease free survival, B) regional lymph node-free survival, C) distant metastasis-free 
survival and D) melanoma-specifi c survival in melanoma patients managed by sentinel node biopsy 
or nodal observation.
Figuur 1 - A) Disease free survival, B) regional lymph node-free survival, C) distant metastasis-free  
survival and D) melanoma-specific survival in melanoma patients managed by sentinel node biopsy or  
nodal observation. 
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in 77 (19.5%). Eighty-nine (3.5%) of the 2515 SN-negative patients had regional node 
recurrence as a first recurrence (false-negative SNB) and underwent a delayed lymph-
adenectomy. The SN false-negative rate (defined as false-negative / (false-negative 
+ true-positive) was 18.4%.10 In the OBS group, 417 patients (14.2%) recurred in the 
regional node field and 385 received a “delayed” TLND. Patients who received an 
early CLND had a mean number of positive nodes of 1.69, which was significantly 
less compared to 2.92 and 2.57, respectively, in the OBS group and the SN false-
negative group (p<0.001) at the time of delayed lymphadenectomy. Furthermore, 
15.2% of early CLND patients had N3 disease (> 3 involved nodes) compared to 
32.5% and 29.2%, respectively, in the OBS group and the SN false-negative group 
(p<0.001) (Table 1).
SN-positive patients having early CLND had a significantly prolonged DMFS com-
pared with OBS patients having a “delayed” TLND on multivariate analysis (Figure 
Table 3 – Multivariate analysis of disease-free survival and melanoma-specific survival in A) all 
patients and B) the sentinel node biopsy (SNB) group
A DFS (n=4671) MSS (n=4473)
Factor Value HR 95% CI P-value HR 95% CI P-value
Management* Observation 1.40 1.23 - 1.58 <0.001 1.04 0.88 - 1.22 0.642
Gender Male 1.17 1.02 - 1.34 0.021 1.50 1.24 - 1.80 <0.001
Age (years) 1.01 1.00 - 1.01 0.005 1.01 1.00 - 1.01 0.003
Breslow thickness (mm) 1.11 1.09 - 1.14 <0.001 1.15 1.11 - 1.18 <0.001
Mitotic rate (/mm2) 1.03 1.02 - 1.04 <0.001 1.02 1.01 - 1.04 <0.001
Clark level (ref: II-III) IV-V 1.52 1.30 - 1.78 <0.001 1.37 1.11 - 1.68 0.003
Ulceration Present 1.73 1.52 – 1.98 <0.001 1.82 1.53 - 2.16 <0.001
Primary site Trunk 0.97 0.84 - 1.13 0.707 1.19 0.98 - 1.45 0.072
(ref: extremity) Head & Neck 1.15 0.98 - 1.36 0.093 1.31 1.05 - 1.64 0.017
B DFS (n=2479) MSS (n=2352)
Factor Value HR 95% CI P-value HR 95% CI P-value
Sentinel Node status Positive 3.04 2.50 - 3.70 <0.001 2.97 2.34 - 3.77 <0.001
Gender Male 0.96 0.82 - 1.21 0.957 1.21 0.94 - 1.57 0.148
Age (years) 1.02 1.01 - 1.03 <0.001 1.02 1.01 -1.02 <0.001
Breslow thickness (mm) 1.13 1.09 - 1.18 <0.001 1.16 1.11 - 1.22 <0.001
Mitotic rate (/mm2) 1.03 1.02 - 1.04 <0.001 1.03 1.01 - 1.04 0.001
Clark level (ref: II-III) IV-V 1.32 1.05 - 1.67 0.018 1.22 0.92 - 1.63 0.168
Ulceration Present 1.50 1.24 - 1.82 <0.001 1.98 1.55 - 2.52 <0.001
Primary site Trunk 0.91 0.74 - 1.12 0.359 1.35 1.04 - 1.75 0.026
(ref: extremity) Head & Neck 1.16 0.90 - 1.50 0.264 1.39 1.00 - 1.94 0.053
HR = Hazard Ratio, CI = Confidence Interval, DFS=Disease-free Survival, MSS= Melanoma-specific 
Survival
*SNB versus OBS
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2A). In multivariate analysis, however, this result was clearly signifi cant (OBS HR=1.36, 
95% CI: 1.08-1.72, p=0.010) (Figure 2A, Table S2), but this just failed to reach statisti-
cal signifi cance in univariate analysis (p=0.052). DMFS was not signifi cantly different 
for the SN-positive (CLND) group compared with the OBS (“delayed” TLND) group 
for patients with T2 and T3 melanomas in univariate analysis (p=0.072), but again 
the difference was statistically signifi cant on multivariate analysis (OBS HR=1.36, 
95% CI: 1.01-1.84, p=0.042).
MSS was not signifi cantly infl uenced by early CLND or “delayed” TLND in either 
univariate or multivariate analyses (Figure 2B, Table S2). Five-year Kaplan-Meier 
MSS estimates were 64.1% for CLND patients and 60.5% for TLND patients (p=0.144). 
For T2 and T3 patients, fi ve-year Kaplan-Meier MSS estimates were 68.3% following 
CLND and 62.7% following “delayed” TLND, but the difference was not statistically 
signifi cant in either univariate or multivariate analysis.
figuur 2 - A) Disease free survival and B) melanoma-specifi c survival for sentinel node status and 
C) distant-metastasis free survival and D) melanoma-specifi c survival for the type of lymph node 
dissection, i.e. completion lymph node dissection, delayed therapeutic lymph node dissection and 
therapeutic lymph node dissection in patients with a false negative sentinel node
Figuur 2 - A) Disease free survival and B) melanoma-specific survival for sentinel node status and C)  
distant-metastasis free survival and D) melanoma-specific survival for the type of lymph node dissection,  
i.e. completion lymph node dissection, delayed therapeutic lymph node dissection and therapeutic lymph  
node dissection in patients with a false negative sentinel node 
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diSCuSSioN
In this retrospective study, the MSS of patients having WLE followed by observation 
(OBS) was not signifi cantly different from the MSS of those having WLE and SNB. 
However, SNB patients had improved DFS and improved regional control compared 
with patients not undergoing SNB.
Several previous retrospective studies have also compared the outcomes of SNB 
patients with that of OBS patients (Table 4).12-17 To overcome the limitations of 
retrospective studies, prospective RCTs are necessary. A large RCT addressing the is-
sue of SNB or nodal observation is MSLT-I, the primary aim of which is to report the 
outcome following SNB or OBS in patients with intermediate thickness melanomas 
(1.2-3.5mm).1 In the third interim analysis of MSLT-I, patients who underwent SNB 
had no improved MSS over patients in the OBS group. However, the subgroup of 
SN-positive patients had signifi cantly prolonged MSS after undergoing early CLND 
compared to WE-only patients who had a delayed TLND for regional node recur-
rence.1
figuur 3 - A) Distant metastasis-free and B) melanoma-specifi c survival for management in patients 
with T2 and T3 melanoma and C) distant metastasis-free survival and D) melanoma-specifi c survival 
for the type of lymph node dissection in patients with T2 and T3 melanoma.
Figuur 3 - A) Distant metastasis-free and B) melanoma-specific survival for management in patients with  
T2 and T3 melanoma and C) distant metastasis-free survival and D) mel noma-specific survival for the  
type of lymph node dissection in patients with T2 and T3 melanoma. 
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Table 4 – Published series reporting overall (OS) or melanoma-specific (MSS) and disease-free 
survival (DFS) for sentinel node biopsy (SNB) and observation (OBS) patients respectively, following 
immediate completion lymph node dissection after a positive sentinel-node biopsy (CLND) and 
delayed therapeutic lymph node dissection (TLND) after regional lymph node recurrence
Author
(year)
Group of 
patients
Number 
of 
patients
Median 
follow-up
(mo)
Thickness
(mm)
p†
(DFS)
p†
(MSS/OS*)
HR
MSS/OS*
5-yr MSS/
OS* (%)
Mohrle
(2004)
OBS
SNB
2617
271
58
35 Any NA 0.37 0.80
NA
NA
Gutzmer 
(2005)
OBS
SNB
377
296
59.7
35.5 Any 0.0064 0.317 0.98
NA
NA
Morton
(2006)
OBS
SNB
500
769
48.4
48.4 1.20 - 3.50 0.009 0.58 0.92
86.6
87.1
Koskivuo 
(2007)
OBS
SNB
616
305
74
16 Any 0.414 0.656 0.70
85.2
87.8
OBS
SNB
324
159
74
16 > 1.00 - 4.00 0.499 0.646 NA
NA
NA
Starz
(2007)
OBS
SNB
61
87
115
74 0.76 - 1.00 0.01 0.03 NA
±93
100
Leiter
(2010)
OBS
SNB
440
439
57.6
54.3 > 1.00 0.003 0.09 0.74
81.5
85.5
Satzger
(2010)
OBS
SNB
377
296
64.0
72.5 > 1.00 0.001 0.049 NA
80.3
84.8
Present 
study
OBS
SNB
2931
2909
40
44 Any <0.001 0.561 0.96
85.8
85.0
OBS
SNB
1726
2168
40
44 > 1.00 – 4.00 <0.001 0.011†† 0.79
85.3
86.8
OBS
SNB
2120
2581
40
44 > 1.00 <0.001 0.012†† 0.82
82.2
83.6
Morton
(2003)
CLND
TLND
287
287 12-360 Any NA <0.001 2.0
73
51
Kretschmer
(2004)
CLND
TLND
314
623
32
123 Any NA 0.002 1.82
62.5
50.2
Morton 
(2006)
CLND
TLND
122
78
48.4
48.4 1.20 - 3.50 NA 0.004 1.95
72.3
52.4
Van Akkooi
(2007)
CLND
TLND
64
124
37
56 Any NA 0.115 1.60
±70
±57
Nowecki
(2008)
CLND
TLND
258
286
35
37 Any NA 0.04 1.24
52.5
39.5
CLND
TLND
111
100
35
37 > 1.00 - 4.00 NA 0.0006 NA
57.2
37.9
Pasquali
(2010)
CLND
TLND
100
90
50
56 Any NA 0.17 1.07
68.9
50.4
CLND
TLND
58
58
50
56 > 1.00 - 4.00 NA 0.49 NA
71
57.8
Leiter
(2010)
CLND**
TLND
72
72
47.0
48.0 > 1.00 NA 0.196‡ 2.2
52.9
42.0
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Our results also suggest that patients with intermediate thickness melanomas 
(defined as >1.0–4.0mm in our study) who undergo SNB and early CLND if SN-
positive may have an overall survival benefit. SNB patients with melanomas ≤1mm 
in thickness did not have a survival benefit in our dataset. Patients with melanomas 
>1.0-4.0mm who underwent SNB had significantly better DMFS and MSS than OBS 
patients in univariate analysis. Patients with T1 melanomas (≤1.0mm) might not 
demonstrate a benefit from SNB because they have a very low rate of distant me-
tastasis (Table 2). Conversely, patients with melanomas >4mm have a high rate of 
distant metastasis regardless of management, suggesting that they might not obtain a 
survival benefit from SNB29. Nevertheless, these patients are likely to benefit not only 
from the prognostic information SNB provides, but also from the improved node 
field control provided by early CLND.29
Of the 2515 SN-negative patients in the study, 89 (3.5%) had a first recurrence 
in the regional lymph node field. The clinical false-negative rate is conventionally 
reported as the rate of patients with a negative SN procedure who have a first recur-
rence in the same regional lymph node field as the SN procedure (false-negative / 
(true positive + false-negative)).10, 30 Calculated in this way, this study has a SN false-
negative rate of 18.4% (89/483). This is in line with rates reported in the literature, 
which range from 7% to 24.8%.15, 31 MSLT-I had a SN false-negative rate of 17.6%.10 
The clinical false-negative rate of SNB may result from deficiencies in nuclear medi-
Table 4 (continued)
Author
(year)
Group of 
patients
Number 
of 
patients
Median 
follow-up
(mo)
Thickness
(mm)
p†
(DFS)
p†
(MSS/OS*)
HR
MSS/OS*
5-yr MSS/
OS* (%)
Satzger
(2010)
CLND
TLND
77
147
72.5
64.0 > 1.00 NA 0.006 NA
NA
NA
Present 
study
CLND
TLND
394
417
44
40 Any <0.001 0.146 1.18
64.1
60.5
CLND
TLND
256
290
44
40 > 1.00 - 4.00 <0.001 0.147 1.24
68.3
62.7
CLND
TLND
374
364
44
40 > 1.00 <0.001 0.149 1.19
63.1
57.9
OBS = Observation, SNB = Sentinel Node-biopsy, NA= Not applicable/not reported, CLND = early 
Completion Lymphadenectomy after a positive SNB, TLND = delayed Therapeutic Lymphadenectomy 
when melanoma recurred in the regional lymph node in follow-up
* When assessed in paper, melanoma specific survival results are shown above. Otherwise, overall 
survival results are shown.
**Patients with recurrence after a negative SNB followed by a delayed TLND were added to the CLND 
group.
† results of univariate analysis
†† not significant after adjusting for prognostic factors in multivariate analysis
‡ p=0.009 in multivariate analysis
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cine, surgery or pathology, or may be a result of biologic events such as the presence 
of microscopic in-transit disease at the time of SNB, or subsequent metastasis from 
clinically apparent or occult loco-regional recurrences.8,32 Our results indicate that the 
more experience a surgeon has with SNB, the lower the number of false-negative SNs 
will be. Between 1992 and 2000, the false-negative rate was 23.6% (35 / (35+113)), 
but between 2001 and 2008 it was 16.1% (54 / (54+281)). Considering that SNB was 
first introduced in 1992, the reduction in the false-negative rate over time most likely 
reflects the learning curve of surgeons conducting a new, technically demanding 
procedure. Approximately one third (909/2909) of patients in the SNB group were 
treated during the earlier timeframe (1992-2000). A stratified analysis was conducted 
to assess whether changes in experience with SNB or management over time affected 
outcome. Separately in the patient cohorts treated in the earlier (1992-2000) and the 
later (2001-2008) timeframes, MSS was statistically similar, and DFS continued to be 
statistically different when comparing SNB and OBS groups (data not shown).
The rate of SN-positivity in this study was 13.5%, which is fairly low compared to 
rates reported in literature, which range from 14% to 29%.33, 34 However, the median 
tumor thickness for the patients in the study was 1.70 mm, which is lower than in 
most other reported studies. Additional NSN positivity was 19.5% (77/394). In the 
OBS group, 417 (14.2%) patients recurred in the regional lymph node field (Table 1). 
The hypothesis being tested in MSLT-I is that SNB accurately identifies occult nodal 
metastases that will grow to palpable size if a “watch and wait” policy is adopted. In 
our study, SNB identified metastases in 13.5% of patients, with a false-negative result 
in 3.5% of patients (making a total of 17.0%). This is a higher percentage than the 
proportion of patients who subsequently had regional node metastases diagnosed 
clinically in the OBS group (14.2%). This difference of 2.8% requires explanation. 
The suggestion has been made that some patients with very low volume micrometa-
static disease in a SN might never progress to clinically detectable metastatic disease 
in the node field35-37 However, the MSLT-I data indicating that all SN-positive patients 
will eventually develop clinically detectable nodal metastases do not support this 
concept.38 The lower rate of detection of metastases in the OBS group in this study 
is most likely due to the median follow-up time of only 42 months. Longer follow-up 
of the patients in the present study will undoubtedly identify more patients with 
nodal metastases in the OBS group if there is the same pattern of time to nodal 
recurrence in the OBS group as occurred in MSLT-I, where it was not until ten years 
of follow-up had elapsed that nodal recurrence in the OBS group reached a plateau. 
This was at a level that was virtually identical to the SN-positive plus false-negative 
value (20.5% versus 20.8%)1, 38.
In addition to the inherent biases of any retrospective study, selection bias is an 
inevitable consequence of the design of the current study due to the exclusion of 
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patients receiving either ELND or no immediate CLND following a positive SNB. The 
proportion of patients receiving ELND at MIA varied significantly over time, from 
15% of all regional node operations during 1992-2000 to 2% during 2001-2008. Based 
on the results of the aforementioned analysis stratified by timeframe, this bias likely 
does not significantly influence our results. In the study, 144 patients were excluded 
on the basis of no immediate CLND following a positive SNB, of which 113 (78%) 
were N1a and the remainder (31, 22%) were N2a. As a result there are 82 more N1a 
(than N2a) patients removed from the dataset who had a lower probability of benefit 
from SNB compared with N2a patients, however this small number of patients is 
unlikely to have significantly influenced the results of the study. Nevertheless, selec-
tion bias should be considered when interpreting its resultss.
In this large, non-randomized study, the overall outcome of patients having WLE 
alone was not significantly different from that of patients having additional SNB. 
However, the results indicate that the outcome for patients with T2 and T3 melano-
mas (>1.0mm – 4.0mm) may be improved if they undergo SNB, as did the interim 
results of MSLT-I, a large prospective trial. As well, SNB provided significantly 
improved regional disease control and overall disease-free survival. SN status was 
the most important prognostic factor for survival, with disease recurrence and death 
approximately three times greater for SN-positive patients.
Pending the final results of MSLT-I, it is likely that most clinicians caring for 
patients with melanomas ≥1.0mm in thickness will continue to recommend SNB 
as a staging procedure. SNB not only enables patients to be given more accurate 
prognostic information, but it also improves regional control and DFS. In addition 
there may be an improvement of MSS in node-positive patients with intermediate 
thickness melanomas following SNB and early CLND, but long-term follow-up of 
patients in randomized trials (such as MSLT-I) will be necessary to confirm this. With 
trials of potentially more effective systemic adjuvant therapies likely to commence 
soon, SNB will also be necessary for selection and stratification of high risk patients.
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Supplementary Table 1 - Multivariate analysis of regional lymph node recurrence-free survival for 
the entire cohort and distant metastasis-free survival for patients having T2 and T3 tumors
Regional Lymph Node Recurrence 
Free Survival (n=4591)
Distant Metastasis Free 
Survival (n=3234)
Factor Value HR 95% CI P-value HR 95% CI P-value
Management* Observation 3.23 2.66 - 3.94 <0.001 1.23 1.01 - 1.50 0.041
Gender Male 1.36 1.12 - 1.66 0.002 1.36 1.09 - 1.70 0.007
Age (years) 1.00 0.99 - 1.00 0.134 1.00 0.99 - 1.00 0.538
Breslow thickness (mm) 1.09 1.05 - 1.12 <0.001 1.53 1.36 - 1.73 <0.001
Mitotic rate (/mm2) 1.03 1.02 - 1.04 <0.001 1.02 1.01 - 1.04 0.004
Clark level (ref: II-III) IV-V 1.41 1.13 - 1.76 0.002 1.29 1.02 - 1.63 0.035
Ulceration Present 1.78 1.47 - 2.16 <0.001 1.56 1.26 – 1.91 <0.001
Primary site Trunk 0.74 0.60 – 0.92 0.006 1.39 1.10 - 1.76 0.005
(ref: extremity) Head & Neck 0.84 0.66 - 1.07 0.147 1.36 1.03 - 1.78 0.029
HR = Hazard Ratio, CI = Confidence Interval
*SNB versus OBS
Supplementary Table 2 – Multivariate distant metastasis-free and melanoma-specific survival 
analyses of the sub-group of patients with nodal metastases
Distant Metastasis-Free 
Survival (n=812)
Melanoma Specific Survival 
(n=812)
Factor Value HR 95% CI P-value HR 95% CI P-value
Nodal Surgery SN False-Negative 1.68 1.18 - 2.40 0.004 1.63 1.14 - 2.32 0.007
(ref: CLND) “Delayed” TLND 1.36 1.08 - 1.72 0.010 1.26 0.99 - 1.59 0.057
Gender Male 1.36 1.08 - 1.72 0.009 1.32 1.05 - 1.66 0.019
Breslow thickness (mm) 1.13 1.09 - 1.18 <0.001 1.13 1.08 - 1.17 <0.001
Ulceration Present 1.54 1.23 – 1.93 <0.001 1.71 1.37 - 2.14 <0.001
HR = Hazard Ratio, CI = Confidence Interval
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AbSTRACT
The ear is known to have variable lymphatic drainage. The aim of the present 
study was to better define the lymphatic drainage patterns of the ear by correlating 
the location of primary tumors, classified according to the embryologically-derived 
anatomical subunits of the ear, with their mapped sentinel nodes (SNs) identified by 
lymphoscintigraphy (LS).
Lymphatic drainage data for patients with a primary melanoma of the ear were 
reviewed, and correlated with the precise primary melanoma site.
Between 1993 and 2010, LS was performed in 111 patients with a primary melano-
ma on the ear, identifying 281 SNs in 195 lymph node (LN) fields. The mean numbers 
of SNs and LN fields identified by LS per patient were 2.65 and 1.76. SN biopsy (SNB) 
was performed in 71 patients (64%). The mean number of SNs removed was 2.36. 
The 111 ear melanomas were mostly located on the helical rim (55.0%), followed 
by the lobule (24.3%). The five different primary ear sites drained mainly to SNs in 
level CII, level CV and the pre-auricular region. Drainage was most often to level CII 
(36.4%). Drainage to the contralateral neck was not observed.
Lymphatic drainage of the ear has no predictable pattern and can be to SNs 
anywhere within the ipsilateral neck. Most commonly drainage is to cervical level II 
and the preauricular and postauricular LN fields. LS defines the lymphatic drainage 
pattern in individual melanoma patients and is essential for accurate SN identification 
and reliable SNB.
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iNTRoduCTioN
The sentinel node (SN) biopsy (SNB) technique was introduced by Morton et al.1 In 
the early 1990’s, using lymphatic mapping with blue dye to identify SNs. Subsequently, 
lymphoscintigraphy (LS) was used to identify SNs preoperatively, and a handheld 
gamma probe was used intraoperatively to assist in the localization of blue-stained SNs 
and provide greater reliability of SN identification.2, 3 SNB has since become a standard 
procedure for patients with early-stage melanoma in most melanoma treatment centers 
around the world.4, 5 In 7-18% of melanoma patients, the primary tumor is located in the 
head and neck region, and SNB procedures in the head and neck are recognised to be 
more technically demanding than procedures in the axilla or groin.6-15 The greater diffi-
culty of SNB for head and neck melanomas is partly due to the unpredictable lymphatic 
drainage from tumors located in this region.8, 16-18 Some believe that it is inappropriate 
to claim that metastatic patterns from head and neck melanomas are unpredictable.19, 20 
Nevertheless, there can be no doubt that preoperative LS is of great value in directing 
the surgical management of patients with cutaneous head and neck malignancies.8, 21, 22
In approximately 1% of patients with cutaneous melanomas, the primary tumor is 
located on the external ear.23 The prognosis for these patients is generally believed 
to be similar to that of patients with melanomas at other cutaneous sites, although 
some have reported a worse prognosis.9, 24 What has become clear is that the worse 
overall prognosis of patients with head and neck melanomas is primarily attribut-
able to melanomas of the scalp, which have a significantly worse prognosis than 
melanomas arising elsewhere in the head and neck region.25 Based on concerns 
about the reported complexity of lymphatic drainage patterns from the ear, the 
Multicenter Selective Lymphadenectomy Trial (MSLT–1), designed to validate the 
SN hypothesis and test the reliability of SNB as a staging procedure for melanoma, 
excluded patients with primary tumors on the ear.26
Lymphatic drainage from the skin of the external ear has been studied previously 
in patients with melanoma.19, 27-32 These studies considered the ear and immediately 
surrounding tissues as a single site. However, the ear is comprised of anatomically 
defined areas related to its embryological development. The auricle arises from the 
figure 1: Embryological development of the external ear
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first and second pharyngeal arches via six developmental hillocks; number 1 forms 
the tragus, numbers 2 and 3 the helical root and rim, number 4 the scapha and anti-
helix, number 5 the concha, and number 6 the ear lobe.33 (Figure 1) Each of these 
areas might be expected to have different lymphatic drainage.
The purpose of this study was to define the lymphatic drainage patterns of the 
ear by correlating the precise location of primary tumors, classified according to the 
embryologically derived anatomical subunits of the ear, with their correspondingly 
mapped SNs identified by LS.
PATieNTS ANd MeThodS
Patients
This retrospective study included patients with melanomas located on the external ear, 
treated at Melanoma Institute Australia (MIA) (formerly the Sydney Melanoma Unit) be-
tween 1993 and 2010, who underwent lymphatic mapping using lymphoscintigraphy. 
From the prospectively collected information in the MIA database, data for 111 patients 
were extracted, including patient and primary melanoma characteristics, pathology 
reports, lymphoscintigraphy reports, operation details and follow-up information.
Primary melanomas
The location of each primary melanoma was documented as part of the routine 
recording of lymphoscintigraphy injections, using a graphics grid superimposed over 
the outline of an ear. X and Y co-ordinates were recorded for each primary site. 
The ear was subdivided into five sites: lobule, tragus, concha, scapha/anti-helix and 
helical rim. The helical rim included all tissue 5 mm on either side of the most lateral 
part of the ear margin, extending from the helical root medially and then superiorly 
down to the lobule. (Figure 1) Patients were grouped into these five anatomical sites 
according to the location of their primary tumor.
Lymphatic mapping
Lymphoscintigraphy utilizing Technetium 99 m antimony trisulfide colloid, which 
has a particle size of 5-40 nm, was performed using a standardized technique within 
the 24hr period before surgery.34 Standard regional surface anatomy classification 
was used by the nuclear medicine physician to record the location and number of 
the SNs that were identified, i.e., the cervical levels I-V (CI-CV), postauricular, preau-
ricular and supraclavicular lymph node regions.35 (Figure 2) The lymphatic drainage 
from the five anatomical sites of the primary on the ear to the lymph node fields 
classified according to the surface anatomy was evaluated. All identified SNs were 
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examined with high-resolution ultrasound immediately after lymphoscintigraphy to 
assess the internal architecture of each node for abnormalities, which if seen could 
represent metastatic disease. Ultrasound further assisted in the localization of each 
node, particularly its depth beneath the skin surface.
Sentinel node biopsy
Thirty-seven patients (33.3%) did not undergo SNB after lymphoscintigraphy. Many 
of these were patients undergoing wide excision only (i.e., without SNB), when 
SNB was considered likely to be unduly complicated (e.g., when multiple SNs in 
different node fields were found), when the possibility of morbidity was a concern 
(e.g., when intraparotid SNs were identified), or if the patient was elderly or had 
significant medical comorbidities. Patients who did not undergo SNB after wide 
excision of their primary tumor underwent serial clinical review and periodic repeat 
high-resolution ultrasound examination of the SNs that had been identified on the 
preoperative lymphoscintigram.
SNB was performed under general anesthesia utilizing conventional techniques. 
Pre-operatively, 0.3–1 ml of Patent Blue V dye (Guerbert, Aulnay-Sous-Bois, France) 
was injected intradermally close to the centre of the excision-biopsy site. Intraopera-
tively, a handheld gamma probe was used to confirm the location of the SNs that had 
been identified by LS. Wide local excision of the primary melanoma site on the ear 
was routinely performed before the SNB, thereby reducing radioactivity in the region 
of the primary tumor site and facilitating SN identification with the gamma probe.
figure 2: Location of the five cervival levels
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follow-up
Median follow-up time was 30 months (interquartile (IQR) range 13 – 60 months). 
Time to recurrence and survival time were calculated from the date of primary 
diagnosis to the date of recurrence, date of death due to melanoma, or date of last 
follow-up.
ReSuLTS
Patients
Between 1993 and 2010, 111 patients with a primary melanoma located on the ear 
underwent lymphatic mapping using lymphoscintigraphy at Melanoma Institute Aus-
tralia (MIA), Sydney, Australia. There was a predominance of males (80.2%, n=89) 
compared with females (19.8%, n=22). The median age was 64 years (IQR 44 - 74 
years).
Primary melanoma site
Fifty-six (50.5%) of the patients had a primary melanoma on the left ear and 55 
(49.5%) a melanoma on the right ear. Median Breslow thickness was 1.90 mm (IQR 
1.20 – 3.20 mm). The primary tumor was ulcerated in 32 patients (33.0%). (Table 1) 
The distribution of primary disease by anatomical location is shown in Table 1.
Lymphoscintigraphy
The number and location of SNs identified by lymphoscintigraphy (LS) are docu-
mented in tables 1 and 2. Although technically part of levels CIV and CV, the “su-
praclavicular” designation was included as a separate field, because the reporting 
nuclear medicine physician had specifically indicated this as the SN location. Drain-
age to the contralateral neck was not observed.
Table 1 – baseline characteristics of the patient, the primary melanoma disease, 
lymphoscinitgraphy and sentinel node biopsy
Characteristic N (%) Characteristic N (%)
Gender Number of SNs identified on LS
Female 22 (19.8) Median (IQR) 3 (2 – 3)
Male 89 (80.2) 1 12 (11.3)
Age (years) 2 40 (37.7)
Median (IQR) 64 (44 – 74) ≥ 3 54 (50.9)
< 60 48 (43.2) Missing 5
≥ 60 63 (56.8)
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Table 1 (continued)
Characteristic N (%) Characteristic N (%)
Primary, LS and SNB side Drainage sites of identified SNs†
Left 56 (50.5) Preauricular 39 (20.0)
Right 55 (49.5) Cervical I 3 (1.5)
Site of primary on the ear Cervical II 71 (36.4)
Lobule 27 (24.3) Cervical III 3 (1.5)
Tragus 4 (3.6) Cervical IV 3 (1.5)
Concha 14 (12.6) Cervical V 22 (11.3)
Scapha / Anti-helix 5 (4.5) Postauricular 51 (26.2)
Helical rim 61 (55.0) Supraclavicular 3 (1.5)
Breslow (mm) Number of drainage sites
Median (IQR) 1.90 (1.20 – 3.20) 1 47 (42.3)
≤ 1.00 21 (19.1) 2 48 (43.2)
> 1.00 – ≤ 2.00 43 (39.1) 3 12 (10.8)
> 2.00 – ≤ 4.00 28 (25.5) 4 4 (3.6
> 4.00 18 (16.4) Surgery
Missing 1 No 37 (33.0)
Mitoses SNB 71 (64.0)
Median (IQR) 3 (2 – 6) LND 3 (2.7)
0 9 (9.0) Number of harvested SNs*
≥ 1 91 (91.0) Median (IQR) 2 (2 – 3)
Missing 11 1 15 (22.4)
Clark level 2 27 (40.3)
II 8 (7.5) ≥ 3 25 (37.3)
III 24 (22.6) Missing 4
IV 56 (52.8) SN status*
V 18 (17.0) Negative 62 (92.5)
Missing 5 Positive 5 (7.5)
Ulceration Missing 4
Absent 65 (67.0) SN removed / identified ratio*
Present 32 (33.0) Median (IQR) 1.00 (0.67 – 1.00)
Missing 14 < 1 (Incomplete SNB) 25 (38.5)
≥ 1 (Complete SNB) 40 (61.5)
Missing 6
IQR = Interquartile range; LS = Lymphoscintigraphy; SNB = Sentinel Node Biopsy; LND = Lymph Node 
Dissection
†The total number of 195 drainage site is larger than 111 since multiple drainage sites were identified 
in 57.3% of the patients.
* The number of 111 is not reached for these characteristics since 71 of the 111 patients underwent 
sentinel node biopsy
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Surgery
Sentinel node biopsy (SNB) was performed in 71 patients (64.0%) and a lymph node 
dissection (LND) was performed in 3 patients (2.7%). (Table 1) No nodal surgery was 
performed in 37 (33.0%) patients, for the reasons outlined previously. Full details of 
the SN results are given in tables 1 and 3.
Eight of the 158 SNs (5.0%) that were removed contained metastatic melanoma, 
whereas 2 of the 52 (3.8%) NSNs that were removed were positive. In the 67 patients 
with known SN status, the SN positivity rate was 7.5% (n=5). An incomplete SNB 
procedure was recorded when less SNs were removed than were identified by LS. 
Using this criterion, SNB was complete in 61.5% of the patients. (Table 3).
Three patients did not undergo SNB, but underwent a complete cervical LND. The 
number of nodes removed was 18, 21 and 46. The number of positive nodes was 5, 
0 and 1, respectively.
Table 3 – Numbers of sentinel nodes identified and removed for 65 patients
Number of SNs removed
Number of SNs 
identified
1 2 3 4 5 7 Total 
Patients
1 4 1 5
2 6 16 3 1 1 27
3 3 9 9 2 1 24
4 1 2 2 2 7
5 1 1
8 1 1
Total Patients 14 27 14 8 1 1 65
The gray area corresponds with incomplete SNBs performed i.e. when fewer SNs were removed than 
were identified by lymphoscintigraphy
follow-up
Mean and median follow-up times were 41 and 30 months (IQR 13 – 60 months). 
Nine patients were lost to follow-up (8.1%). Of 102 patients with follow-up, 14 
(13.7%) recurred, with mean and median times to first recurrence of 28 and 10 
months (IQR 7–36): 12 patients had locoregional recurrence as a first recurrence; 2 
patients had visceral metastases as a first recurrence.
Excluding the 3 patients who had a complete LND and no SNB, 6 of 37 (16.2%) 
patients without SNB recurred, whereas 8 of 71 (11.3%) SNB patients had any type 
of recurrence. At the time of last follow-up, 3 of the 102 patients (2.9%) had died of 
melanoma, whereas 91 patients were alive with no disease (89.2%). Two patients 
were alive with melanoma, four had died of other known causes, one was alive with 
unknown status and one had died of an unknown cause.
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diSCuSSioN
This study confirms that the lymphatic drainage pattern from melanomas on the ear 
is unpredictable, with drainage to eight different lymph node fields within the head 
and neck region. Five different primary sites on the ear were identified, based on 
anatomically defined areas relating to embryological development. The frequency 
and location of primary tumors found in this study, classified by auricular anatomical 
subunits, matched previous reports for melanoma.29, 36
Determination of lymphatic drainage patterns requires precise documentation of 
the primary tumor site and accurate mapping of the draining SNs. X-Y coordinates, 
routinely documented to record the LS injection site, were interpreted to represent 
the location of the primary tumor. SNs were most frequently identified in level CII 
(36.4%), the postauricular region (26.2%), the preauricular region (20.0%) and level 
CV (11.3%). Stratification by embryologically derived anatomical subunits confirmed 
that the lymphatic drainage pattern from each specific location was unpredictable with 
drainage to between three and six different LN fields from each location. (Table 2)
Lymphatic drainage of the ear has been investigated previously, either as part 
of an overall review of head and neck malignancy or in the context of regionally 
recurrent disease.19, 27-32 Reynolds et al32 used data from MIA to produce an elegant 
interactive internet-based software tool (http://www.bioeng.auckland.ac.nz/head), 
which depicts lymphatic drainage of the head and neck. This tool suggests that a 
primary located on the ear would most often be expected to drain to cervical level 
II (69% for the left ear and 59.1% for the right ear). As far as we are aware, the only 
previous study that has related the anatomical subunits of the ear to the subsequently 
identified SNs was by Cole et al.29 Only 9 of their 19 patients underwent SN mapping 
by LS. Lymphatic drainage patterns were reported to be highly variable and unpre-
dictable, but the site-specific drainage patterns were not evaluated.29 Our study, 
specifically examining drainage from anatomical subunits on the ear, along with 
several other studies of head and neck malignancies, confirms the highly variable 
pattern of lymphatic drainage from melanoma sites on the head and neck.8, 16-18, 28, 29
Gray’s textbook of anatomy divides the ear into three sections when discussing its 
lymphatic drainage: an upper lateral area that drains to superficial parotid nodes; an 
upper medial area that drains to postauricular and deep upper cervical nodes; and 
the ear lobule that drains to superficial or deep upper cervical nodes.37 This ordered 
arrangement of lymphatic drainage is not what we found. (Table 2) Drainage was 
mostly to nodes in close proximity to the primary site but not necessarily to an 
immediately adjacent node. There was no contralateral node involvement, although 
lymphatic drainage to the contralateral neck has been reported from other cutaneous 
head and neck sites.11
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In general, the establishment of lymphatic drainage follows the embryological 
pattern of vascular development. We have shown that 83.6% of peripherally located 
primaries, i.e., on the lobule or helical rim, drain directly to the posterior auricular 
area as would be predicted. However, the terminal branches of the post-auricular 
artery are well-documented perforating vessels that pass through the anterior and 
posterior surfaces of the ear before finally anastamosing anteriorly with branches of 
the superficial temporal artery.33 Lymphatic vessels accompanying these perforating 
vessels are likely to explain our unexpected observation of transaural lymphatic 
drainage to postauricular nodes in 29% of conchal primary sites.
This study has confirmed that lymphatic drainage of the ear is highly variable; 
therefore, it follows that no specific selective neck lymph node dissection can be 
recommended for an ear primary without lymphatic mapping for that individual. 
However, certain observations are relevant to the planning process: up to 30% of 
patients displayed lymphatic drainage to SNs anterior and posterior to the ear; the 
lobule was the only site to drain to the supraclavicular region; levels CII, CV and 
preauricular nodes were the only areas to receive drainage from all sites on the ear; 
the lobule and concha were the only sites to drain to level CI; however, these nodes 
only accounted for 1.5% of all nodes retrieved and 4.5% of all nodes associated with 
these two sites (Table 2). Dissection of the postauricular region is not included in a 
standard elective node dissection in head and neck surgery.11 However, we found 
that postauricular drainage occurred from the concha, helical rim and lobule in 28% 
of all nodes associated with these three sites, which accounted for 26% of all nodes 
retrieved.
Based on Table 2, this study could be used to set a threshold of identified nodes 
below which a specific region is not dissected, e.g., 6% for the concha would mean 
the dissection should include preauricular and postauricular nodes and those in 
levels CI and CII. Raising the threshold to 10% would mean excluding the level CI 
nodes. However, the numbers were small in many of the subgroups and we do not 
think this is a safe argument. We recommend that CLND following a positive SNB 
should include at least all of the levels mapped by the LS. Our study highlights those 
unexpected regions of drainage that could be considered for inclusion in a lymph 
node dissection, particularly for macroscopic disease, rather than those that should 
be excluded.
In conclusion, lymphatic drainage from melanomas of the ear occurs in a retro-
grade, antegrade or transaural pattern in our study but never contralaterally. The 
most frequent sites for SNs from ear melanomas were level CII and the preauricular 
and postauricular LN fields; this knowledge may influence surgical planning for a 
cervical lymph node dissection. Even in this group of patients with clearly defined 
anatomical boundaries, detailed primary site information and high quality lymphatic 
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mapping, we were unable to demonstrate any correlation between the location of 
the primary tumor on the ear, its embryological development and the pattern of 
lymphatic drainage.
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AbSTRACT
Sentinel node (SN) status is the most important prognostic factor for disease free 
(DFS) and overall survival (OS) in stage I-II melanoma. We evaluated the positive 
sentinel node identification rate of the EORTC Melanoma Group (MG) protocol as 
well as its capacity to identify minimal tumour burden, according to the Rotterdam 
Criteria in 421 consecutive patients. Correlations between primary tumour charac-
teristics and SN tumor burden were investigated. The same 2 pathologists worked 
up all SNs according to the EORTC MG protocol and tumour burden was scored 
according to the Rotterdam Criteria (<0.1 mm, 0.1 – 1.0 mm and >1.0 mm for the 
largest diameter of the largest metastasis in the SN).
The positive SN detection rate was 28.7% with a false negative rate of 10.4% at a 
median Breslow thickness of 2.1 mm. The high positive identification rate of about 
30% of the EORTC MG protocol has been confirmed in this study. The protocol is 
sensitive and identifies submicrometastases (<0.1 mm) in a high percentage (18%). 
The variables SN tumour load, non SN (NSN) status and ulceration of the primary, 
were independent prognostic factors for DFS and OS in the multivariate analysis. At 
a median follow up time of 4.3 years patients with minimal tumour burden (<0.1 
mm) had a 5 year OS rate of 91%, virtually identical to 90% for SN negative patients. 
The NSN positivity rate of 0% in these patients indicates that they may be spared a 
completion lymph node dissection (CLND) and its morbidity.
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iNTRoduCTioN
In the early 90s Morton and colleagues introduced a new procedure for clinical 
stages I-II melanoma, the sentinel lymph node (SN) procedure.1 The SN is the first 
regional lymph node for tumour cells spreading from the primary tumour. Thus it 
may be the first site to demonstrate that a primary melanoma may have spread, as 
regional lymphatic spread appears in general more frequently as first dissemination 
site than distant haematogenous spreading sites.1 The SN status is the most important 
prognostic factor for disease free (DFS) and overall survival (OS) in stage I - II mela-
noma.2 Although the SN procedure has not been demonstrated to have a therapeutic 
effect,2 it has become a widely accepted diagnostic procedure for patients with 
clinically negative lymph nodes.
Identification rates of SN positivity in patients with melanoma are described in 
many studies. SN positivity rates differ from 13.9%3 to 29.4% in our institute.4 These 
differences may occur due to differences in primary tumour characteristics, different 
populations or different protocols for histopathological workup.
The aim of this single institute retrospective study was to evaluate the positive 
sentinel node identification rate of the EORTC Melanoma Group (MG) protocol as 
well as its capacity to identify minimal tumour burden, according to the Rotterdam 
Criteria. Correlations between primary tumour characteristics and SN tumour burden 
were investigated.
PATieNTS ANd MeThodS
Patients
From October 1997 to December 2008, 421 patients with malignant melanomas 
underwent a SN procedure at our institute (Erasmus University Medical Centre, 
Daniel den Hoed Cancer Centre, Rotterdam, the Netherlands). Data of all patients 
were included in this retrospective, single institute study and were collected into a 
database with patient, primary tumour and follow-up data.
Median age was 49 years (range 15 – 83 years). Mean and median Breslow thick-
ness was 2.79 mm and 2.10 mm (range 0.30 – 15.00 mm) respectively. Baseline 
characteristics are described in Table 1.
All patients underwent therapeutic re-excision of the melanoma before the SN 
procedure according to National Guidelines. Tumour-free margins of at least 1 cm 
were achieved in melanomas smaller than or equal to 2 mm Breslow thickness. 
Melanoma larger than 2 mm in Breslow thickness were excised with a tumour-free 
margin of at least 2 cm or less for distal acral and head and neck primaries for 
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Table 1 – Patient characteristics for all 421 patients.
N 2010 (%) 2006 (%)
Gender
Male 204 49 44 
Female 217 51 56 
Age
≤ 50 yrs 222 53 52 
> 50 yrs 199 47 48 
Melanoma location
Extremities 224 53 58 
Trunk 174 41 35 
Head & neck 23 6 7 
Histology
SSM 206 48 48 
NM 138 33 34 
ALM 7 2 2 
Other 9 2 1 
Unclassified 61 15 15 
Breslow thickness
≤ 1.00 mm 18 4 5 
1.01 – ≤ 2.00 mm 182 43 45 
2.01 – ≤ 4.00 mm 137 33 30 
> 4.00 mm 75 18 16 
Unknown 9 2 4 
Clark
II 8 2 2 
III 159 38 42 
IV 200 47 46 
V 29 7 4 
Undeterminable 25 6 6 
Ulceration
Present 119 37 28 
Absent 202 63 72 
SN status
Negative 300 71.3 70.6 
Positive 121 28.7 29.4 
Rotterdam Criteria
< 0.1 mm 22 18 - 
0.1 – 1.0 mm 57 47 - 
> 1.0 mm 42 35 - 
NSN status
Negative 95 89 85 
Positive 12 11 15 
SSM = Superficial Spreading Melanoma, NM = Nodular Melanoma, ALM = Acrolentiginous Melanoma, 
SN = Sentinel Node, NSN = Non Sentinel Node.
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feasibility limits or cosmetic reasons. Finally, the defected areas were closed via 
primary closure or split skin graft. At the same time as wide local excision of the 
malignant melanoma the SN procedure was performed.
The SN procedure was offered to patients with Breslow thickness >1.0 mm or 
to patients with histopathological features as ulceration or Clark level IV or V (see 
Table 2).
Table 2 – Cox univariate regression analyses of disease-free and overall survival.
Univariate DFS OS
HR 95% CI P HR 95% CI P
Gender
Female 1 1
Male 1.31 0.90 – 1.90 0.16 1.73 1.09 – 2.76 0.02
Age
≤ 50 yrs 1 1
> 50 yrs 1.31 0.90 – 1.91 0.15 1.32 0.83 – 2.09 0.24
Location
Extremities 1 1
Head and neck/trunk 1.53 1.05 – 2.23 0.03 1.90 1.19 – 3 03 0.006
Histology
SSM 1 1
NM 1.70 1.13 – 2.55 0.01 2.03 1.24 – 3.32 0.004
Breslow
≤ 2.00 mm 1 1
2.01 – ≤ 4.00 mm 1.91 1.20 – 3.05 1.87 1.05 – 3.34
> 4.00 mm 3.53 2.18 – 5.70 < 0.00005 3.59 2.00 – 6.46 < 0.00005
Clark
II, III 1 1
IV 1.13 0.74 – 1.72 0.85 0.51 – 1 41
V 2.80 1.49 – 5.28 0.003 2.23 1.02 – 4.91 0.044
Ulceration
Absent 1 1
Present 2.49 1.71 – 3.64 < 0.00005 3.40 2.14 – 5.39 < 0.00005
SN status
Negative 1 1
Positive 3.75 2.57 – 5.47 < 0.00005 3.64 2.29 – 5.77 < 0.00005
NSN status
Negative 1 1
Positive 6.43 3.90 – 10.60 < 0.00005 3.92 2.11 – 7.30 < 0.00005
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Sentinel lymph node procedure
At our centre the SN is identified by the use of the triple technique, described in de-
tail elsewhere.4 Basically, patients are first seen at the nuclear medicine department 
for a pre-operative lymphoscintigraphy (LS). The LS should be undertaken within 
24 h of the operation being performed, by four intradermal injections of radioactive 
nanocolloid around the primary tumour or the scar of the primary tumour excision. 
Scanning should be carried out immediately after the injection for approximately 
10 – 15 min and again (=delayed) after 2 hours. Secondly, intraoperative use of a 
handheld gamma detection probe should be used to verify the location of the SNs. 
Thirdly, patent blue should be injected pre-operatively in the operating theatre, 
again through four intradermal injections around the primary tumour or the scar of 
the primary tumour excision (this does not have to be the same 4 locations). The 
blue is also used to verify the identity of the SNs. A lymph node was considered to 
be a SN if it was stained blue, or if it had an in situ radioactivity count of at least 
three times that of the background count, or if it had an ex vivo radioactivity count 
of at least ten times greater than that of the background count.
After the surgical procedure the SNs will be sent to the pathology department for 
examination and in positive cases to establish the SN tumour burden.
Pathological features
All SNs were worked up according to the EORTC MG protocol.5 Within 24 h lymph 
nodes are placed in formalin. After fixation the SN will be bivalved through the 
hilum. Each half sentinel node will be examined in six serial step sections cut at 
50 μm intervals. All sections are stained with H&E and S100 and/or Melan A. Spare 
sections are made at each level for a number of difficult cases where additional 
Table 2 (continued)
Univariate DFS OS
HR 95% CI P HR 95% CI P
Rotterdam Criteria
Negative 1 1
<0,1 1.06 0.38 – 2.93 0.82 0.20 – 3.42
0,1-1,0 3.90 2.45 – 6.22 < 0.00005 3.47 2.00 – 6.01
>1,0 6.86 3.99 – 11.82 6.62 3.69 – 11.87 < 0.00005
Rotterdam Criteria
Negative, < 0.1 1 1
0.1 – 1.0 3.83 2.44 – 5.99 3.58 2.08 – 6.18
> 1.0 7.21 4.45 – 11.68 < 0.00005 7.29 4.08 – 13.02 < 0.00005
SSM = Superficial Spreading Melanoma; NM = Nodular Melanoma; SN = Sentinel Node; NSN = Non 
Sentinel Node
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immunochemistry is needed. Two individual specialized pathologists at our institute 
worked up all SNs. Tumour burden was scored according to the Rotterdam Criteria 
(< 0.1 mm, 0.1 – 1.0 mm and > 1.0 mm largest diameter of the largest metastasis in 
the SN).6
follow-up
Most patients were followed in our outpatient’s clinic. Some patients were followed 
at other hospitals by dermatologists or surgeons. Follow-up time was defined as 
the date between the SN procedure and the date of last follow-up or death. Recur-
rence sites were scored as primary relapse, in-transit metastasis, local regional lymph 
node metastasis, distant subcutaneous, distant lymph node metastasis or visceral 
metastasis.
Statistics
Univariate analyses of potential prognostic factors were performed using the Kaplan-
Meier method and the logrank test. Multivariate analyses of the significant factors in 
the univariate analyses were performed with Cox proportional hazards regression. 
(Table 3 and 4)
Table 3 – Cox multivariate proportional hazard regression analyses of disease-free and 
overall survival
Multivariate DFS OS
HR 95% CI P HR 95% CI P
Location
Extremities 1
Head and neck/Trunk 2.95 1.73 – 5.03 < 0.0005
Histology
SSM 1
NM 1.86 1.07 – 3.26 0.03
Ulceration
Absent 1 1
Present 2.23 1.49 – 3.33 < 0.0005 2.76 1.55 – 4.90 0.001
NSN status
Negative 1 1
Positive 4.80 2.75 – 8.35 < 0.0005 4.29 2.13 – 8.65 < 0.0005
Rotterdam Criteria
Negative, < 0.1 mm 1 1
0.1 – 1.0 mm 2.63 1.63 – 4.24 2.20 1.18 – 4.11
> 1.0 mm 5.00 2.75 – 8.35 < 0.0005 4.27 2.27 – 8.02 < 0.0005
SSM = Superficial Spreading Melanoma, NM = Nodular Melanoma, NSN = Non Sentinel Node.
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Analyses were executed with the following variables: sex (female or male), age (≤ 
50 or > 50 years), location of the melanoma (extremities or trunk/head&neck), histol-
ogy of the melanoma (superficial spreading melanoma (SSM) or nodular melanoma 
(NM)), Breslow thickness (≤ 2.00 mm, 2.01 – ≤ 4.00 mm or > 4.00 mm), Clark level (II 
and III, IV or V), ulceration (absent or present), SN status (positive or negative), NSN 
status (no additional nodes or additional nodes) and Rotterdam Criteria (negative 
and < 0.1 mm, 0.1 – 1.0 mm or > 1.0 mm).
Disease free survival (DFS) and overall survival (OS) were calculated from the op-
eration date of the SN procedure to the date of death or the last follow-up. Patients 
without such an event at their time of last follow-up were censored at that time.
All calculations were performed with STATA version 11.0 (StataCorp LP, College 
Station, TX, USA).
ReSuLTS
Patient characteristics and SN status
This study included 421 melanoma patients (217 women and 204 men) who under-
went the SN procedure in a period over more than 11 years. In this group of patients, 
a total of 732 sentinel nodes were collected during the operations, with an average of 
1.74 (range 1 – 7) lymph nodes per patient. In 255 patients, just one single SN was 
located and excised (60.6%) At least one SN was found in all patients, which defines 
a SN detection rate of 100%.
SN positivity was found in 121 patients (28.7%) after pathological examination. 
During pathological examination of the nodes, all were classified according to the 
Rotterdam Criteria. Median tumour size according to the Rotterdam Criteria was 
0.6 mm. 79 of SN positive patients (65%) showed tumour load of < 1.0 mm and 22 
patients (18%) showed tumour load of < 0.1 mm. (Table 1)
Table 4 – Non-sentinel node (NSN) positivity rates.
SN positivity rate # Patients SN 
positive
NSN positivity rate # Patients with 
additional NSN tumour 
after positive SN(s)
Our 
institute
28.7% 121
(0.287*421)
11.2% 14
(0.112*121)
Other 
literature
20%
(13.9%-29.4%)
84
(0.2*421)
(58.5-123.8)
(0.139*421-0.294*421)
20%
(14-28%)
17
(0.2*84)
(8.2-34.7)
(0.14*58.5-0.28*123.8)
SN = Sentinel Node; NSN = Non Sentinel Node
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A total of 107 CLND were performed in the group of 121 SN-positive patients. The 
CLND was not performed seven times due to factors as high age, rejection of further 
treatment or diagnosis of distant metastases prior to undergoing CLND. Due to a 
change in hospital policy since 2004, 7 patients did not undergo a CLND because of 
presence of minimal SN tumour burden according to the Rotterdam Criteria (< 0.1 
mm). The patients are followed up by ultrasound exams of the regional node basin 
at regular intervals and none have developed a regional nodal relapse. The median 
follow-up of these 7 patients is 3.1 (range 1.1 – 7.0) years. The other 15 patients with 
submicrometastases in the SN underwent CLND and 0% showed NSN positivity in 
the CLND specimen.
Of the 107 patients who underwent CLND, 12 had additional positive nodes 
(11.2%). Five patients (4.6%) had one additional metastatic node and 7 patients 
(7.6%) had multiple additional metastatic nodes.
The false negative rate for the population of SN patients at our clinic is 10.4% 
(14/14+121).7 Until now, 14 of the 299 patients with a negative SN procedure had 
regional lymph node recurrence in the same lymphatic basin as the one of the SN 
procedure.
Survival
The median follow-up time for the entire group was 4.3 (range 0.1 – 11.6) years. 
The median follow-up time for SN-positive patients was 3.2 (range 0.1 – 10.3) years. 
The median follow-up time for SN-negative patients was 4.6 years (range 0.3 – 11.6) 
years.
The 3, 5 and 10 year estimated overall survival (OS) rate for patients undergoing 
the SN procedure after an excised primary melanoma were, respectively, 87%, 82% 
en 70%. The 3, 5 and 10 year estimated OS rate according to the SN status were re-
spectively 94%, 90% and 76% for SN-negative and 73%, 62% and 55% for SN-positive 
patients (both p<0.00005). (Figure 1a)
The 3, 5 and 10 year estimated disease free survival (DFS) rate for patients under-
going the SN procedure were 78%, 73% and 64%. The 3, 5 and 10 year estimated DFS 
rate according to the SN status were, respectively, 89%, 82% and 72% for SN-negative 
and 52%, 51% and 44% for SN-positive patients (p < 0.00005) (figure 1b).
The 5 year estimated OS rates for patients in the four different categories of 
Breslow thickness, i.e. ≤1.0 mm, >1.0-≤2.0, >2.0-≤4.0 and >4.0, were 100%, 88%, 80% 
and 67% (p<0.00005). The 5 year estimated OS rates for patients with presence or 
absence of ulceration at the primary melanoma were, respectively, 65% in presence 
of ulceration and 88% in absence of ulceration (p<0.00005).
The 5 year estimated OS rates for patients with Rotterdam Criteria divided into 
three categories, namely, <0.1 mm, 0.1-1.0 mm and >1.0 mm, were respectively 
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91%, 65% and 36% (p=0.002). The 5-year estimated OS rate was 90% for SN negative 
patients. (Figure 2)
Prognostic factors
Table 3 shows the Cox’s univariate regression analyses for DFS and OS. All variables 
except age are significant for OS and all variables except age and gender are signifi-
cant for DFS (p < 0.05).
Table 4 shows the result of the multivariate proportional hazard regression analy-
sis. The Rotterdam Criteria, ulceration and NSN status had an independent significant 
influence on both DFS and OS. The location and histology of the primary melanoma 
had a significant influence on OS. For the purpose of the multivariate analysis, SN 
negative and tumour burden < 0.1 mm were grouped as one, because in the univari-
ate analysis they had a virtually identical outcome.
diSCuSSioN
In this single institution study we have confirmed the high positive Sentinel Node 
(SN) identification rate of the EORTC Melanoma Group (MG) protocol as well as 
its capacity to identify minimal tumour burden, according to the Rotterdam Criteria.
This study identified a high SN positivity rate of 28.7% (121/421). SN positivity 
rates in literature differ from 13.9% to 29.4% with median Breslow thicknesses from 
1.1 to 3.0 mm.2-4, 7-28 A previous report from our centre identified the highest rate of 
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SN positive patients.4 The factors ulceration rate, mean and median Breslow thick-
ness, false negative rates, survival rates and number of patients included do not seem 
to be correlated with SN positive rates. For example, the current study has a lower 
ulceration rate, lower mean and median tumour thickness than several other studies, 
yet our SN positivity rate is higher.11, 20, 22
Reasons for the differences in SN positivity may be found in the differences 
in pathological assessments. We speculate that the cause of the high SN positivity 
rate at our institution is due to the specific pathological workup of the EORTC MG 
according to the examination designed by Cook, which can detect melanoma in up 
to 33.8% of SNs.5, 29
The sensitivity of the EORTC MG SN pathology protocol is apparent, because 
the current study demonstrated that 65% of SN positive patients have metastases < 
1.0 mm and 18% has metastases < 0.1 mm in maximum diameter according to the 
Rotterdam Criteria.30
(Table 1) 7 patients with minimal SN tumour burden have not undergone a CLND, 
yet none of these has developed a recurrence or died due to melanoma. Furthermore, 
none of the 15 patients with submicrometastases who underwent a CLND showed 
non-SN positive lymph nodes. This indicates that in this group of patients CLND 
may be forfeited. Although our pathological work-up of the SN is very sensitive, 
the question remains if all detected tumour cells are of clinical importance. These 
are merely preliminary results; further prospective studies on SN tumour burden are 
currently ongoing to examine the clinical relevance of minimal SN tumour burden, 
figure 2: Overall Survival – Rotterdam criteria
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such as the EORTC MG MINITUB registry study or the randomized phase III MSLT-2 
trial.31-32
The false negative rate of this study is 10.4% (14/135), which is somewhat higher 
than the general rate of 5% reported in the literature. Yet, false negative rates have 
been incorrectly calculated, which leads to an underestimation of the actual false 
negative rate. Re-calculations of actual false negative rates have demonstrated a 
range from 8.6% to 21%.2, 4, 7-8, 10, 12, 15-17, 20-21, 23, 26-27 The false negative rate is described 
as the rate of patients with a negative SN procedure who had regional lymph node 
recurrence in the same lymph basin as the SN procedure was performed in (false 
negative / (true positive + false negative)).33 Although the current study demon-
strated a higher SN positivity rate with similar Breslow thickness and ulceration rates 
as other studies, it had not lead to a decrease in false negative rates, which suggests 
that failure of the SN procedure might not be due to pathological analysis of the SN. 
Rather, it may be due to detection failures in lymphoscintigraphy. Perhaps it might 
be due to the tumours’ biological activity, which could not to be detected at all since 
it passed the sentinel node and immediately disseminated haematogenously.
The 5-year overall survival (OS) rates of the present study are 90% and 62% for 
SN negative and SN positive patients respectively. These rates are comparable with 
many other studies showing OS rates from 87.5% to 94% for SN negative patients 
and rates from 42.9% to 75.4% for SN positive patients.2-4, 10-12, 15, 17-20, 23, 26-27 The 5-year 
disease free survival (DFS) rates of this study are 82% among those with a negative 
SN procedure and 51% among those with a positive SN procedure. Both survival 
rates are comparable with several other studies showing rates from 75.9% to 89.1% 
for SN negative patients and rates from 35.2% to 65% for patients with a positive SN
.2, 4, 9, 12, 15, 18-19, 23, 25-26 Compared to our previous report, the OS and DFS rates of SN 
negative and SN positive patients has only changed marginally, due to the increased 
follow-up with more events. Interestingly, the high SN positivity rate with the detec-
tion of increasingly more patients with early metastatic disease has not improved 
survival rates for SN positive, nor for SN negative patients, when compared to other 
studies. This might suggest a lack of therapeutic benefit of undergoing a SN followed 
by early CLND.
A benefit of the SN is that it is a minimally invasive procedure with a low compli-
cation rate compared to the morbidity and expense of a lymph node dissection.34-37 It 
spares SN negative patients an unnecessary CLND. However, only 14-28% of the SN 
positive patients undergoing a CLND of the regional nodes has positive non-SNs.38 
Thus, approximately 80% of the SN positive patients will have undergone an unnec-
essary operation with the possible risks of known complications and morbidity, such 
as wound infections and lymph oedema.34, 39 The current study shows an additional 
positive nodal rate in the CLND specimen of 11.2% (12/107), which is quite low 
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compared to the literature and our previous report, which demonstrated a CLND 
positivity rate of 14.7% (10/68). The clinical procedure regarding a CLND has not 
changed in recent years. Our hypothesis is that our high sensitive pathology
model could explain our low CLND positivity rate. Higher detection rate of SN 
minimal tumour burden correlates with more negative nodes in the CLND specimen. 
Moreover, our SN positivity rate is higher than others in the literature; therefore our 
CLND positivity rate is relatively lower than others in the literature. Yet, in absolute 
numbers the amount is equal. (Table 4)
SN staging has become a widely accepted and implemented routine staging pro-
cedure providing important prognostic information and in case of node positivity ar-
guments that will play a role in determining whether to embark on adjuvant therapy 
with interferon (IFN). This has become evident in the light of the outcome of the two 
largest adjuvant trials conducted to date, i.e. EORTC 18952 regarding intermediate 
doses of IFN, or the EORTC 18991 regarding the role of pegylated-IFN.40-41 These 
trials indicated that IFN-based adjuvant therapy was clearly more effective in the 
SN-positive patients than in patients with palpable nodal disease.
Adjuvant IFN-therapy is highly unlikely to have had any influence on the inci-
dence of submicrometastases since only 9% or patients with metastases < 0.1 mm 
(2/22) received adjuvant IFN. In patients with 0.1 – 1.0 mm metastases this was 14% 
(8/57) and in patients with metastases > 1.0 mm this was 2% (1/42). Survival in these 
patients that received adjuvant IFN was not improved in any way.
In conclusion, this study confirms the high detection rate of nearly 30% of the 
EORTC MG protocol in SN positive patients, its capacity to identify minimal tumour 
burden according to the Rotterdam Criteria and verifies that the Rotterdam Criteria 
is an independent prognostic factor for survival. Further research is required to 
investigate which SN positive patients should be the target of CLND.
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AbSTRACT
Prognosis in patients with sentinel node (SN)–positive melanoma correlates with 
several characteristics of the metastases in the SN such as size and site. These factors 
reflect biologic behavior and may separate out patients whom may or may not need 
additional locoregional and / or systemic therapy.
Between 1993 and 2008, 1080 patients (509 women and 571 men) were diagnosed 
with tumor burden in the SN in nine European Organisation for Research and Treat-
ment (EORTC) melanoma group centers. In total, 1009 patients (93%) underwent 
completion lymph node dissection (CLND). Median Breslow thickness was 3.00 mm. 
The median follow-up time was 37 months. Tumor load and site were reclassified 
in all nodes by the Rotterdam Criteria for size and in 88% by the Dewar Criteria for 
topography.
Patients with submicrometastases (< 0.1 mm in diameter) were shown to have an 
estimated 5-year overall survival rate of 91% and a low nonsentinel node (NSN) posi-
tivity rate of 9%. This is comparable to the rate in SN-negative patients. The strongest 
predictive parameter for NSN positivity and prognostic parameter for survival was 
the Rotterdam-Dewar Combined (RDC) criteria. Patients with submicrometastases 
that were present in the subcapsular area only, had a NSN positivity rate of 2% and 
an estimated 5- and 10-year melanoma-specific survival (MSS) of 95%.
Patients with metastases <0.1 mm, especially when present in the subcapsular 
area only, may be overtreated by a routine CLND and have an MSS that is indis-
tinguishable from SN-negative patients. Thus the RDC Criteria provide a rational 
basis for decision making in the absence of conclusions provided by randomized 
controlled trials.
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iNTRoduCTioN
Sentinel lymp node biopsy (SNB), introduced by Morton et al,1-2 is widely accepted 
as a highly accurate diagnostic method of identifying early lymph node micrometas-
tasi in patients with melanoma.
Sentinel node (SN) tumor burden is the most important prognostic factor for pa-
tients with early-stage melanoma.3 Prognosis in patients with SN-positive melanoma 
correlates with several characteristics of the metastases in the SN such as size and 
site. These factors reflect biologic behavior and may separate out patients who may 
or may not need additional locoregional and / or systemic therapy.
SN positivity rates depend on median and mean Breslow thickness of the pri-
mary, ulceration rates and the SN workup protocol and vary in the literature from 
14% to 30%.4-6 Approximately 20% of patients who are SN-positive have further 
nodes involved, which are demonstrated by completion lymph node dissection 
(CLND) findings, the so called nonsentinel node (NSN) positivity rate. Many spe-
cialists in the melanoma field have tried to identify the correct patient group to 
undergo a CLND and to identify those patients who can safely be spared unneces-
sary CLND and its associated morbidity, such as wound infections and chronic 
lymph edema.6-39 Ongoing prospective multicenter studies aim to identify the group 
of patients who can be considered for observation instead of CLND. The two most 
prominent studies are the Multicenter Selective Lymphadenectomy Trial II (MSLT-II) 
and the European Organisation for Research and Treatment of Cancer (EORTC) 
MINITUB studies.40
In this study, two important morphometric parameters are assessed: the microana-
tomical location (Dewar criteria)28 and the maximum diameter of the largest tumor 
lesion (Rotterdam criteria).6, 12 The EORTC Melanoma Group (MG) recommends that 
all pathologists report these criteria for each SN-positive patient.41
The aim of this study, which uses the largest reclassified database of SN positivity, 
was to determine the role of tumor load and tumor site in the SN as prognostic 
factors for survival and as predictive factors for NSN positivity.
PATieNTS ANd MeThodS
Patients
Patients with a positive SNB after wide local excision of a malignant melanoma in 
nine major collaborating EORTC MG centers were included in this retrospective 
study. Participating EORTC MG centers are listed in table 1. Between 1993 and 2008, 
1080 patients were diagnosed with tumor burden in the SN. A database with personal 
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Table 1 – baseline Characteristics of SN–Positive Patients (N = 1080)
Characteristic N %
Sex
Male 571 53
Female 509 47
Center
DDHCC 115 11
CHUB 86 8
MMCCIO 245 23
RSCH 214 20
AVL 116 11
IGR 68 6
VU 107 10
UMCG 56 5
EIO 73 7
Age, years
≤ 50 523 48
> 50 557 52
Location
Extremity 643 60
Trunk 405 37
Head and neck 32 3
Histology
SSM 401 37
NM 347 32
Other 332 31
Breslow, mm
T1 (≤ 1.00 mm) 53 5
T2 (1.01 – ≤ 2.00 mm) 270 25
T3 (2.01 – ≤ 4.00 mm) 434 40
T4(> 4.00 mm) 323 30
Clark
I 2 0
II 33 3
III 266 25
IV 614 57
V 117 11
Unknown 48 4
Ulceration
Present 603 56
Absent 477 44
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information and information on previous medical history, disease and follow-up was 
created for these patients. Baseline characteristics are summarized in Table 1.
In general, patients underwent the SNB in the same session as the re-excision pro-
cedure, after the diagnostic excision of the primary melanoma. Common procedure 
was to achieve margins of 1 cm for melanomas < 2 mm and margins of 1 to 2 cm 
for melanomas > 2 mm. The SNB procedure was offered to patients with Breslow 
thickness ≥ 1.0 mm or to patients with histopathological features such as ulceration 
or Clark level IV or V invasion.
CLND was not performed in all SN-positive patients. In 71 patients (6.6%), CLND 
was not performed for several reasons: refusal of further treatment, the diagnosis of 
distant metastasis between SNB and CLND, or the presence of minimal tumor burden 
in the SN.
The triple technique
After wide local excision of the malignant melanoma, the SN surgical procedure was 
done by using the triple technique, described in detail elsewhere.5, 42-43 In short, the 
Table 1 (continued)
Characteristic N %
Rotterdam criteria
< 0.1 mm 113 10
0.1 – 1.0 mm 457 42
> 1.0 mm 510 47
Dewar criteria
Subcapsular 181 17
Combined 423 39
Parenchumal 154 14
Multifocal 41 4
Extensive 152 14
Unknown 129 12
NSN status
Negative 797 74
Positive 212 20
Unknown 71 7
SN = Sentinel Node; DDHCC = Erasmus University Medical Center – Daniel Den Hoed Cancer Center, 
Rotterdam, the Netherlands; CHUB = the Charité, Humboldt University of Berlin, Berlin, Germany; 
MMCCIO = M.Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; 
RSCH = Royal Surrey County Hospital, Guildford, UK; AVL = Netherlands Cancer Institute, Antoni van 
Leeuwenhoek Hospital, Amsterdam, the Netherlands; IGR = Institut de cancérologie Gustave Roussy, 
Villejuif, France; VU = Vrije Universiteit, Amsterdam, the Netherlands; UMCG = University Medical 
Center Groningen, Groningen, the Netherlands; EIO = European Insitute of Oncology, Milan, Italy; 
SSM = Superficial Spreading Melanoma, NM = Nodular Melanoma
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triple technique consists of preoperative lymphoscintigraphy, undertaken within 24 
hours of the operation being performed; perioperative use of patent blue; and use 
of a handheld gamma detection probe to detect the SN or SNs. A lymph node is 
identified as an SN if it stained blue, if it had an in situ radioactivity count at least 
three times that of the background count, or if it had an ex vivo radioactivity count 
at least ten times greater than the background count.
After the surgical procedure, the SNs were sent to the pathology department for 
pathological examination. SN tumor burden was reviewed, for the purpose of this 
study, by a second pathologist, in a later phase.
Pathology
In the nine EORTC centers, all SNs were worked-up according to the EORTC MG 
pathology protocol designed by Cook et al.44 First, the SNs were fixed for 24 hours 
in buffered formalin. Second, after fixation, the lymph nodes were halved through 
the hilum in its longest dimension and embedded in paraffin. From each face of the 
lymph node five serial step sections of 4 μm each were cut with 50 μm intervals 
between different numbers of sections. Finally, all sections were stained with hema-
toxylin & eosin and S100 and/or MelanA. There were slight local differences in the 
Cook protocol regarding the number and distance of step sections in different time 
periods; however, the main principles remained unchanged.
All SNs with tumor burden were reviewed by different members of the EORTC 
MG. In seven of nine EORTC Centers, SN tumor load was re-classified by van Ak-
kooi. In two EORTC centers (Antoni van Leeuwenhoek Hospital, Netherlands Cancer 
Institute, Amsterdam, the Netherlands and University Medical Center Groningen, 
Groningen, the Netherlands), other experienced melanoma specialists reclassified 
the SN tumor load. SN tumor load was classified according to the Rotterdam criteria 
and Dewar Criteria. All positive SNs were classified according to the Rotterdam 
criteria.6, 12 Dewar criteria were available for 951 patients (88%).28
Dewar Criteria define the micro anatomic location of the melanoma lesion.28 Micro 
anatomic locations are subcapsular, parenchymal, combined, multifocal, or extensive. 
Because Dewar criteria showed that the subcapsular group had a better prognosis 
than any other, we have also grouped the locations into two groups: subcapsular 
and nonsubcapsular (which we called the Dewar Criteria II). The Rotterdam criteria 
(< 0.1 mm, 0.1 – 1.0 mm, > 1.0 mm) consists of the measurement of the maximum 
diameter in any direction of the largest lesion overall on a slide. Several other studies 
included the maximum diameter of the largest tumor lesion as a parameter of SN 
tumor load and used other cut-off points.7-11, 13-17, 19-21 For this reason, we used cutoff 
points other than < 0.1 mm in our analyses (ie, < 0.2 mm [Rotterdam Criteria II], < 
0.3 mm [Rotterdam Criteria III] and < 0.4 mm [Rotterdam Criteria IV]. We also created 
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a new variable after first analysis: Rotterdam-Dewar Combination (RDC) criteria (< 
0.1 mm subcapsular, < 0.1 mm nonsubcapsular), combining the two most predictive 
and prognostic subgroups of the parameters. Patients with tumors for which it was 
difficult to determine the different micromorphometric parameters were discussed 
during EORTC MG meetings, which took place every 6 months.
Statistics
Univariate analyses for NSN positivity were performed using a χ2 test. Univariate 
analyses of end points for survival were performed by using the Kaplan-Meier 
method and the log-rank test. Multivariate analyses to determine the prognostic 
value of covariates regarding melanoma-specific survival (MSS), disease-free survival 
(DFS) and overall survival (OS) were performed using the Cox’s proportional hazards 
model. DFS and OS were calculated from the operation date of the SNB to the date 
of first disease recurrence or the date of death or the last follow-up, respectively. 
MSS was calculated from the operation date of the SNB to the date of death caused 
by melanoma disease. Follow-up time was defined as the date of last follow-up or 
death starting from the date of the SN procedure.
For the survival analyses and analysis for NSN status, the following variables 
were included: sex (male, female), centers (nine EORTC centers), age (≤ 50, > 50 
years), location of the melanoma (extremities, trunk, head and neck), histology of 
the melanoma (superficial spreading melanoma, nodular melanoma, other), Breslow 
thickness (T1, T2, T3, T4), Clark level (II, III, IV, V), ulceration (absent/unknown 
and present), Rotterdam criteria (< 0.1 mm, 0.1 to 1.0 mm, or > 1.0 mm), Rotterdam 
criteria II (< 0.2 mm, 0.2 to 1.0 mm or > 1.0 mm), Rotterdam criteria III (< 0.3 mm, 
0.3 to 1.0 mm, or > 1.0 mm), Rotterdam criteria IV (< 0.4 mm, 0.4 to 1.0 mm, or > 
1.0 mm), Dewar criteria (subcapsular, parenchymal, combined, multifocal, extensive, 
unknown), Dewar criteria II (subcapsular, nonsubcapsular), RDC criteria (<0.1 mm 
subcapsular, <0.1 mm nonsubcapsular) and, for survival analysis only, NSN status 
(negative, positive, unknown). Statistics were performed with STATA version 11.1 
(StataCorp LP, College Station, TX).
ReSuLTS
Characteristics
Baseline characteristics are summarized in Table 1. This study included 1080 patients 
with melanoma (509 women and 571 men) with a positive SN procedure over a 
16-year period. Average age was 51 years (range, 6 to 88 years). Mean and median 
Breslow thicknesses were 4.00 mm and 3.00 mm (range, 0.1 to 90 mm), respectively. 
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The mean and median follow-up times for the entire group were 3.8 and 3.1 years 
(46 and 37 months; range, 1 to 172 months). The mean and median times to first 
recurrence were 3.2 and 2.3 years (38 and 27 months). At last follow-up, 336 (31%) 
of 1080 patients were deceased.
In Table 2, the characteristics of Breslow thickness, ulceration rate, and subgroups 
of the Rotterdam Criteria and the Dewar Criteria are compared among the nine 
EORTC MG centers. With a median Breslow thickness of 4.00 mm and an ulceration 
percentage of 64%, the M. Sklodowska-Curie Memorial Cancer Center and Institute 
of Oncology (MMCIO; Warsaw, Poland) is the center with the group of SN-positive 
patients who have the worst prognosis. This is reflected by the large proportion of 
patients with advanced SN metastases (> 1.0 mm in Rotterdam Criteria; extensive for 
the Dewar Criteria).
NSN status
Of the 1009 patients who underwent a CLND, 21% (212 patients) had one or more 
positive NSNs. Table 3 shows NSN positivity and negativity rates for all factors as-
sessed in this study. The following factors were significant regarding NSN status: 
age; center; histology and location of the primary; Clark level; Breslow thickness; 
Table 2 – Characteristics per EORTC Center
Characteristic DDHCC CHUB MMCCIO RSCH AVL IGR VU UMCG EIO
Median Breslow (mm) 3.00 3.34 4.00 2.40 3.00 2.90 2.10 2.50 3.00
Ulceration percentage 45 50 64 31 40 47 25 30 49
Rotterdam criteria percentage
< 0.1 mm 17 26 3 11 4 9 11 23 4
0.1 – 1.0 mm 48 35 33 46 32 50 49 57 52
> 1.0 mm 35 40 64 43 64 41 40 20 44
Dewar criteria percentage
Subcapsular 30 40 4 18 34 15 15 N/A N/A
Combined 30 29 47 50 41 50 56 N/A N/A
Parenchymal 13 12 22 17 0 26 19 N/A N/A
Multifocal 12 8 4 1 5 3 0 N/A N/A
Extensive 15 12 24 13 21 6 10 N/A N/A
DDHCC = Erasmus University Medical Center – Daniel Den Hoed Cancer Center, Rotterdam, the 
Netherlands; CHUB = the Charité, Humboldt University of Berlin, Berlin, Germany; MMCCIO = 
M.Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; RSCH 
= Royal Surrey County Hospital, Guildford, UK; AVL = Netherlands Cancer Institute, Antoni van 
Leeuwenhoek Hospital, Amsterdam, the Netherlands; IGR = Institut de cancérologie Gustave Roussy, 
Villejuif, France; VU = Vrije Universiteit, Amsterdam, the Netherlands; UMCG = University Medical 
Center Groningen, Groningen, the Netherlands; EIO = European Insitute of Oncology, Milan, Italy; 
N/A = Not Applicable
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Table 3 – Association between clinicopathological factors and the detection of metastases in NSNs
Predictive factor NSN P
Positive
N (%)
Negative
N (%)
unknown
n (%)
Sex
Female 111 (22) 360 (71) 38 (7)
Male 101 (18) 437 (77) 33 (6) .094
Center
DDHCC 11 (10) 90 (78) 14 (12)
CHUB 24 (28) 52 (60) 10 (12)
MMCCIO 66 (27) 178 (73) 1 (0)
RSCH 25 (12) 164 (77) 25 (12)
AVL 15 (13) 101 (87) 0 (0)
IGR 11 (16) 55 (81) 2 (3)
VU 25 (24) 72 (67) 10 (9)
UMCG 10 (18) 45 (80) 1 (2)
EIO 25 (34) 40 (55) 8 (11) < .001
Histology
SSM 76 (19) 297 (74) 28 (7)
NM 88 (25) 244 (70) 15 (4)
Other 48 (14) 256 (77) 28 (8) .003
Location
Extremity 123 (19) 466 (72) 54 (8)
Trunk 82 (20) 310 (77) 13 (3)
Head and neck 7 (22) 21 (66) 4 (13) .011
Age, years
≤ 50 101 (19) 398 (76) 24 (5)
> 50 111 (20) 399 (72) 47 (8) .032
Clark
II 8 (23) 25 (71) 2 (6)
III 39 (15) 218 (82) 9 (3)
IV 126 (21) 440 (72) 48 (8)
V 33 (28) 75 (64) 9 (8)
Unknown 6 (13) 39 (81) 3 (6) .011
Breslow
T1 7 (13) 41 (77) 5 (9)
T2 37 (14) 210 (78) 23 (9)
T3 74 (17) 333 (77) 27 (6)
T4 97 (29) 546 (66) 16 (5) < .001
Ulceration
Absent 103 (17) 457 (76) 43 (7)
Present 109 (23) 340 (71) 28 (6) .052
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Table 3 (continued)
Predictive factor NSN P
Positive
N (%)
Negative
N (%)
unknown
n (%)
Rotterdam criteria, mm
< 0.1 10 (9) 87 (77) 16 (14)
0.1 – 1.0 73 (16) 349 (76) 35 (8)
> 1.0 129 (25) 361 (71) 20 (4) < .001
Rotterdam criteria II, mm
<0.2 27 (14) 140 (73) 24 (13)
0.2 – 1.0 56 (15) 296 (78) 27 (7)
> 1.0 129 (25) 361 (71) 20 (4) < .001
Rotterdam criteria III, mm
<0.3 38 (14) 202 (75) 30 (11)
0.3 – 1.0 45 (15) 234 (78) 21 (7)
> 1.0 129 (25) 361 (71) 20 (4) < .001
Rotterdam criteria IV, mm
<0.4 43 (13) 253 (76) 38 (11)
0.4 – 1.0 40 (17) 183 (78) 13 (6)
> 1.0 129 (25) 361 (71) 20 (4) < .001
Dewar criteria
Subcapsular 12 (7) 152 (84) 17 (9)
Combined 80 (19) 319 (75) 24 (6)
Parenchymal 25 (16) 119 (77) 10 (7)
Multifocal 7 (17) 29 (71) 5 (12)
Extensive 53 (35) 93 (61) 6 (4)
Unknown 35 (27) 85 (66) 9 (7) < .001
Dewar Criteria II
Subcapsular 12 (7) 152 (84) 17 (9)
Non-subcapsular 165 (21) 560 (73) 45 (6)
unknown 35 (27) 85 (66) 9 (7) < .001
RDC Criteria
<0.1 subcapsular 1 (2) 47 (80) 11 (19)
<0.1 non-subcapsular 82 (16) 402 (77) 41 (8)
<0.1 unknown 129 (26) 797 (74) 71 (7) < .001
NSN = Non Sentinel Node; DDHCC = Erasmus University Medical Center – Daniel Den Hoed Cancer 
Center, Rotterdam, the Netherlands; CHUB = the Charité, Humboldt University of Berlin, Berlin, 
Germany; MMCCIO = M.Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 
Warsaw, Poland; RSCH = Royal Surrey County Hospital, Guildford, UK; AVL = Netherlands Cancer 
Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; IGR = Institut de 
cancérologie Gustave Roussy, Villejuif, France; VU = Vrije Universiteit, Amsterdam, the Netherlands; 
UMCG = University Medical Center Groningen, Groningen, the Netherlands; EIO = European Insitute 
of Oncology, Milan, Italy; SSM = Superficial Spreading Melanoma; NM = Nodular Melanoma; RDC 
Criteria= Rotterdam – Dewar Combined (criteria).
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Rotterdam criteria; Rotterdam criteria II, III and IV; Dewar criteria; Dewar criteria II; 
and RDC criteria.
The rate of additional positive lymph nodes in the group of patients with submi-
crometastases (< 0.1 mm, Rotterdam criteria) was 9%, although 16% of patients with 
Rotterdam Criteria 0.1 to 1.0 mm had positive NSNs and 25% of patients had > 1.0 
mm of SN tumor burden. NSN positivity rates for the other cut-off points were simi-
lar. Patients with < 0.2 mm, < 0.3 mm and < 0.4 mm had 14%, 14% and 13% positive 
NSNs, respectively. NSN positivity was 7% in patients with subcapsular metastases 
and 22% in patients with nonsubcapsular metastases. The subgroup of patients with 
the best predictivity for NSN status was the group with subcapsular metastases < 0.1 
mm, which showed positive NSNs in only 2% of patients.
Survival
Results of univariate and multivariate analyses are provided in Table 4. Because of 
multicollinearity in multivariate analyses due to the covariates Rotterdam Criteria 
(with different cutoff values) and RDC Criteria, separate multivariate analyses were 
performed. On multivariable analyses of the covariates regarding MSS, sex, Breslow 
thickness (T3 and T4), ulceration, Rotterdam Criteria (with different hazard ratios for 
different cutoff values), RDC Criteria, and NSN status were independent prognostic 
factors. Dewar or Dewar II Criteria were not significant on multivariate analyses.
Table 4 – Univariate and multivariate analyses of covariates regarding melanoma specific survival
Univariate Multivariate
HR 95% CI P HR 95% CI P
Sex
Female 1 1
Male 1.38 1.10 – 1.73 .006 1.31 1.04 – 1.64 .022
Center
DDHCC 1
CHUB 1.75 1.02 – 3.01 .042
MMCCIO 1.93 1.23 – 3.04 .004
RSCH 1.53 0.95 – 2.46 .081
AVL 1.09 0.65 – 1.84 .74
IGR 1.07 0.51 – 2.22 .87
VU 1.54 0.93 – 2.55 .091
UMCG 0.83 0.43 – 1.60 .58
EIO 1.78 1.02 – 3.10 .041 N/S
Stijn BW.indd   87 04-Dec-13   13:32:36 PM
88 Chapter 5
Table 4 (continued)
Univariate Multivariate
HR 95% CI P HR 95% CI P
Histology
SSM 1
NM 1.44 1.10 – 1.88 .009
Other 1.51 1.13 – 2.01 .005 N/S
Location
Extremity 1
Trunk 1.07 0.85 – 1.36 .55
Head and neck 1.18 0.66 – 2.13 .57 N/S
Age, years
≤ 50 1
> 50 1.24 0.99 – 1.55 .063 N/S
Clark
II 1
III 1.45 0.63 – 3.36 .39
IV 2.07 0.92 – 4.66 .081
V 3.43 1.48 – 7.99 .004
Unknown 2.23 0.84 – 5.96 .108 N/S
Breslow
T1 1 1
T2 1.07 0.51 – 2.27 .85 - - N/S
T3 1.92 0.94 – 3.93 .075 1.53 1.10 – 2.13 .012
T4 3.74 1.83 – 7.64 < .001 2.45 1.73 – 3.45 < .001
Ulceration
Absent 1 1
Present 2.11 1.68 – 2.64 < .001 1.50 1.18 – 1.92 .001
Rotterdam criteria, mm
< 0.1 1 1
0.1 – 1.0 3.28 1.72 – 6.25 < .001 2.65 1.38 – 5.06 .003
> 1.0 5.36 2.83 – 10.13 < .001 3.30 1.73 – 6.31 < .001
Rotterdam criteria II, mm
<0.2 1 1
0.2 – 1.0 1.60 1.05-2.44 1.40 0.93 – 2.12 N/S
> 1.0 2.84 1.91-4.21 < .001 1.83 1.23 – 2.72 .003
Rotterdam criteria III, mm
<0.3 1 1
0.3 – 1.0 1.67 1.14-2.45 1.42 0.98 – 2.05 N/S
> 1.0 2.75 1.96-3.88 < .001 1.77 1.26 – 2.50 .001
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Table 4 (continued)
Univariate Multivariate
HR 95% CI P HR 95% CI P
Rotterdam criteria IV, mm
<0.4 1 1
0.4 – 1.0 1.61 1.12-2.33 1.24 0.87 – 1.76 N/S
> 1.0 2.57 1.89-3.50 < .001 1.59 1.17 – 2.17 .003
Dewar criteria
Subcapsular 1
Combined 1.88 1.29 – 2.76 .001
Parenchymal 1.94 1.23 – 3.05 .004
Multifocal 1.46 0.72 – 2.95 .297
Extensive 3.62 2.38 – 5.51 < .001
Unknown 1.61 1.02 – 2.56 .042 N/S
Dewar criteria II
Subcapsular 1
Non-subcapsular 2.04 1.43 – 2.92 < .001 N/S
RDC criteria
<0.1 subcapsular 1 1
<0.1 non-subcapsular 2.57 0.66 – 9.95 N/S - - N/S
0.1 – 1.0 subcapsular 5.23 1.60 – 17.15 .006 4.53 1.37 – 14.91 .013
0.1 – 1.0 non- 
subcapsular
5.92 1.87 – 18.69 .002 5.01 1.58 – 15.88 .006
> 1.0 non and 
subcapsular
9.36 2.99 – 29.32 < .001 6.17 1.95 – 19.45 .002
NSN status
Negative 1 1
Positive 2.46 1.89 – 3.22 < .001 2.12 1.62 – 2.79 < .001
Unknown 1.45 1.09 – 1.93 .011 1.68 1.26 – 2.25 < .001
HR = Hazard Ratio; CI = Confidence Interval; DDHCC = Erasmus University Medical Center – Daniel 
Den Hoed Cancer Center, Rotterdam, the Netherlands; CHUB = the Charité, Humboldt University of 
Berlin, Berlin, Germany; MMCCIO = M.Sklodowska-Curie Memorial Cancer Center and Institute of 
Oncology, Warsaw, Poland; RSCH = Royal Surrey County Hospital, Guildford, UK; AVL = Netherlands 
Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; IGR = Institut de 
cancérologie Gustave Roussy, Villejuif, France; VU = Vrije Universiteit, Amsterdam, the Netherlands; 
UMCG = University Medical Center Groningen, Groningen, the Netherlands; EIO = European Insitute 
of Oncology, Milan, Italy; N/S = Not Significant; SSM = Superficial Spreading Melanoma; NM = 
Nodular Melanoma; NSN= Non-Sentinel Node; RDC Criteria= Combined Rotterdam and Dewar 
Criteria
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The Kaplan-Meier 5- and 10-year OS rates were 91% and 81% for patients with 
Rotterdam Criteria < 0.1 mm, followed by 71% and 54% in the 0.1 to 1.0 mm group, 
and 57% and 46% in the > 1.0 mm group. The Kaplan-Meier 5- and 10-year DFS 
rates were 83% and 83% for patients with Rotterdam Criteria < 0.1 mm, followed by 
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61% and 49% in the 0.1 to 1.0 mm group, and 40% and 32% in the > 1.0 mm group. 
The Kaplan-Meier 5- and 10-year MSS rates were 92% and 87% for patients with 
Rotterdam Criteria <0.1 mm, followed by 74% and 57% in the 0.1 to1.0 mm group 
and 59% and 48% in the > 1.0 mm group. (Fig 1A)
The Kaplan-Meier 5- and 10-year MSS rates of patients with cutoff points < 0.2, < 
0.3 and < 0.4 mm were 81% and 73%, 81% and 74% and 80% and 70%, respectively. 
The Kaplan-Meier 5- and 10-year MSS rates were 81% and 71% for patients with 
subcapsular metastases and 66% and 52% for those with nonsubcapsular metastases. 
(Fig 1B) The Kaplan-Meier 5- and 10-year MSS rates were both 95% for patients with 
RDC Criteria < 0.1 mm subcapsular, although the 5- and 10-year OS rates were 88% 
and 80% for patients with RDC Criteria < 0.1 mm nonsubcapsular. (Fig 1C)
diSCuSSioN
To the best of our knowledge, this is the largest study ever performed in this field, 
evaluating almost three times more SN-positive patients than reports of two studies 
performed in the United States,9, 20 a previous report of the EORTC MG,6 and a report 
from the Melanoma Institute Australia in Sydney.22 This study investigated prognostic 
factors for survival and predictive factors for NSN status by addressing two different 
histological parameters of classifying SN tumor load.
This study confirms that patients with submicrometastases (< 0.1 mm) had an 
estimated 5-year OS rate of 91% comparable with SN-negative patients.6 The NSN 
positivity rate is 9%, which is comparable to a false-negative SN rate in patients who 
underwent SNB. The most predictive and prognostic parameter in our study was 
the RDC Criteria. Patients with submicrometastases present in the subcapsular area 
only had a NSN positivity rate of only 2% and an estimated 5- and 10-year MSS rate 
of 95%. It is highly unlikely that this patient group benefits from a routine CLND. 
We propose that they might be classified as SN-negative in the next American Joint 
Committee on Cancer (AJCC) classification system.
Various micromorphometric parameters for tumor load in the SN have been 
studied, such as SN tumor burden, tumor penetrative depth, square area, percent-
age area, number of metastatic foci, number of positive SNs, extracapsular spread, 
and capsular invasion.14, 17-18, 20, 23-26, 32-33, 36, 39 Others combined primary melanoma 
and/or SN characteristics into working models for predicting survival and/or NSN 
status.16-17, 20, 22, 31-32, 36, 39 Reproducibility and accuracy are important aspects in the 
assessment of micromorphometric parameters in the histopathologic workup and 
measurement of SN tumor deposits.41, 45 Murali et al.45 observed the agreement of 
assessment of histologic parameters among seven different pathologists. Quantitative 
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Table 5 – overview of literature for predictive factors for NSN involvement and 5-year 
estimated oS rates
Parameters 
for SN tumor 
burden
Studies Analyzed 
NSN positive 
patients
N (%)
Most prognostic 
subgroup of 
variable for NSN 
status
NSN 
Positivity 
rate
(%)
5-year 
estimated 
OS rate
(%)
Size as largest 
diameter of 
largest lesion
(eg, Rotterdam 
criteria)
Ranieri et al. 7 13 (14) ≤3 mm - 86 *
Carlson et al. 8 15 (16) Isolated tumor cells - 86 *
≤2 mm - 90 *
Lee et al. 9 46 (24) <2 mm 16 -
Sabel et al. 10 34 (15) Micrometastasis 2 -
Pearlman et al. 11 17 (21) ≤2 mm 6 85
van Akkooi et al. 5, 12 10 (15) <0.1 mm 0 100
Govindarajan et al. 13 20 (16) ≤0.2 mm 0 -
Debarbieux et al. 14 22 (22) ≤2 mm 18 ±80
≤1 mm
(smallest diameter)
13 -
Scheri et al. 15 N/A † ≤0.2 mm 12 87
Roka et al. 16 18 (21) ≥2 mm 8 -
Rossi et al. 18 20 (21) ≤2 mm 16 -
Satzger et al. 17 28 (16) <0.1 mm 0 -
<1 mm 9 -
<2 mm 11 -
Guggenheim et al. 19 22 (22) ≤2 mm 16 -
Gershenwald et al. 20 48 (14) ≤0.5 mm 5 -
≤2 mm 8 -
van Akkooi et al. 6 91 (23) <0.1 mm 3 91
van der Ploeg et al. 21, 27 15 (13) <0.1 mm 0 100
This study 184 (17) <0.1 mm 9 91
Microanatomic
Location
(eg, Dewar 
criteria)
Dewar et al. 28 24 (16) Subcapsular 0 -
van Akkooi et al. 5, 12 10 (15) Combined 9 -
Govindarajan et al. 13 20 (16) Sinusoidal 0 -
Roka et al. 16 18 (21) Non-extensive 13 -
Rossi et al. 18 20 (21) Subcapsular 0 -
Gershenwald et al.20 48 (14) Subcapsular 10 -
Frankel et al. 29 29 (21) Subcapsular 10 -
van Akkooi et al. 6 91 (23) Subcapsular 8 -
van der Ploeg et al. 21, 27 15 (13) Subcapsular 3 83
This study 184 (17) Subcapsular 7 81
NSN = Nonsentinel Node; OS = Overall Survival; SN = Sentinel Node; N/A = Not Applicable
* These rates are 3-year estimated overall survival rates
† Only the group of patients with isolated tumor cells and known NSN status were included. Six of 52 
(12%) patients with ≤ 0.2 mm had NSN positivity in this study.
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parameters like the maximal size of largest SN deposit (Rotterdam Criteria), the tu-
mor penetrative depth (S-classification) and the estimated percentage area occupied 
by metastasis had an excellent degree of interobserver agreement.45 Thus, besides 
containing predictive and prognostic value, a measurement of SN tumor load must 
be simple and reproducible.
Many studies addressed cutoff points other than 0.1 mm and 1.0 mm used by the 
Rotterdam Criteria measuring the largest diameter of the largest lesion.6-21 (Table 5) 
We scrutinized the cutoff point of 0.1 mm in this study and examined other cutoff 
points, for example, 0.2 mm as used for patients with SN-positive breast cancer46-47 
and as addressed in other studies,13, 15 0.3 mm as in the S-Classification,24 and 0.4 
mm as suggested by van der Ploeg et al.21 NSN positivity increased rapidly and in 
agreement with these other cutoff points, which had positive NSNs in 13% to 14% 
of SN-positive patients. (Table 3) Survival rates in these groups showed similar poor 
outcome. Five-year MSS survival rates were 80% to 81% and 10-year MSS survival 
rates were 70% to 74%. Of the four different cut-off points, < 0.1 mm according to 
the Rotterdam Criteria had the best prognostic and predictive value. (Tables 3 and 4) 
The other three cutoff points addressed had worse survival than SN negative patients 
(80% to 81% compared to 88% to 94%), while patients with submicrometastases 
according to the Rotterdam Criteria had similar survival (91%).
Tumor load and topography characteristics predict NSN positivity, but whether 
they can play a role in identifying patients, who may or may not benefit from routine 
CLND is another important question. Our study strongly suggests that some patients 
may not benefit from routine CLND. Because almost all patients underwent CLND, 
the question remains as to whether these patients would have had the same outcome 
without a CLND. The outcome of a group of patients with good prognosis but 
without CLND has never been published, although two recent studies described the 
difference between a group of SN-positive patients without CLND after a positive 
SN.48-49 There was no significant difference in locoregional control and disease-specific 
survival between groups, indicating that CLND may not influence survival. It seems 
obvious that patients who are SN-positive with no CLND with high-volume SN tumor 
burden have worse outcome than patients with low- volume SN tumor burden.
Obviously, all retrospective studies including this one have the traditional down-
side that can be overcome only by a prospective randomized controlled trial. Several 
prospective trials are currently under way to further investigate the possibility of 
reducing the 80% of unnecessary CLND operations. The two most prominent studies 
are the MSLT-II and the EORTC MINITUB studies.40 When the outcomes of these 
studies are final, alternative options to CLND can be discussed and proposed.
Another issue is the biologic significance of minimal SN tumor burden. We pose 
two hypotheses: (1) These are dormant cells that will inevitably become active 
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metastatic cells after a long period of time. Thus, the removal of such deposits (by 
excising the SN) can be curative. (2) These are cells presented to the immune system 
that has led to an immune response to destroy circulating tumor cells; therefore, 
these cells will never progress to viable metastatic cells and should be considered 
prognostically false positive. This is difficult to study, because the SN has been 
removed in both cases to establish the presence of minimal SN tumor burden.
There are additional arguments for classifying tumor load in the SN because it 
may help identify which patients could benefit from adjuvant systemic therapy with 
Interferon, since the large EORTC 18952 and 18991 trials both clearly demonstrated 
that patients with less disease had the greater benefit.50-51
In conclusion, this study of the EORTC MG proposes that patients with tumor 
burden < 0.1 mm might safely be spared a routine CLND, especially when found in 
the subcapsular area only. We acknowledge that long-term follow-up is necessary, 
and these results need to be validated prospectively. We invite surgical oncologists 
to participate in studies, such as the MSLT-II or the EORTC MINITUB study. The RDC 
criteria provide the strongest prognostic information for survival and most accurately 
predict NSN positivity. The simplicity of these classification systems is an argument 
for their standard implementation.
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AbSTRACT
Sentinel node (SN) biopsy (SNB) and completion lymph node dissection (CLND) 
when SN positive have become standard of care in most cancer centers for melanoma. 
Various SN tumor burden parameters are assessed to determine the heterogeneity of 
SN positivity. The aim of the present study was to validate the prognostic significance 
of various SN tumor burden micromorphometric features and classification schemes 
in a large cohort of SN-positive melanoma patients.
In 1539 SN-positive patients treated between 1993 and 2008 at 11 melanoma 
treatment centers in Europe and Australia, indices of SN tumor burden (intranodal 
location, tumor penetrative depth (TPD) and maximum size of SN tumor deposits) 
were evaluated.
Non-subcapsular location, increasing TPD and increasing maximum size were all 
predictive factors for non-SN (NSN) status and were independently associated with 
poorer melanoma-specific survival (MSS). Patients with subcapsular micrometasta-
ses <0.1mm in maximum dimension had the lowest frequency of NSN metastasis 
(5.5%). Despite differences in SN biopsy protocols and clinicopathologic features of 
the patient cohorts (between centers), most SN parameters remained predictive in 
individual center populations. Maximum SN tumor size >1mm was the most reliable 
and consistent parameter independently associated with higher non-SN positivity, 
poorer DFS, and poorer MSS.
In this large retrospective, multicenter cohort study, several parameters of SN 
tumor burden including intranodal location, TPD and maximum size provided prog-
nostic information, but their prognostic significance varied considerably between the 
different centers. This could be due to sample size limitations or to differences in SN 
detection, removal and examination techniques.
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iNTRoduCTioN
Twenty years ago, sentinel node (SN) biopsy (SNB) was introduced as a staging 
technique for patients with early-stage melanoma.1, 2 Since then, SN status has been 
shown to be the strongest independent prognostic factor in patients with clinically 
localized primary cutaneous melanoma.3-6
First introduced in the 6th edition (2001) of the American Joint Commission on 
Cancer (AJCC)/Union Internationale Contre le Cancer (UICC) staging system for 
cutaneous melanoma, sentinel lymph node tumor burden is now established as an 
N1-2a staging criterion in the TNM staging system7, 8. However, specific subgroups of 
SN-positive patients have vastly differing survival rates, ranging from approximately 
30% to over 90%.3, 10-14 Patient characteristics, primary tumor and SN parameters, and 
models for risk stratification of SN-positive patients have been assessed in numerous 
studies with respect to prediction of non-SN (NSN) status and survival.11-14, 16-22 Ideally, 
the parameters utilized for prognostic stratification must be easy and quick to assess 
and reproducible.23, 24 The best validated prognostic SN tumor burden parameters 
to date are: tumor penetrative depth beneath the SN capsule, maximum size of SN 
tumor deposits and intranodal location of SN tumor.6, 11, 13, 16-19, 22, 25-31
In recent years, the European Organisation for Research and Treatment of Cancer 
(EORTC) Melanoma Group (MG) and Melanoma Institute Australia (MIA) have each 
gathered large independent datasets of SN-positive patients, assessed micromorpho-
metric parameters of tumor in SNs and demonstrated the prognostic importance of 
these factors.6, 16, 28 The aim of the current study was to combine the large European 
and Australian patient cohorts, and evaluate the prognostic significance of SN tumor 
burden parameters and classification schemes overall. A secondary aim was to as-
sess and compare the predictive power of these parameters in individual melanoma 
treatment centers.
PATieNTS ANd MeThodS
Patients
Patients diagnosed between 1993 and 2008 with primary melanoma and a positive 
SN, at eleven melanoma treatment centers (ten EORTC MG centers in six different 
countries and one center, MIA, in Sydney, Australia) were studied. Patient demo-
graphics, information on previous medical history and follow-up data were collected 
by each center. SN tumor burden was measured and classified by at least two of the 
following morphometric parameters: intranodal location (9/11 centers)17, maximum 
size of the largest discrete SN tumor deposit (11/11 centers)13, 31) and tumor penetra-
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tive depth (7/11 centers;11, 19, 30). The RDC (Rotterdam-Dewar Combined) classification 
was derived from the Rotterdam classification and the modified Dewar classification 
(9/11 centers).6
Lymphatic mapping, sentinel node biopsy and completion lymph node 
dissection
At all centers, SNB was offered to patients with Breslow thickness ≥ 1mm or to 
patients with thinner tumors with adverse prognostic features such as ulceration, 
a high mitotic rate or Clark level IV or V invasion. SNB was performed using the 
triple technique identifying SNs with a combination of lymphoscintigraphy, pre-
operative injection of blue dye at the primary melanoma site and intraoperative 
use of a gamma probe. Full details have been reported previously.14, 32-35 However, 
there were some differences in the procedures for identifying and removing SNs 
at the different centers. These included differences in the radiocolloids used for 
preoperative lymphoscintigraphy, the timing and planes of view utilized for lympho-
scintigraphy, the type and volume of blue dye used, the type and sensitivity of the 
hand-held gamma probe and the criteria utilized for defining a SN, as well as the 
experience of the nuclear medicine physicians, radiologists and surgical oncologists 
performing these procedures. Excised SNs were fixed in buffered formalin and sent 
for pathologic examination. Subsequently, SN tumor burden was determined by 
histopathologic review of available tissue sections. CLND was performed in 1381 of 
1539 (90%) SN-positive patients. Reasons for not performing CLND were eligibility 
for the EORTC 1208 (Minitub) study36, the presence of micrometastases <0.1mm in 
maximum dimension since an excellent survival is to be expected, enrolment in the 
observation arm of the second Multicenter Selective Lymphadenectomy Trial (MSLT-
II)( Clinicaltrials.gov identifier NCT00297895), patient refusal of further treatment, or 
when surgical and anesthetic risks associated with CLND were considered too great 
due to patient co-morbidities.
Pathology processing and analysis
There were also differences in the pathology processing and analysis of retrieved SNs 
between the eleven different centers. Generally, SNs from most of the ten EORTC 
MG centers were processed and assessed according to the basic principles of the 
EORTC MG SN pathology protocol as described by Cook et al,14, 37 while the SNs at 
MIA were processed according to a different protocol.38, 39
Briefly, for the EORTC MG protocol, SNs were bisected through the hilum in its 
longest dimension after 24h placement in formalin. After cutting several sections 
from each SN, sections were stained with hematoxylin & eosin (H&E) and for S-100, 
Melan-A and/or HMB-45. Six pairs of 4μm-thick sections were cut with a 50μm 
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interval between them. Spare sections were made at each level for additional stain-
ing if required for interpretation. In 2003 the protocol was revised, and the distance 
between the step sections changed from 250μm to 50μm, but the main principles of 
bisecting through the hilum and cutting sections from the hilum remained the same.
At MIA, SNs were bisected along their longest axis after 24 hours fixation in 10% 
buffered formalin. Each half of the SN was cut in four sequential sections 5μm thick 
(i.e. eight sections were examined routinely). Additional sections were cut when 
examination of further sections was deemed necessary for the assessment of the 
presence or absence of metastasis or to determine the site, size or TPD of tumor 
deposits.
An average of 12 slides per SN was taken at the EORTC MG centers versus 
8 slides at MIA. In comparison to SN samples, CLND specimens were examined 
routinely with a less extensive protocol at all centers, consisting of only bivalving 
and H&E staining of the lymph nodes. Four experienced pathologists and a non-
pathologist specialist in the melanoma area reviewed SNs belonging to European 
patients. Two pathologists at Royal Prince Alfred Hospital (RPAH) (R.A.S. and R.M.) 
and a non-pathologist melanoma specialist in the field of analyzing SN slides who 
also reviewed the EORTC MG patients (A.C.J.v.A.) reviewed the MIA SN slides. 
Consensus in analyzing SN tumor burden was reached and metastases were analyzed 
according to equivalence principles, which are explained in another study.24
Statistical Methods
Statistics were performed with STATA version 11 (StataCorp LP, College Station, TX) 
and IBM SPSS Statistic v 19.0 (Chicago, IL). Variables were coded and assessed as 
described in Table 1. Pearson’s chi-square, Fisher’s exact and the Mann-Whitney U 
tests were employed where appropriate. Binary logistic regression was employed to 
assess factors that were predictive of NSN status. The Kaplan-Meier method together 
with the Log Rank test and Cox regression were executed for univariate survival 
analyses. Four separate Cox regression multivariate models were performed to as-
sess disease-free survival (DFS) and melanoma-specific survival (MSS), in order to 
account for the correlation of SN tumor burden parameters. Disease-free survival 
(DFS) was measured from date of SNB to date of first recurrence and melanoma-
specific survival (MSS) from date of SNB to date of death caused by melanoma, 
or last follow-up (censored). Two–tailed p-values less than 0.05 were considered 
statistically significant.
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ReSuLTS
Between 1993 and 2008, 1539 patients diagnosed with primary melanoma were found 
to have a positive SN. Clinicopathologic characteristics of all SN-positive patients 
are summarized in Table 1. The numbers of patients from each center were: MIA 
(n=350), Warsaw (n=245), Guildford (n=214), Amsterdam – NKI (n=116), Rotterdam 
Table 1 – Clinicopathologic factors for all sentinel node positive patients (n=1539).
Characteristic n % Characteristic n %
Gender Intranodal location (Dewar 
classification)
Female 702 46 Subcapsular 248 18
Male 837 54 Non-subcapsular 1155 82
Age (years) Missing 136
mean±SD 52.3±15.3 Tumor penetrative depth (mm)
≤ 50 693 45 median (IQR) 0.80 (0.30 – 1.95)
> 50 846 55 S-Classification
Location SI 246 30
Extremity 779 51 SII 227 28
Trunk 533 35 SIII 344 42
Head&Neck 211 14 Missing 722
Other 14 1 Tumor penetrative depth (mm)
Missing 2 ≤ 0.5 333 41
Melanoma subtype > 0.5 484 59
SSM 572 48 Missing 722
NM 536 45 Maximum size (mm)
Other 89 7 median (IQR) 0.90 (0.30 – 2.50)
Missing 342 Rotterdam classification (mm)
Breslow thickness (mm) < 0.1 146 10
mean±SD 3.74±0.10 0.1 – 1.0 665 43
median (IQR) 2.95 (1.80 – 4.50) > 1.0 728 47
T1 90 6 Maximum size (mm)
T2 394 26 ≤ 2 1094 71
T3 616 40 > 2 445 29
T4 435 28 Maximum size (mm)
Missing 4 ≤ 1
Clark level > 1
I-II 37 3 RDC classification
III 350 24 < 0.1mm subcapsular 69 5
IV 921 62 < 0.1mm non-subcapsular 55 4
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(n=115), Padova (n=109), Amsterdam – VUMC (n=107), Berlin (n=86), Milan (n=73), 
Villejuif (n=68) and Groningen (n=56) (Table S1). Mean age was 52.3 (standard 
deviation (SD) ± 15.3) years. Median Breslow thickness was 2.95mm (interquartile 
range (IQR) 1.80-4.50mm). Ulceration was present in 46% of the melanomas. Median 
maximum SN tumor size was 0.90mm (IQR 0.30-2.50mm) (Tables 1 and S1). Mean 
and median follow-up times were 42 and 32 (IQR 20-58) months, respectively. In 
1381 (90%) patients, CLND was performed.
differences between centers
Significant differences in primary tumor and SN characteristics were observed be-
tween centers (Table S1 and Fig. 2). Median Breslow thickness was 3.00mm for the 
European cohort and 2.43mm for the Australian cohort (p=0.001), and ulceration was 
more common in the European than the Australian cohort (45% vs. 35%, p=<0.001). 
The median maximum SN tumor sizes for the European and Australian cohorts were 
not significantly different (0.95mm and 0.80mm, respectively, p=0.126).
NSN status
Details of NSN status were available for 1381 patients who had a CLND. Breslow 
thickness, ulceration, Clark level of invasion, number of SNs removed, and all mi-
cromorphometric parameters were significant predictors of NSN status (p< 0.05) 
(Table 2). Of the SN tumor burden parameters, the RDC classification subgroup 
V 172 12 0.1 – 1.0mm subcapsular 160 11
Missing 59 0.1 – 1.0mm non-subcapsular 435 31
Ulceration > 1.0mm 684 49
Absent 781 54 Missing 136
Present 655 46 CLND performed
Missing 103 no 158 10
Number of removed SNs yes 1381 90
1 468 36 NSN status
2 426 33 Negative 1098 80
3 411 32 Positive 283 21
Missing 234 Time SNB
Number of positive SNs 1993 – 2002 714 46
1 1030 79 2003 – 2008 825 54
 2 228 17  
 ≥3 53 4  
 Missing 230  
SSM=Superficial spreading melanoma; NM=Nodular melanoma; IQR=Interquartile range, SD = 
standard deviation
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Table 2 – Factors predictive of non-sentinel node status.
Characteristic Total NSN-positive p-value*
n n %
Age
≤ 50 637 118 18.5
> 50 744 165 22.2 NS
Breslow thickness
T1 80 10 12.5 Ref
T2 348 61 17.5 NS
T3 549 94 17.1 NS
T4 400 117 29.3 0.003
Ulceration
Absent 686 122 17.8 Ref
Present 600 144 24.0 0.006
Dewar classification
subcapsular 217 19 8.8 Ref
 non-subcapsular 1040  229 22.0  < 0.001 
S-Classification
SI 202 23 11.4 Ref
 SII 195  35 17.9  NS 
 SIII 309  76 24.6  <0.001 
Tumor penetrative depth (mm)
≤ 0.5 274 30 10.9 Ref
> 0.5 432 104 24.1 < 0.001
Rotterdam Classification (mm)
< 0.1 117 14 12.0 Ref
 0.1 – 1.0 589  93 15.8  NS 
 >1.0 675  176 26.1  0.001 
Maximum size (mm)
≤ 1 706 107 15.1 Ref
> 1 675 176 26.1 <0.001
Maximum size (mm)
≤ 2 964 150 15.6 Ref
> 2 417 133 31.9 < 0.001
RDC classification
< 0.1mm subcapsular 55 3 5.5 Ref
 < 0.1mm non-subcapsular 43  9 20.9  0.030 
 0.1 – 1.0mm subcapsular 146  16 11.0  NS 
 0.1 – 1.0mm non-subcapsular 379  55 14.5  NS 
 > 1.0mm 634  165 26.0  0.003 
*Univariate binary logistic regression was used to calculate the significance of individual strata for 
each classification system in predicting NSN status; only the p-values are reported here.
NSN=Non-sentinel node
NS=Not significant
Ref=reference category
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with subcapsular micrometastases <0.1mm in maximum dimension had the lowest 
NSN-positivity rate (5.5%). (Table 2).
As continuous variables measured in millimeters, maximum SN metastasis size 
(OR=1.11, 95%CI: 1.07-1.15, p<0.001) and tumor penetrative depth (OR=1.26, 95%CI: 
1.15-1.38, p<0.001) were signifi cant predictors of NSN status in the overall cohort 
figure 1 – Melanoma specifi c-survival curves for all SN-positive patients.
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Figure 1 – Melanoma specific-survival curves for all SN-positive patients. 
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Nr at Risk Nr at Risk
SI 246 227 187 136 104 71 Subcapsular 248 223 189 135 94 63
SII 225 207 61 120 67 Non-subcapsular 1155 992 735 474 227
SIII 396 339 259 176 128 85 Total 1403 1215 924 609 439 290
Total 867 773 607 432 320 223
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(Table S2). The categorization of maximum size (≤1 vs. >1mm and ≤2 vs. >2mm), 
TPD (≤0.5 vs. >0.5mm) and intranodal location (sub-capsular vs. non-subcapsular) 
resulted in a statistically significant stratification of risk for NSN-positivity (Table 2). 
When comparing the eleven melanoma centers, there was variation in the prediction 
of NSN positivity by the proposed classification systems (Table S3). Classifications of 
maximum SN tumor size using a 1mm or 2mm cutoff significantly stratified risk for 
NSN positivity in 5/11 and 6/11 centers, respectively. The Rotterdam system, RDC 
system, TPD, S-classification and intranodal location significantly stratified risk for 
NSN positivity in only 2/11, 1/9, 2/7, 2/7 and 2/9 centers, respectively (Table S3).
Survival
In univariate analysis of the overall cohort, factors significantly associated with 
melanoma-specific survival (MSS) were: patient sex, age, melanoma subtype, Bre-
slow thickness, Clark level, ulceration, Dewar classification, TPD, S-classification, 
maximum size, Rotterdam classification, RDC classification (only in the subgroups of 
patients with tumor deposits >1.0mm in maximum dimension and in patients with 
deposits >0.1-1.0mm in maximum dimension and non-subcapsular) and NSN status 
(Table 3).
Table 3 – Univariate analyses for melanoma-specific survival of all sentinel node positive patients.
Characteristic Univariate analysis
HR 95% CI p-value
Gender
Female 1
 Male 1.30 1.07-1.57 0.009 
Age (years)
continuous 1.02 1.01-1.02 <0.001
 ≤ 50 1   
 > 50 1.36 1.12-1.65 0.002 
Location
Extremity 1
 Trunk 0.99 0.80-1.22 NS 
 Head&Neck 0.99 0.74-1.32 NS 
Melanoma subtype
SSM 1
 NM 1.59 1.27-2.00 <0.001 
 Other 1.87 1.27-2.75 0.002 
Breslow thickness (mm)
continuous 1.08 1.06-1.09 <0.001
 T1 1   
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Table 3 (continued)
Characteristic Univariate analysis
HR 95% CI p-value
 T2 1.71 0.88-3.31 NS 
 T3 2.67 1.41-5.07 0.003 
 T4 5.09 2.69-9.63 <0.001 
Clark level
I-III 1
 IV 1.47 1.15-1.89 0.002 
 V 2.27 1.64-3.15 <0.001 
Ulceration
Absent 1
 Present 2.49 2.03-3.05 <0.001 
Dewar classification
subcapsular 1
 non-subcapsular 1.75 1.31-2.35 <0.001 
Tumor penetrative depth (mm)
continuous 1.19 1.13-1.26 <0.001
≤ 0.5 1
> 0.5 1.77 1.34-2.35 <0.001
S-classification
SI 1
 SII 1.58 1.09-2.28 0.016 
 SIII 1.93 1.38-2.70 <0.001 
Maximum size (mm)
continuous 1.10 1.08-1.12 <0.001
≤ 1 1
 >1 1.96 1.61-2.37 <0.001 
≤ 2 1
 >2 2.17 1.79-2.64 <0.001 
Rotterdam classification (mm)
< 0.1 1
 0.1 – 1.0 1.99 1.21-3.28 0.007 
 >1.0 3.55 2.17-5.80 <0.001 
RDC classification
< 0.1mm subcapsular 1
 < 0.1mm non-subcapsular 1.17 0.43-3.24 NS 
 0.1 – 1.0mm subcapsular 1.80 0.84-3.86 NS 
 0.1 – 1.0mm non-subcapsular 2.05 1.00-4.2 0.050 
 > 1.0mm 3.43 1.69-6.93 0.001 
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Because of multicollinearity between SN tumor burden parameters, four different 
multivariate models were used. Each multivariate model contained the following 
variables: Breslow thickness, age, NSN status, ulceration, and one of the four SN 
tumor burden parameters. Other significant prognostic factors at univariate analyses, 
i.e. sex, melanoma subtype and Clark level, were not included due to insignificance in 
the multivariate model. Significant prognostic factors for poorer MSS in the multivari-
ate models included the presence of non-sub-capsular metastases, TPD >1mm, and 
maximum SN tumor size >1mm (Table 4). The SII sub-group of the S-classification 
and the 0.1-1mm sub-group of the Rotterdam classification did not vary significantly 
from the reference groups (SI and <0.1mm, respectively). (Table 4).
A comparison of the eleven melanoma centers revealed variation in the accuracy 
of survival prediction using the various classification systems (Tables S4, S5). The 
two classifications of maximum SN tumor size (≤ 1mm vs. > 1mm and ≤ 2mm vs. > 
2mm) were the most consistently significant, distinguishing prognostic sub-groups 
for MSS in 6/11 and 5/11 centers and prognostic sub-groups for DFS in 7/11 and 8/11 
centers. TPD and the S-classification were more frequently predictive of DFS than 
MSS. Non-subcapsular tumor location was significantly associated with DFS and MSS 
in only one of nine centers.
diSCuSSioN
Micromorphometric parameters of SN tumor burden (TPD, intranodal tumor loca-
tion and maximum tumor size) were all predictive factors for NSN status (Table 
2), DFS (Table S5) and MSS (Table 3) in this large cohort of SN-positive patients 
Table 3 (continued)
Characteristic Univariate analysis
HR 95% CI p-value
NSN status
Negative 1
 Positive 2.03 1.63-2.52 <0.001 
CLND performed
no 1
 yes 0.87 0.62-1.20 NS 
Year of SNB
1993 - 2002 1
 2003 - 2008 0.89 0.72-1.10 NS 
HR = Hazard Ratio; CI = Confidence Interval; SE = Standard Error; SSM = Superficial Spreading 
Melanoma; NM = Nodular Melanoma; SN = sentinel node; NSN = Non-sentinel node; NS=Not significant
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treated at eleven different centers. The SN classification systems assessed in the study 
significantly differentiated MSS outcomes for each sub-group on univariate analysis 
(Table 3). However, when adjusting for known prognostic factors in multivariate MSS 
analysis, at least one cut-off for each system (S-classification, RDC and Rotterdam 
classifications) failed to significantly differentiate outcome (Table 4). Similarly, not 
all cut-offs significantly stratified risk of NSN positivity or univariate DFS outcomes 
(Table 2 and S5). After adjustment for other clinico-pathologic factors, increasing 
age, increasing Breslow thickness, presence of ulceration and NSN status, non-
subcapsular location (Dewar classification), high TPD (SIII of S-classification) and 
increasing maximum size of tumor (>1mm or >2mm or the Rotterdam comparison 
Table 4 – four different stepwise multivariate Cox’s hazard regression models for 
melanoma-specific survival for all sentinel node positive patients.
Multivariate
Model*
(n)
Significant Variable for SN tumor burden Melanoma Specific Survival
HR 95% CI p-value
#1 Dewar Classification
(n=1159) Breslow° Subcapsular 1
 Age°  Non-Subcapsular 1.49 1.07-2.08 0.018 
 NSN status  
 Ulceration  
#2 S-Classification
(n=679) Breslow° SI 1
Age°  SII 1.49 0.99-2.26 NS 
NSN status  SIII 1.63 1.12-2.38 0.011 
Ulceration  
#3 Rotterdam Classification
(n=1278) Breslow° < 0.1mm 1
Age°  0.1 - 1.0mm 1.75 0.99-3.11 NS 0.001 
NSN status  > 1.0mm 2.56 1.45-4.50 
Ulceration  
#4 RDC Classification
(n=1159) Breslow° < 0.1mm Subcapsular 1
Age°  < 0.1mm Non-Subcapsular 1.26 0.41-3.91 NS 
NSN status  0.1 - 1.0mm Subcapsular 1.54 0.64-3.69 NS 
Ulceration  0.1 - 1.0mm Non-Subcapsular 1.85 0.81-4.25 NS 
 > 1.0mm 2.37 1.05-5.37 0.038 
HR = Hazard Ratio; CI = Confidence Interval; NSN = Non-sentinel node
* Four different multivariate analyses were performed due to multicollinearity between the four 
classifications for sentinel node tumor burden, i.e. modified Dewar Classification, S-Classification, 
Rotterdam Classification and RDC Classification.
° The variables Age and Breslow are continuous variables.
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of >1mm with <0.1mm) were independently associated with poorer MSS (Table 4). 
Patients within the RDC classification subgroup having micrometastases <0.1mm in 
maximum dimension in a subcapsular location had the lowest NSN-positivity rate 
(5.5%) (Table S2).
There was considerable heterogeneity between centers with regard to primary 
tumor characteristics and SN tumor burden features. The differences between centers 
are clear. Median Breslow thickness and ulceration rate ranged from 2.1mm and 
25.5% in the Amsterdam – VUMC center (n=107) to 4.00mm and 67.7% in the Warsaw 
center (n=245) (Table S1). Patients from the Amsterdam – NCI center (n=116) had 
no patients with <0.1mm SN metastases, whilst 27% of the Berlin cohort had <0.1mm 
SN metastases. The percentage of SN-positive patients with subcapsular metastases 
ranged from 4% in the Warsaw cohort to 38% in the Berlin cohort. The median 
maximum SN tumor size for the total group of patients was 0.90mm, with a range of 
0.50-1.70mm. Moreover, no clear correlation between the thickness of the primary 
lesion and the SN tumor burden at each center was apparent (Figure 2). These large 
variations may not only reflect differences in clinical presentation and management 
of melanoma patients in the different centers, but also differences in the methodolo-
figure 2 - Box plot showing the median and 95 percentile of A) the Breslow thickness and B) the 
maximum sentinel node tumor size per center
 
Figure 2  - Box plot showing the median and 95 percentile of A) the Breslow thickness and B) the 
maximum sentinel node tumor size per center 
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gies used to identify, remove and examine SNs, and possibly the use of preoperative 
SN ultrasound screening in some centers.40, 41
SN tumor burden parameters were not of prognostic and predictive value in 
each individual center (Tables S2-S5). In the combined cohort of SN-positive pa-
tients (n=1539), all four SN tumor burden classification systems were independently 
prognostic in univariate analysis for MSS (Table 3, Figure 1), which is in line with 
previous studies of these parameters.6, 22. In those studies, patients with minimal SN 
tumor burden, i.e. < 0.1mm metastases in a subcapsular location, had an excellent 
estimated 5-year MSS of approximately 90%, which is equivalent to that of SN-neg-
ative patients.6 However, in the combined cohort of the present study, patients with 
micrometastases <0.1mm had an 83% 5-year MSS, whilst patients with subcapsular 
metastases (of any size) had a 5-year MSS of 72% (Figure 1). This suggests that the 
excellent 5-year MSS estimate reported in the earlier studies6 may have been influ-
enced by lead-time bias. However, follow-up has not been extended compared to 
the earlier study. The only difference between earlier results and results of this study 
is the addition of data from two centers. It is nevertheless important to bear in mind 
that for patients with SN micrometastases <0.1mm in maximum dimension, 5-year 
survival figures may be misleading because if recurrence does occur, it is likely 
to be much later than recurrence in patients with larger SN metastases. This was 
demonstrated clearly in the AJCC Melanoma Database analysis, which highlighted 
the very great differences in prognosis and time to recurrence for patients with 
nodal micrometastases and those with nodal macrometastases10. When the data were 
analyzed by center, there were substantial differences in the prognosis for patients 
with minimal SN tumor burden (<0.1mm), with the MSS ranging from 54% to 100% 
in different centers.
In all centers, SNs were detected by preoperative lymphoscintigraphy and identi-
fied at the time of surgery with blue dye and a gamma probe.32, 33, 42, 43 However, 
as detailed in the Methods section, there were some important differences in how 
SNs were identified in different centers. These differences may have influenced the 
results of this study because it is well documented that variations in any part of the 
SNB technique (including in nuclear medicine, surgery and pathology) can affect 
the accuracy of SNB.44-46 There were also differences between protocols utilized for 
SN pathology assessment at MIA and most of the European melanoma centers. The 
main difference was the larger number of sections cut from each half of the SN in 
European centers. Furthermore, the EORTC protocol was altered slightly during the 
period of this study (as detailed in the supplementary methods). Potentially these 
differences could be important because examination of extra sections of SNs can 
increase the SN positivity rate.14, 34, 37, 39, 47-49 The number of sections pathologically 
examined and the distance between the sections may also affect the reported size, 
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location and TPD of melanoma metastases in a SN and therefore its sub-classification 
according to the various proposed classification schemes. In view of this it might 
be predicted that an increase in the SN-positivity rate might be associated with an 
increase in the detection rate of minimal SN tumor burden cases.14 Interestingly, 
the percentage of patients with minimal SN tumor burden (<0.1mm) in our study 
differed significantly between individual European centers (where a greater number 
of sections were cut, allegedly according to the same protocol) (Table S1, Figure 2) 
but was not significantly different in the Australian cohort compared to the European 
cohort overall.
In conclusion, primary tumor and SN tumor burden parameters assessed in this 
large retrospective multicenter study have been shown to provide valuable prognos-
tic information in SN-positive patients. A maximum SN tumor size >1mm separated 
the cohort into two groups of similar size, and was the most consistent independent 
predictor of NSN positivity and poorer DFS and MSS in individual centers, and in the 
combined cohort. The study has provided valuable insights into the prognostic value 
of SN tumor burden assessment in patients with melanoma. However, prospective 
studies with long term follow-up are clearly required to establish a classification 
system for SN tumor burden that consistently and accurately stratifies patients into 
meaningful prognostic groups with respect to NSN-positivity and survival outcomes, 
and is not unduly affected by minor variations in SN identification and examination 
protocols.
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Table S2 – Maximum size and tumor penetrative depth (mm) assessed as continuous variables at 
each individual center and in the total cohort, for the following outcomes: non-sentinel node (NSN) 
status, melanoma-specific survival (MSS), and disease-free survival (DFS).
Centre Name N
Maximum Size (mm)
N
Tumor Penetrative Depth (mm)
OR/HR 95% CI P-value OR/HR 95% CI P-value
NSN Status
Rotterdam 101 - - NS 69 - - NS
Berlin 77 2.07 1.33-3.20 0.001 29 - - NS
Warsaw 243 1.09 1.02-1.16 0.009 - - - -
Guildford 189 - - NS - - - -
Amsterdam NKI 116 1.32 1.02-1.72 0.035 116 - - NS
Villejuif 66 1.41 1.07-1.87 0.015 - - - -
Amsterdam VU 97 - - NS - - - -
Groningen 55 - - NS 55 - - NS
Milan 65 - - NS 65 - - NS
Padova 104 1.18 1.05-1.32 0.005 104 1.38 1.16-1.64 <0.001
Sydney 268 - - NS 268 1.44 1.18-1.75 <0.001
Overall 1381 1.11 1.07-1.15 <0.001 706 1.26 1.15-1.38 <0.001
MSS
Rotterdam 113 1.13 1.02-1.26 0.016 80 1.23 1.01-1.51 0.045
Berlin 87 1.33 1.03-1.72 0.032 28 - - NS
Warsaw 238 1.06 1.02-1.10 0.002 - - - -
Guildford 211 1.11 1.04-1.18 0.001 - - - -
Amsterdam NKI 114 1.18 1.00-1.39 0.057 114 1.18 1.00-1.39 0.055
Villejuif 61 - - NS - - - -
Amsterdam VU 103 - - NS - - - -
Groningen 55 - - NS 55 - - NS
Milan 65 1.28 1.09-1.50 0.003 65 1.27 1.06-1.53 0.01
Padova 109 1.16 1.08-1.24 <0.001 109 1.18 1.07-1.29 <0.001
Sydney 345 1.11 1.05-1.18 <0.001 345 1.18 1.05-1.33 0.005
Overall 1533 1.1 1.08-1.12 <0.001 807 1.19 1.13-1.26 <0.001
DFS
Rotterdam 115 1.1 1.02-1.20 0.018 80 1.26 1.07-1.48 0.007
Berlin 87 1.31 1.10-1.57 0.003 32 - - NS
Warsaw 242 1.05 1.02-1.08 0.003 - - - -
Guildford 206 1.08 1.02-1.15 0.009 - - - -
Amsterdam NKI 114 1.26 1.10-1.44 0.001 114 1.3 1.14-1.48 <0.001
Villejuif 67 1.18 1.00-1.38 0.049 - - - -
Amsterdam VU 107 - - NS - - - -
Groningen 56 - - NS 56 - - NS
Milan 71 - - NS 71 - - NS
Padova 109 1.15 1.08-1.22 <0.001 109 1.16 1.07-1.25 <0.001
Sydney 350 1.1 1.04-1.16 <0.001 350 1.18 1.06-1.31 0.002
Overall 1539 1.09 1.07-1.11 <0.001 817 1.18 1.13-1.24 <0.001
OR=Odds ratio computed for NSN status; HR=Hazard ratio computed for MSS and DFS; NS=Not 
significant; NSN=Non-sentinel node; MSS=Melanoma-specific survival; DFS=Disease-free survival
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AbSTRACT
The therapeutic value of immediate completion lymph node dissection (CLND) for 
sentinel node (SN)-positive melanoma patients is unknown. The aim of this study 
was to evaluate the impact of immediate CLND on the outcome of patients with 
SN-positive melanoma.
Patients with SN metastases treated between 1993 and 2008 at ten cancer centers 
from the European Organization for Research and Treatment of Cancer Melanoma 
Group. Maximum tumor size, intranodal location and penetrative depth of SN metas-
tases were measured. Outcome in those who had CLND was compared with that in 
patients who did not undergo completion lymphadenectomy.
Of 1174 patients with SN-positive melanoma, 1113 (94.8 per cent) underwent 
CLND and 61 (5.2 per cent) did not. Median follow-up for the two groups was 34 and 
48 months respectively. In univariable survival analysis, CLND did not significantly 
influence disease-specific survival (hazard ratio (HR) 0.89, 95 per cent confidence 
interval 0.58 to 1.37; P = 0.600). However, patients who did not undergo CLND had 
more favourable prognostic factors. Matched-pair analysis, with matching for age, 
Breslow thickness, tumour ulceration and SN tumour burden, showed that CLND 
had no influence on survival (HR 0.86, 0.46 to 1.61; P = 0.640). After adjusting for 
prognostic factors in multivariable survival analyses, no difference in survival was 
found.
In these two cohorts of patients with positive SN and with prognostic heterogene-
ity, outcome was not influenced by CLND.
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iNTRoduCTioN
In most countries, sentinel node biopsy (SNB) has become part of the standard 
management of patients with early-stage melanoma. SN tumour burden is the most 
important prognostic factor for survival, but an overall survival benefit for patients 
undergoing SNB versus wide local excision (WLE) alone has not been demonstrated1. 
Approximately 80 per cent of patients with early-stage melanoma who undergo SNB 
have a negative SN and no further surgical treatment is indicated. Completion lymph 
node dissection (CLND) for patients diagnosed with one or more positive SNs is 
performed routinely in most centres, although therapeutic evidence for such routine 
treatment is lacking2,3. In roughly 80 per cent of patients treated with CLND no 
additional non-SN metastases are detected. The value of CLND could therefore be 
questioned. This is important because the morbidity of CLND can be significant in 
terms of wound infections and chronic lymphoedema.
It might not be justified to consider patients with SN-positive disease as a single 
group because their prognosis is heterogeneous4. Patients with a high SN tumour 
burden have a significantly worse outcome than those with a low burden4–6. Mi-
crometastases located in the subcapsular space have a better prognosis than those 
located elsewhere4,7. Outcome might be based on tumour biology and not on earlier 
removal of low-volume nodal disease. Some authors have suggested that not all 
patients with a positive SN might need to undergo CLND2,4,6,8–12, whereas others have 
reported that CLND is necessary in all patients with SN-positive disease13–17.
Two retrospective studies have described no significant difference in outcome 
of patients with SN-positive melanoma between those who underwent CLND and 
those who did not2,3. However, heterogeneity with respect to SN tumour burden was 
not taken into consideration in these reports. The aim of the present study was to 
evaluate the influence of immediate CLND on outcome in patients with SN-positive 
melanoma. The maximum tumour size, intranodal location and penetrative depth of 
the SN metastases were considered in the analyses.
MeThodS
Patients
Patients diagnosed with SN metastases after WLE of malignant melanoma between 
1993 and 2008 at ten major cancer centres collaborating in the European Organiza-
tion for Research and Treatment of Cancer Melanoma Group (EORTC MG) who did 
not undergo CLND were included in this retrospective multicentre study. Tumour 
size, location and penetrative depth of SN tumour were measured. The control group 
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comprised patients with SN-positive melanoma who were treated with immediate 
CLND at the same centres, within the same time frame. Data were registered in a 
database, including patient details, and information on the primary melanoma, SNB, 
SN tumour burden and follow-up.
Surgery
After diagnostic excision or biopsy of the primary melanoma, all patients underwent 
WLE to achieve margins of 1 cm for melanomas with a Breslow thickness of 2 mm 
or less and at least 2 cm for melanomas larger than 2 mm. In most patients SNB was 
performed simultaneously with WLE of the primary tumour. Patients were eligible 
for SNB if the primary tumour had a Breslow thickness of 1 mm or more, or if the 
tumour had other adverse prognostic factors such as ulceration or Clark level IV or V.
The SNB procedure has been described in detail elsewhere18,19. It consisted of 
preoperative lymphoscintigraphy, undertaken within 24 h of perioperative injection 
of patent detection probe toγblue dye near the excision mark and use of a handheld 
detect SNs. Lymph nodes were identified as SNs if they had an afferent blue lymph 
duct originating at the melanoma site, were stained blue, had an in situ radioactivity 
count of at least three times the background count or an ex vivo radioactivity count 
of at least ten times the background count20,21.
Pathology
After SNB, the identified SNs were sent to the pathology department. The EORTC MG 
pathology protocol described by Cook and colleagues22 was used for investigation of 
the nodes. SNs were fix in buffered formalin for 24 h, bisected through the hilum in 
its longest dimension and embedded in paraffin. Five serial step sections of 4 μm each 
were cut at 50–100-μm intervals from each side of the lymph node. All sections were 
stained with haematoxylin and eosin, and S100 and/or Melan-A. There were slight local 
differences in protocol between centres, but the main principles remained the same.
Three melanoma specialists and/or pathologists of the EORTC MG reviewed the 
SN slides. Patients for whom it was difficult to determine parameters of SN tumour 
burden were discussed during twice yearly EORTC MG meetings. The maximum size 
of the largest lesion was measured and classified according to the Rotterdam criteria 
(smaller than 0.1 mm, 0.1–1.0 mm, larger than 1.0 mm)4,6,9, tumour penetrative depth 
according to the S-classification (less or equal to 0.3 mm, 0.3–1.0 mm, larger than 1.0 
mm)5, and the intranodal location of metastases according to a modified version of 
the Dewar criteria (subcapsular, non-subcapsular)7. The Rotterdam– Dewar combined 
(RDC) criteria were derived from the size and location of the metastases (less than 
0.1 mm subcapsular, less than 0.1 mm non-subcapsular, 0.1–1.0 mm subcapsular, 
0.1–1.0 mm non-subcapsular, larger than 1.0 mm)4.
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Statistics
Continuous variables are reported as median (interquartile range), unless specified 
otherwise. The Mann–Whitney U χtest, 2 test and Fisher’s exact test were used to de-
termine differences between groups. To allow for differences in group characteristics 
identified in the overall univariable analysis, a matched-pair analysis was performed, 
in which patients from the study group were matched with those in the control 
group with respect to age category, Breslow thickness, tumour ulceration, Rotterdam 
criteria, Dewar criteria, S-classification and RDC criteria.
Disease-specific survival (DSS) was calculated from date of SNB until the date of 
death from melanoma. Univariable survival analyses were carried out by means of 
Kaplan–Meier curves and log rank tests. Multivariable analyses were performed with 
four Cox hazard regression models owing to multicolinearity between the four mi-
cromorphometric parameters of SN tumour burden (Dewar criteria, S-classification, 
Rotterdam criteria and RDC criteria). A statistical measure of model fit, the Akaike 
information criterion index (AIC index = –2 × log likelihood of the model + 2 
× number of parameters included in the model) was assessed for each model23; 
lower values of the index indicated the preferred model, which included the fewest 
parameters and had the strongest prognostic importance. Statistical analysis was 
done using Stata® version 11 (StataCorp LP, College Station, Texas, USA).
ReSuLTS
Among a total of 1174 patients with SN-positive melanoma, 1113 (94.8 per cent) 
underwent immediate CLND and 61 (5.2 per cent) did not. Reasons for not having 
immediate completion lymphadenectomy included: refusal of further treatment or 
significant co-morbidity (46 patients), minimal SN tumour burden (smaller than 0.1 
mm) or decision not to undergo CLND after consultation with physician(s) (15). The 
distribution of patients among the ten participating centres is shown in Table S1 
(supporting information).
The Rotterdam criteria were determined in all 61 patients who did not undergo 
immediate CLND, the S-classification in 32 (52 per cent), and the Dewar and RDC 
criteria in 53 (87 per cent). The Rotterdam criteria were determined in all 1113 
patients who underwent CLND, the S-classification in 483 (43.4 per cent), and the 
Dewar and RDC criteria in 989 (88.9 per cent).
The median Breslow thickness was 2.50 (1.60–4.00) mm in patients did not un-
dergo CLND and 3.00 (1.90–4.80) mm in those who did (P = 0.121). Patients without 
immediate CLND were less likely to have melanoma located on the trunk and had 
fewer positive SNs; they more often had subcapsular micrometastases (Dewar crite-
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ria), smaller tumours (Rotterdam criteria) and less penetrative depth (S-classification). 
The patients who underwent CLND were younger (Table 1) .
Median follow-up was 48 (25–70) and 34 (20–60) months in the CLND and no-
CLND groups respectively (P = 0.030). Median follow-up among the 61 matched 
patients who underwent CLND was 44 months (P = 0.704).
Table 1 – Baseline characteristics of 1174 patients with sentinel node-positive melanoma
Characteristic CLND
n (per cent)
1113 (94.8)
No CLND
n (per cent)
61 (5.2)
p*
Gender
Female 525 (47.2) 33 (54.1)
Male 588 (52.8) 28 (45.9) 0.296
Age (years)
Median (IQR) 51 (40 – 62) 60 (49 – 73) < 0.001
≤ 50 518 (46.5) 16 (26.2)
≥ 50 595 (53.5) 45 (73.8) 0.002
Site of primary
Extremity 489 (44.5) 37 (60.7)
Trunk 463 (42.1) 18 (29.5)
Head & Neck 148 (13.5) 6 (9.8) 0.047
Missing 13 [1.2] 0 [0.0]
Histology
SSM 406 (47.9) 28 (65.1)
NM 380 (44.8) 13 (30.2)
Other 62 (7.3) 2 (4.7) 0.088
Missing 265 [23.8] 18 [27.7]
Breslow thickness (mm)
Median (IQR) 3.00 (1.90 – 4.80) 2,50 (1,60 – 4,00) 0.121
≤ 1.00 58 (5.2) 5 (8.2)
> 1.00 – ≤ 2.00 275 (24.8) 19 (31.2)
> 2.00 – ≤ 4.00 440 (39.8) 22 (36.1)
> 4.00 334 (30.2) 15 (24.6) 0.449
Missing 6 [5.4] 0 [0.0]
Clark level
II-III 310 (29.1) 9 (15.0)
IV 635 (59.6) 42 (70.0)
V 121 (11.4) 9 (15.0) 0.059
Missing 47 [4.2] 1 [1.7]
Ulceration
Absent 516 (50.6) 31 (55.4)
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Table 1 (continued)
Characteristic CLND
n (per cent)
1113 (94.8)
No CLND
n (per cent)
61 (5.2)
p*
Present 504 (49.4) 25 (44.6) 0.496
Missing 93 [8.4] 5 [8.2]
Site of SNB
Groin 286 (39.5) 23 (53.5)
Axilla 384 (53.0) 15 (34.9)
Neck 55 (7.6) 5 (11.6) 0.067
Missing 388 [34.9] 18 [29.5]
Number of excised SNs
Median (range) 2 (1 – 12) 2 (1 – 5) 0.778
1 359 (39.6) 20 (44.4)
2 307 (33.9) 12 (26.7)
≥ 3 240 (26.5) 13 (28.9) 0.976
Missing 207 [18.6] 16 [14.4]
Number of positive SNs
Median (range) 1 (1 – 5) 1 (1 – 3) 0.008
1 716 (78.5) 43 (95.6)
2 157 (17.2) 1 (2.2)
≥3 38 (4.2) 1 (2.2) 0.093
Missing 202 [18.1] 16 [14.4]
Intranodal location
(Dewar)
Subcapsular 173 (17.5) 16 (30.7)
Non-subcapsular 816 (82.5) 36 (69.2) 0.025
Missing 124 [11.1] 9 [14.8]
Tumor penetrative depth (mm)
(S-classification)
Median (IQR) 0.80 (0.30 – 2.10) 0.40 (0.20 – 1.27) 0.024
SI 126 (26.1) 13 (40.6)
SII 132 (27.3) 10 (31.3)
SIII 225 (46.6) 9 (28.1) 0.092
Missing 630 [56.6] 29 [47.5]
Maximum size (mm)
(Rotterdam criteria)
Median (IQR) 1.40 (0.40 – 4.00) 0.40 (0.08 – 1.15) < 0.001
< 0.1 101 (9.1) 15 (24.5)
0.1 – 1.0 462 (41.5) 30 (49.2)
> 1.0 550 (49.4) 16 (26.2) < 0.001
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Survival
Univariable analyses demonstrated that the following factors were associated with 
DSS: sex, age, histology of the primary tumour, Breslow thickness, Clark level, tumour 
ulceration, number of positive SNs, Dewar criteria, S-classification, Rotterdam criteria 
and RDC criteria (Table 2). CLND was not a significant prognostic factor for DSS 
(hazard ratio (HR) 0.89, 95 per cent confidence interval (c.i.) 0.58 to 1.37; P = 0.600).
Table 1 (continued)
Characteristic CLND
n (per cent)
1113 (94.8)
No CLND
n (per cent)
61 (5.2)
p*
Maximum size and location
(RDC criteria)
< 0.1 mm subcapsular 45 (4.4) 10 (18.2)
< 0.1 mm non-subcapsular 37 (3.6) 4 (7.3)
0.1 – 1.0 mm subcapsular 114 (11.1) 5 (9.1)
0.1 – 1.0 mm non-subcapsular 284 (27.6) 20 (36.4)
> 1.0 mm 509 (53.4) 13 (29.1) < 0.001
Missing 124 [11.1] 9 [14.8]
SN = sentinel node; SNB=sentinel node biopsy; CLND = completion lymph node dissection; IQR = 
Interquartile range; RDC = Rotterdam Dewar Combined; SSM = Superficial spreading melanoma; NM 
= Nodular melanoma;
*p-values are calculated using the Fisher exact test, chi-square test or Mann-Whitney U test to evaluate 
differences between patients with CLND (n=1113) and patients without CLND (n=61)
Table 2 – Univariable analysis of disease-specific survival for all patients with sentinel node-positive 
melanoma
Univariable analyses
Variable HR 95 per cent CI p*
Gender
Female 1
Male 1.32 1.06 – 1.64 0.014
Age 1.14 1.06 – 1.22 0.001
Site of primary
Extremity 1
Trunk 1.09 0.86 – 1.38 0.485
Head and neck 1.06 0.76 – 1.48 0.738
Missing 0.97 0.40 – 2.40 0.954
Histology
SSM 1
NM 1.40 1.08 – 1.82 0.011
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Table 2 (continued)
Univariable analyses
Variable HR 95 per cent CI p*
Other 2.03 1.31 – 3.15 0.002
Missing 1.34 0.99 – 1.81 0.058
Breslow thickness (mm)
≤ 2.00 1
> 2.00 – ≤ 4.00 1.76 1.30 – 2.39 < 0.001
> 4.00 3.44 2.55 – 4.64 < 0.001
Clark level
II-III 1
IV 1.49 1.13 – 1.98 0.005
V 2.52 1.76 – 3.59 < 0.001
Missing 1.46 0.79 – 2.71 0.226
Ulceration
Absent 1
Present 2.49 1.96 – 3.16 < 0.001
Missing 1.54 1.01 – 2.34 0.047
Site of SNB
Groin 1
Axilla 1.32 1.00 – 1.75 0.051
Neck 1.33 0.84 – 2.11 0.223
Missing 0.92 0.69 – 1.22 0.544
Number of excised SNs
1 1
2 0.83 0.63 – 1.10 0.202
≥ 3 1.07 0.80 – 1.44 0.641
Missing 0.95 0.69 – 1.30 0.745
Number of positive SNs
1 1
2 1.56 1.16 – 2.10 0.003
≥3 1.08 0.56 – 2.11 0.813
Missing 1.07 0.80 – 1.44 0.646
Intranodal location
(Dewar)
Subcapsular 1
Non-subcapsular 2.08 1.46 – 2.97 < 0.001
Missing 1.23 0.77 – 1.97 0.393
Tumour penetrative depth
(S-classification)
SI 1
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The results of the matched-pairs analysis of patients with and without CLND are 
shown in Table 3. Median Breslow thickness was 2.50 mm in both groups, and 31 
per cent of patients in each group had subcapsular metastases. Median maximum SN 
tumour size was 0.40 mm in both groups. In matched-pair analysis, CLND did not 
significantly influence DSS (HR 0.86, 0.46 to 1.61; P = 0.640).
To adjust for the prognostic imbalance in baseline factors between groups, 
multivariable analysis was carried out, using four different models owing to the 
multicolinearity of the SN tumour burden characteristics (Table 4). Factors indepen-
dently associated with significantly worse DSS in all four analyses were older age, 
increased Breslow thickness and tumour ulceration. In all models, the SN tumour 
burden characteristic was also a significant prognostic factor, but CLND had no 
significant influence on prognosis in any of the models (Table 4). However, there 
was a trend towards improved outcome for patients who underwent CLND. HRs in 
the four models were 0.81 (95 per cent c.i. 0.52 to 1.25; P = 0.340), 0.82 (0.53 to 1.27; 
P = 0.377), 0.74 (0.48 to 1.16; P = 0.189) and 0.73 (0.47 to 1.14; P = 0.169) for CLND 
Table 2 (continued)
Univariable analyses
Variable HR 95 per cent CI p*
SII 2.00 1.21 – 3.31 0.007
SIII 2.63 1.65 – 4.19 < 0.001
Missing 2.52 1.63 – 3.89 < 0.001
Maximum size (mm)
(Rotterdam criteria)
< 0.1 1
0.1 – 1.0 2.33 1.29 – 4.23 0.005
> 1.0 4.28 2.39 – 7.67 < 0.001
Maximum size and location
(RDC criteria)
< 0.1 mm subcapsular 1
< 0.1 mm non-subcapsular 2.08 0.59 – 7.38 0.256
0.1 – 1.0 mm subcapsular 2.77 0.97 – 7.88 0.056
0.1 – 1.0 mm non-subcapsular 3.49 1.28 – 9.56 0.015
> 1.0 mm 5.70 2.12 – 15.36 0.001
Missing 2.78 0.99 – 7.85 0.053
CLND
Not performed 1
Performed 0.89 0.58 – 1.37 0.600
HR = Hazard ratio; CI= Confidence Interval; SSM = Superficial spreading melanoma; NM = Nodular 
melanoma; SNB = sentinel node biopsy; SN = sentinel node; CLND = Completion lymph node dissection
*p-values are calculated using the log rank test
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Table 3 – Baseline characteristics of patients selected for matched-pair analysis.
Characteristic No CLND
n (per cent)
61 (5.2)
CLND †
(matched)
n (per cent)
61
p*
Gender
Female 33 (54.1) 28 (45.9)
Male 28 (45.9) 33 (54.1) 0.469
Age (years)
Median (IQR) 60 (49 – 73) 59 (49 – 68) 0.458
≤ 50 16 (26.2) 16 (26.2)
≥ 50 45 (73.8) 45 (73.8) 1.000
Site of primary
Extremity 37 (60.7) 33 (54.1)
Trunk 18 (29.5) 21 (34.4)
Head & Neck 6 (9.8) 7 (11.5) 0.765
Missing 0 [0.0] 0 [0.0]
Histology
SSM 28 (65.1) 26 (56.5)
NM 13 (30.2) 18 (39.1)
Other 2 (4.7) 2 (4.4) 0.677
Missing 18 [27.7] 15 [24.6]
Breslow thickness (mm)
Median (IQR) 2,50 (1,60 – 4,00) 2,50 (1,55 – 4,00) 0.959
≤ 1.00 5 (8.2) 5 (8.2)
> 1.00 – ≤ 2.00 19 (31.2) 19 (31.2)
> 2.00 – ≤ 4.00 22 (36.1) 22 (36.1)
> 4.00 15 (24.6) 15 (24.6) 1.000
Missing 0 [0.0] 0 [0.0]
Clark level
II-III 9 (15.0) 20 (34.5)
IV 42 (70.0) 33 (56.9)
V 9 (15.0) 5 (8.6) 0.042
Missing 1 [1.7] 3 [4.9]
Ulceration
Absent 31 (55.4) 31 (55.4)
Present 25 (44.6) 25 (44.6) 1.000
Missing 5 [8.2] 5 [8.2]
Site of SNB
Groin 23 (53.5) 21 (42.0)
Axilla 15 (34.9) 24 (48.0)
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Table 3 (continued)
Characteristic No CLND
n (per cent)
61 (5.2)
CLND †
(matched)
n (per cent)
61
p*
Neck 5 (11.6) 5 (10.0) 0.438
Missing 18 [29.5] 11 [18.0]
Number of excised SNs
Median (range) 2 (1 – 5) 2 (1 – 5) 0.176
1 20 (44.4) 28 (53.9)
2 12 (26.7) 16 (30.8)
≥ 3 13 (28.9) 8 (15.4) 0.552
Missing 16 [14.4] 16 [14.4]
Number of positive SNs
Median (range) 1 (1 – 3) 1 (1 – 2) 0.142
1 43 (95.6) 45 (86.5)
2 1 (2.2) 7 (13.5)
≥3 1 (2.2) 0 (0.0) 0.079
Missing 16 [14.4] 9 [14.8]
Intranodal location
(Dewar)
Subcapsular 16 (30.7) 16 (30.7)
Non-subcapsular 36 (69.2) 36 (69.2) 1.000
Missing 9 [14.8] 9 [14.8]
Tumor penetrative depth (mm)
(S-classification)
Median (IQR) 0.40 (0.20 – 1.27) 0.45 (0.20 – 1.10) 0.989
SI 13 (40.6) 13 (40.6)
SII 10 (31.3) 10 (31.3)
SIII 9 (28.1) 9 (28.1) 1.000
Missing 29 [47.5] 29 [47.5]
Maximum size (mm)
(Rotterdam criteria)
Median (IQR) 0.40 (0.08 – 1.15) 0.40 (0.10 – 1.10) 0.881
< 0.1 15 (24.5) 15 (24.5)
0.1 – 1.0 30 (49.2) 30 (49.2)
> 1.0 16 (26.2) 16 (26.2) 1.000
Maximum size and location
(RDC criteria)
< 0.1 mm subcapsular 10 (18.2) 10 (18.2)
< 0.1 mm non-subcapsular 4 (7.3) 4 (7.3)
0.1 – 1.0 mm subcapsular 5 (9.1) 5 (9.1)
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Table 3 (continued)
Characteristic No CLND
n (per cent)
61 (5.2)
CLND †
(matched)
n (per cent)
61
p*
0.1 – 1.0 mm non-subcapsular 20 (36.4) 20 (36.4)
> 1.0 mm 13 (29.1) 16 (29.1) 1.000
Missing 9 [14.8] 9 [14.8]
The two groups were matched for age category, Breslow thickness category, ulceration, Dewar criteria, 
S-classification, Rotterdam criteria and Rotterdam-Dewar combined (RDC) criteria. SN = sentinel 
node; SNB=sentinel node biopsy; CLND = completion lymph node dissection; IQR = Interquartile 
range; RDC = Rotterdam Dewar Combined
* p-values are calculated using the Fisher exact test, chi-square test or Mann-Whitney U test to evaluate 
differences between the matched pairs, i.e. patients with CLND (n=61) and patients without CLND 
(n=61)
Table 4 four different multivariable analyses of disease-specific survival for all patients with 
sentinel node-positive melanoma
Model Target variable HR 95 per cent c.i. p Other included (all significant) 
variables
AIC index *
A CLND Age - 224.08
Not performed 1 Breslow thickness
Performed 0.81 0.52 – 1.25 0.34 Ulceration
Intranodal location (Dewar criteria)
B CLND Age -223.04
Not performed 1 Breslow thickness
Performed 0.82 0.53 – 1.27 0.38 Ulceration
Tumor penetrative depth 
(S-classification)
C CLND Age -242.86 *
Not performed 1 Breslow thickness
Performed 0.74 0.48 – 1.16 0.19 Ulceration
Maximum size (Rotterdam criteria)
D CLND Age -235.86
Not performed 1 Breslow thickness
Performed 0.73 0.47 – 1.14 0.17 Ulceration
Maximum size and intranodal 
location (RDC criteria)
HR = Hazard ratio; c.i.= Confidence Interval; SN = sentinel node; CLND = Completion lymph node 
dissection; RDC = Rotterdam Dewar Combined;
AIC = Akaike Information Criteria
* AIC index = statistical model fit measure for aid to choosing between competing models. Lower values 
of the index indicate the preferred model, that is, the one with the fewest parameters and the strongest 
prognostic importance (Model C).
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versus no CLND. The AIC index indicated that the model including the Rotterdam 
criteria was the preferred model (AIC index –242.86) (Table 4).
Subgroup analyses were performed in which the DSS was stratified by SN tumour 
burden. After correcting for age, Breslow thickness and tumour ulceration in multi-
variable analyses, no significant benefit of CLND was found in any subgroup (Table 
S2, supporting information).
Three and 5-year DSS rates were 74 and 66 per cent for patients who did not 
undergo CLND, compared with 76.9 and 66.9 per cent respectively for those who 
had immediate CLND (HR 0.89, 0.58 to 1.37; P = 0.600) (Fig. 1a). Rates for the 61 
patients who underwent CLND included in the matched-pair analysis were 79 and 
69 per cent (HR 0.86, 0.46 to 1.61; P = 0.640) (Fig. 1b).
diSCuSSioN
In the present study patients with SN-positive melanoma who had CLND did not 
have better outcome than those who did not undergo completion lymphadenectomy. 
Estimated 5-year DSS rates were 66.9 and 66 per cent respectively. No significant 
differences in survival were identified by matched-pair analysis or after correcting for 
other significant prognostic factors in multivariable analyses.
figure 1 – Disease specific survival for sentinel node positive patients who did and who did not 
undergo immediate completion lymph node dissection for A) the total group of patients and B) after 
matched pair analysis
Figure A: total cohort Figure B: after matched pair analysis
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Figure 1 Disease specific survival for sentinel node positive patients who did and who did not undergo 
immediate completion lymph node dissection for A) the total group of patients and B) after matched 
pair analysis 
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Nr at Risk Nr at Risk 
No CLND 61 57 49 40 31 22 No CLND 61 57 49 40 31 22 
CLND 1113 990 773 529 396 287 CLND 61 55 45 36 26 22 
Total 1174 1047 822 579 427 309 Total 122 112 94 76 57 44 
Nr at Risk Nr at Risk
No CLND 61 57 49 40 31 2 No D 61 57 49 40 3 22
CLND 1113 990 773 529 396 287 CLND 61 55 45 36 26 22
Total 1174 1047 822 579 427 309 Total 122 112 94 76 57 44
HR = Hazard Ratio, CLND = Completion Lymph Node Dissection
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The group that did not undergo CLND had a favourable prognosis in terms of 
patient characteristics, the primary melanoma and SN tumour burden, including a 
smaller maximum SN tumour size. Therefore, it could not be ruled out that the total 
group of patients with SN-positive disease could benefit from CLND. A matched-pair 
analysis was undertaken to evaluate the outcome, but it did not demonstrate a 
significant different between the two groups. However, the groups of patients were 
not representative of the population with SN-positive melanoma as they had less 
tumour burden, were older and had thinner primary tumours. Thus, selection bias 
occurred in the present study.
In most cancer centres, immediate CLND is standard management for melanoma 
with SN metastases. However, Bilimoria and colleagues24 demonstrated, surprisingly, 
that only 50 per cent of patients with melanoma diagnosed with a positive SN in 
2004 and 2005 underwent CLND. Therefore, it remains uncertain whether CLND is 
of therapeutic benefit in patients with SN-positive melanoma. Some investigators 
have stated that all patients with a positive SN should undergo completion lymph-
adenectomy13–17, whereas other studies have suggested that some of these patients 
might be spared immediate CLND2,4,6,8–10. No additional metastases are detected in 
approximately 80 per cent of patients undergoing CLND. Furthermore, CLND is 
associated with considerable greater morbidity than SNB alone25–30. Results from the 
Sunbelt Melanoma Trial demonstrated complication rates of 23 per cent after CLND 
and 5 per cent for patients who underwent SNB alone29. Quality of life was worse in 
those who underwent CLND than in patients who underwent SNB alone31.
Two retrospective studies of patients with SN-positive melanoma have reported 
comparisons of outcome in those who had CLND versus those who did not2,3. With 
a median follow-up of 36 and 20 months respectively, nodal recurrence-free survival 
and DSS were similar in both groups in the study by Wong and colleagues3. How-
ever, similar to the present study, selection bias was evident, a problem highlighted 
by Henderson32. In the other study, recurrence-free survival and DSS were similar 
in 271 patients who underwent CLND and 42 patients who did not, with median 
follow-up of 43 and 32 months respectively2. These retrospective studies did not 
report on SN tumour burden, although this is the most important prognostic factor 
for survival6. Differences in SN tumour burden between groups could therefore have 
affected outcome.
The prognosis among patients with SN-positive melanoma is highly heteroge-
neous. Patients with a minimal SN tumour burden, especially when located in the 
subcapsular area, might be spared CLND, as their 5-year DSS is 95 per cent and the 
chance of additional non-SN metastases is 2 per cent4. Therefore, subgroup analyses 
were performed in the present study, with comparison of outcomes stratified by 
SN tumour burden. In univariable analyses, the outcome of patients with microme-
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tastases and/or subcapsular located metastases was not significantly different (data 
not shown). After correcting for age, Breslow thickness and tumour ulceration in 
multivariable analyses, no significant difference in outcome was demonstrated in 
any of the subgroups. However, all analyses were based on small subgroups with 
few events and should therefore be interpreted with caution. For S-classification 
and tumour location, HRs for melanoma-related death decreased with increased SN 
tumour burden. These results suggest that patients with a higher SN tumour burden 
might benefit more from CLND than patients with a lower burden. However, this 
was not seen for the Rotterdam or RDC criteria. The AIC index indicated that the 
multivariable model including the Rotterdam criteria was strongest, followed by that 
including the RDC. However, these results should again be interpreted with caution, 
as they are based on subgroups containing a limited number of patients and events 
in a retrospective, non-randomized setting.
This study has demonstrated no significant difference in outcome among patients 
with SN-positive melanoma between those who underwent immediate CLND and 
those who did not, in either in multivariable or matched-pair analysis. However, 
the outcome in patients who did not have CLND was better than expected because, 
among other factors, these patients more often had smaller micrometastases that 
were located subcapsularly. Ongoing prospective studies, such as the MINITUB 
Study and Multicentre Selective Lymphadenectomy Trial II, should provide informa-
tion regarding the possible therapeutic benefit of CLND in patients with a positive 
SN and indicate which patients might safely be spared this procedure, eventually 
leading to a change in practice.
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SuPPLeMeNTARy TAbLeS
Suppl. Table 1 – Number of patients treated in each center
Centre CLND
n (per cent)
1113 (94.8)
No CLND
n (per cent)
61 (5.2)
CLND
(matched)
n (per cent)
61
DDHCC 101 (9.1) 13 (21.3) 13 (21.3)
CHUB 76 (6.8) 9 (14.8) 2 (3.3)
MMCCIO 244 (21.9) 0 (0.0) 10 (16.4)
RSCH 189 (17.0) 16 (26.2) 9 (14.8)
AVL 116 (10.4) 0 (0.0) 2 (3.3)
IGR 66 (5.9) 1 (1.6) 0 (0.0)
VUMC 97 (8.7) 9 (14.8) 8 (13.1)
UMCG 55 (4.9) 1 (1.6) 4 (6.6)
EIO 65 (5.8) 7 (11.5) 5 (8.2)
UP 104 (9.3) 5 (8.2) 8 (13.1)
CLND = Completion Lymph Node Dissection; DDHCC = Daniel den Hoed Cancer Center, Rotterdam, 
the Netherlands; CHUB = the Charité, Humboldt University of Berlin, Berlin, Germany; MMCCIO 
= M.Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; RSCH 
= Royal Surrey County Hospital, Guildford, UK; AVL = Netherlands Cancer Institute, Antoni van 
Leeuwenhoek Hospital, Amsterdam, the Netherlands; IGR = Institut de cancérologie Gustave Roussy, 
Villejuif, France; VUMC = Vrij Universiteit Medical Center, Amsterdam, the Netherlands; UMCG 
= University Medical Center Groningen, Groningen, the Netherlands; EIO = European Insitute of 
Oncology, Milan, Italy; UP = Veneto Institute of Oncology – IRCSS University of Padova, Padova, Italy.
Suppl. Table 2 – Results of multivariable analysis of disease specific survival for subgroups of 
patients with a positive sentinel node who underwent completion lymph node dissection or not, 
stratified by sentinel node tumor burden
SN tumour burden characteristic within 
multivariable analyses
Multivariable analyses
CLND n HR 95 per cent c.i. p*
Dewar criteria Subcapsular Not performed 16 1
Performed 173 0.84 0.52 – 1.36 0.48
Non-subcapsular Not performed 36 1
Performed 816 0.59 0.29 – 1.21 0.15
Unknown location Not performed 9 1
Performed 124 0.88 0.54 – 1.45 0.62
S-classification SI Not performed 13 1
Performed 126 1.02 0.61 – 1.70 0.93
SII Not performed 10 1
Performed 132 0.87 0.54 – 1.42 0.59
SIII Not performed 9 1
Performed 225 0.74 0.46 – 1.22 0.99
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Suppl. Table 2 (continued)
SN tumour burden characteristic within 
multivariable analyses
Multivariable analyses
CLND n HR 95 per cent c.i. p*
Unknown TPD Not performed 29 1
Performed 630 0.61 0.36 – 1.07 0.08
Rotterdam criteria < 0.1 mm Not performed 15 1
Performed 101 0.74 0.47 – 1.17 1.00
0.1 – 1.0 mm Not performed 30 1
Performed 462 0.90 0.46 – 1.77 0.76
> 1.0 mm Not performed 16 1
Performed 550 0.65 0.38 – 1.12 0.12
RDC criteria < 0.1 mm subcapsular Not performed 10 1
Performed 45 0.79 0.48 – 1.29 0.35
< 0.1 mm non-
subcapsular
Not performed 4 1
Performed 37 0.77 0.47 – 1.24 0.28
0.1 – 1.0 mm 
subcapsular
Not performed 5 1
Performed 114 0.89 0.53 – 1.50 0.66
0.1 – 1.0 mm non-
subcapsular
Not performed 20 1
Performed 284 0.78 0.42 – 1.45 0.43
> 1.0 mm with known 
location
Not performed 13 1
Performed 509 0.71 0.39 – 1.32 0.28
Known size, unknown 
location
Not performed 9 1
Performed 124 0.79 0.49 – 1.28 0.34
Multivariable analyses included the following variables: age, Breslow, tumour ulceration and the 
specific subgroup of patients
HR = Hazard ratio; c.i.= Confidence Interval; SN = sentinel node; CLND = Completion lymph node 
dissection; N/A = Not applicable, RDC = Rotterdam Dewar Combined
* p-values are calculated using the log rank test
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AbSTRACT
Current staging algorithms in melanoma patients undergoing lymph node dissection 
(LND) fail to accurately distinguish long term survivors from those at risk of rapid 
relapse. Our goal was to establish and validate nomograms for predicting both recur-
rence and survival after LND.
A prospective cohort of stage IIIB and IIIC melanoma patients was ascertained 
from a tertiary hospital in Brisbane, Australia. Failure-time multivariate analysis iden-
tified key factors that, in adjusted combinations, generated nomograms to predict 
2-year recurrence and melanoma-specific survival. The predictive value of these 
nomograms was further tested in a separate prospective patient cohort from Rot-
terdam, The Netherlands.
In the 494 Australian patients, number of positive lymph nodes, extracapsular 
extension, nodular histopathological subtype and post-operative seroma were inde-
pendent predictors of 2-year recurrence while age, number of positive nodes and 
extra capsular extension were the independent predictors of survival. Predictive 
value was confirmed in The Netherlands cohort of 331 patients. The nomograms 
were able to classify patients according to their 2-year recurrence and survival rates 
even within each stage III sub-class.
Models that include extra-capsular extension predict outcomes in patients with 
clinically invaded lymph nodes. This tool may help tailor treatment and monitoring 
of this group of patients.
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iNTRoduCTioN
Melanoma patients with regional lymph node metastasis can have substantial varia-
tions in outcome despite proper surgical management1-3. Five-year survival rates vary 
between 40% and 59%2, including some patients that survive long-term4. The current 
American Joint Committee on Cancer (AJCC) staging system classifies melanoma 
patients with macroscopic metastases as stages IIIB or IIIC by considering the num-
ber of invaded nodes (1, 2 or 3, 4 or more), presence of ulceration in the primary 
tumour and presence of satellitosis or in-transit metastases2. However, other factors 
of prognostic significance in stage III patients that have been described such as age 
or site of invasion have not been considered in the current staging criteria5, 6. Our 
objective was to identify all independent prognostic factors in a well-characterised 
series of patients with stage IIIB and IIIC melanoma in order to generate predic-
tion models of recurrence and death and then to validate these nomograms in an 
independent cohort.
PATieNTS ANd MeThodS
Cohort characteristics
Patients having regional lymphadenectomy between January 2000 and August 2011 at 
the Melanoma Clinic of the Princess Alexandra Hospital, Queensland, Australia were 
included if they satisfied the following eligibility criteria: had palpable metastatic 
lymph-node field disease; had complete cervical, axillary, inguinal or ilio-inguinal 
lymphadenectomy (LND); the number of involved nodes was 1 or more; and were 
aged at least 18 years7.
All patients having regional nodal surgery were prospectively documented in a 
database. Demographic information, site (head and neck, upper or lower limb, trunk 
or melanoma of unknown primary site7 and histological characteristics of the primary 
melanoma when available including thickness (mm), histological classification and 
the presence of ulceration, satellites or regression were collected. Patients presenting 
with palpable nodal metastasis had the diagnosis confirmed by fine needle aspiration 
cytology and were staged with computerised tomography (CT) scans of the head, 
chest, abdomen and pelvis. From 2004 onwards fluorodeoxyglucose-positon emis-
sion tomography (FDG-PET) scanning was added to this list for routine staging in 
this group of patients. Other investigations were performed as required to assess and 
exclude stage IV disease. Regarding the regional nodal dissection the following data 
were collected: site (neck, axilla, inguinal, ilio-inguinal, iliac only), total number of 
nodes removed, number of invaded nodes, size of largest node (cm) and presence of 
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microscopic or gross extracapsular extension. Post-surgery complications (infection, 
seroma) were also recorded. Seroma was defined as a lymph collection that needed 
additional intervention (such as needle aspiration) beyond the routine use of drains 
immediately post-surgery.
follow-up
Following nodal surgery, patients were followed every 3 months for 2 years, theevery 
6 months for 2 years, then annually up to 10 years. Follow-up assessment consisted 
of a history and physical examination including skin surveillance. Investigations 
were directed to new symptoms or signs that had occurred between visits and/
or were present at follow-up (unless the patient was participating in a trial that 
required specific investigations to be performed). Recurrence was defined as new 
local, regional or disseminated disease and the date of review when new disease was 
identified clinically was recorded.
Validation cohort
The validation cohort has been described previously8. Patients who were treated 
with LND for palpable nodal disease classified as Stage IIIB or C between 1982 and 
2009 at the Erasmus University Medical Center and Daniel den Hoed Cancer Center, 
Rotterdam, The Netherlands, were included. Patients who underwent LND with an 
isolated limb perfusion were excluded. Available patient, primary and metastatic 
tumour characteristics were prospectively collected and details entered into a data-
base. Clinically detectable nodal disease and the absence of visceral metastases were 
confirmed by either ultrasound of the lymph node fields and/or the liver, chest x-ray, 
cerebral magnetic resonance imaging, or CT scan of the thorax and abdomen but not 
ascertained by FDG-PET.
The present study was approved by the Human Research Ethics Committees of 
the University of Queensland, the Princess Alexandra Hospital and the Queensland 
Institute of Medical Research.
outcome
The outcomes of interest were recurrence within two years and melanoma-specific 
survival, calculated from date of LND to date of first recurrence or to the date of 
death from melanoma. Patients who had a recurrence after 2 years were censored 
at the time of recurrence, while patients who did not have a recurrence by their last 
follow-up were censored at that date. For survival, patients who died of causes other 
than melanoma were censored at their date of death.
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Statistical analysis
All potential predictors of two-year recurrence or death were screened using failure-
time procedures, either by log-rank statistics for categorical variables or by univariate 
Cox proportional hazards methods for quantitative variables such as age, Breslow 
thickness, number of nodes dissected, number of positive nodes and size of largest 
positive node. Those that showed an association with time to recurrence or death 
at the 10% level of significance were included in a multivariate proportional hazards 
model to determine the independent predictors. Cut-points in the linear formula 
derived from the resultant coefficients, rounded to one decimal place, were deter-
mined by calculating the proportion of recurrences or death at each realised value 
of the formula and applying the pool-adjacent-violators algorithm9, 10 to achieve a 
monotonic increase in the recurrence or death proportions. Proportions of individu-
als with recurrence within two years or death and actuarial two-year recurrence rates 
or five year survival rates in each band of the nomogram were then computed for 
the predictive and the validation cohorts.
As indications of predictive power, the Area Under the Receiver Operating 
Characteristic curve (AUC) was computed from the Mann-Whitney test11 and the 
C index for failure-time models12 as well as calibration curves13. Calibration curves 
were drawn by grouping patients with respect to their nomogram-predicted prob-
abilities and plotting the mean of predicted probabilities for each group with the 
mean observed Kaplan-Meier 2-year estimate of recurrence-free or 5-year melanoma 
specific survival. As a further indication of predictive power over and above that due 
to the ‘number of positive nodes’ variable, outcomes were computed separately for 
patients staged IIIB and IIIC. The C index and calibration curves were calculated 
using ‘hmisc’, ‘epi’ and ‘rms’ packages in R (version 2.15, R Foundation for Statistical 
Computing, Vienna, Austria 2011). All analyses other than the calculation of the 
C index and calibration curves were performed using Statistical Analysis Software 
(SAS) version 9.2 (SAS Institute, Cary, NC, USA).
ReSuLTS
From January 2000 to June 2011, 560 adult patients underwent regional nodal dis-
section, of whom 494 patients were eligible for the present study (Table 1). Patients 
were excluded because of absence of follow-up data (n=29); ineligible disease stage 
(n=33) including 10 patients with microscopic disease only; or prior radiotherapy 
(n=4). The mean age of males in the study cohort was 58.4 years and of females, 
55.0 years and patients were followed for a median of 17.4 months (Interquartile 
range 32.1). Recurrent metastatic melanoma occurred in 217 patients (44%). Mean 
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time to recurrence in the study cohort was 11±0.9 months and 90% of recurrences 
were systemic (10% local). Among the patients who recurred, 198 (91%) had a recur-
rence within two years of nodal dissection. Death due to melanoma occurred in 150 
patients within the first two years and in 206 patients within 5 years.
Predictors of two-year recurrence at the 10% level of significance were: extra-
capsular extension, whether microscopic or gross; presence of seroma (yes, no); 
stage (IIIB, IIIC), nodular primary melanoma, dissection site (inguinal/ilio-inguinal, 
elsewhere), post-operative radiotherapy (yes, no); number of nodes dissected; and 
number of positive nodes detected. Further assessment of the association of recur-
rence with the number of positive nodes indicated that after eight positive nodes 
no additional association was evident, so number of positive nodes was truncated 
at eight. Post-operative radiotherapy was judged unsuitable for the purpose of a 
generally applicable predictive formula as it relied already on a combination of other 
study variables with its use being subject to local therapeutic modes.
After multivariate proportional hazards analysis, five variables remained for 
inclusion in the linear predictive formula, namely the presence of extra-capsular 
extension, seroma, number of positive nodes, nodular subtype and dissection site. 
Dissection site and seroma added a negligible amount to the predictive value be-
yond the other variables as measured by the AUC and were therefore omitted for 
parsimony. Using the coefficients derived from the proportional hazards model, a 
formula was developed as follows: Nomogram score = 0.49 x extracapsular exten-
sion (coded 0, 1) + 0.41 x presence of nodular subtype of primary melanoma (coded 
0, 1 for known primaries, 0 for unknown primaries ) + 0.187 x number of positive 
nodes (to a maximum of 8). For individuals with missing information on primary 
melanoma histology, that variable was set equal to zero without significantly affect-
ing the predictive value of the formula. This was the case for 82 patients (16.6%) 
with a melanoma of unknown primary and an additional 19 (4.6%) where the 
primary tumour histological subtype was not recorded. The AUC for this formula 
was 0.68 and the C index value was 0.67. Attempts to provide a separate formula 
for patients without information on primary histology yielded no advantage in terms 
of the AUC.
For the Australian cohort, proportions of two-year recurrences in each nomogram 
band and two year recurrence rates calculated by the Kaplan-Meier method rose 
steadily across the bands, from 20.5% and 24.7±4.3%, respectively, in the lowest 
band to 66.1% and 77.7% , respectively, in the highest band (Table 2). In addition, 
this same strategy when applied to Stage IIIB or to stage IIIC patients separately suc-
cessfully classified patients according to their 2-year recurrence rate (Supplemental 
Table 1). Indeed, recurrence rates rose monotonically from the lowest to highest 
band of the nomogram within each stage separately.
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The validation dataset from The Netherlands contained data from 337 patients 
aged 17 years or older who underwent LND (Table 1). Recurrences occurred in 246 
(73%) with mean time to recurrence of 11.0± 1.0 months. Among these 216 (64%) 
recurred in the first two years. Six patients, three with recurrences within two years, 
had no information on the number of positive nodes removed, and were excluded 
from the validation cohort, leaving 331 individuals. Information on primary histology 
was missing for 167, 46 of whom had melanomas of unknown primary. The aver-
age age of patients was 55.3 years in males and 54.1 in females. Compared to the 
Australian cohort, The Netherlands cohort had more dissections in the groin, iliac or 
ilio-inguinal fields (52.3vs37.3%), more patients with greater than 4 positive nodes 
(26.3% v 18.3%), a larger average size of largest node (3.6±2.2 vs 3.2±2.0) but less 
extracapsular extension (30.5% v 45.4%).
When the above nomogram was applied to The Netherlands cohort, two-year 
recurrence rates also rose steadily across the nomogram bands, from 53.5±5.8% in 
Table 2. Nomogram ranges and associated numbers of patients, recurrences and two-year recurrence 
rates in the Australian and The Netherlands cohorts.
Nomo-
gram 
Range
Australia The Netherlands
Recur-
rences/
total
Percent-
age
Two-year 
recurrence 
rate
Standard 
Error
Recur-
rences/
total
Percent-
age
Two-year 
recurrence 
rate
Standard 
Error
≤ 0.2 25/122 20.5 24.7 4.3 40/83 48.2 53.5 5.8
0.3 – 0.6 29/92 31.5 40.5 6.0 56/87 64.4 68.1 5.2
0.7 33/85 38.8 51.4 6.5 19/28 67.9 69.5 8.9
0.8 – 1.2 56/108 51.9 63.0 5.3 45/68 66.2 70.4 5.9
1.3 – 1.4 14/25 56.0 73.7 10.8 9/14 64.3 74.7 12.8
≥ 1.5 41/62 66.1 77.7 6.1 44/51 86.3 88.5 4.6
Total 198/494 40.1 48.5 2.6 213/331 64.4 67.9 2.7
Table 3. Nomogram ranges and associated numbers of patients, deaths within five years and 
actuarial five-year death rates, with 95% confidence intervals (95% CI), in the Australian and The 
Netherlands cohorts.
Nomogram
Range
Australia The Netherlands
Deaths/
total
Percent-
age
Five-year 
death rate
95% CI Deaths/
total
Percent-
age
Five-year 
death rate
95% CI
≤51 38/159 23.9 39.6 28.7 – 50.3 58/122 47.5 60.4 49.3 – 69.8
0.52 – 0.56 26/69 37.7 55.6 38.7 – 69.6 34/66 51.5 62.7 47.7 – 74.5
0.57 – 1.03 42/95 44.2 63.9 50.7 – 74.4 21/33 63.6 74.8 52.6 – 87.7
1.04 – 1.08 20/39 51.3 61.3 40.3 – 76.8 30/42 71.4 76.5 59.4 – 87.2
1.09 – 1.60 43/79 54.4 69.6 54.7 – 80.5 20/23 78.0 89.6 65.4 – 97.2
≥ 1.61 37/53 69.8 87.4 67.1 – 95.5 37/45 82.2 94.4 72.1 – 99.0
Total 206/494 41.7 57.5 51.6 – 63.0 200/331 60.4 70.0 64.0 – 75.2
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the lowest band to 88.5±4.6% in the highest band (Table 2). The clinical significance 
of the nomogram was assessed using calibration curves comparing predicted 2-year 
recurrence-free probabilities with observed probabilities in this validation dataset 
(Figure 1). These calibration curves displayed high concordance between nomogram-
predicted probabilities and the mean observed Kaplan-Meier 2-year recurrence-free 
survival. Within nomogram bands the recurrence rates were uniformly higher in The 
Netherlands cohort compared with those in the Australian cohort, particularly at 
lower bands. Restricting The Netherlands cohort to more recent patients (2000-2009) 
to take into account accuracy of imaging techniques used for stag ng did not change 
the difference in outcome between the cohorts. In this dataset, the AUC for the 
nomogram was 0.63 and the C index was 0.60. When the two-year recurrence rates 
were calculated separately for stage IIIB or IIIC patients recurrence rates rose overall 
in both groups with nomogram scores, although not monotonically (Supplemental 
Table 2).
A similar strategy was adopted regarding melanoma specific survival. Following the 
same methods a nomogram was developed that included the number of positive 
nodes as a categorical variable and the presence or absence of extra-capsular exten-
sion whether microscopic or macroscopic. The resulting formula gave Nomogram 
score = 0.52 x (0 if number of positive nodes=1; 1 if number of positive nodes= 
figure 1: Calibration plots for two-year recurrence-free predictive performance in validation cohort.
Figure 1: Calibration plots for two-year recurrence-free predictive performance in validation cohort. 
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2 to 3, and 3 if number of positive nodes equal or more than 4) + 0.57 x extra-
capsular extension (presence of any type=1, absence=0). No strong evidence for 
multi-collinearity (variance inflation factor<4) was noted between age, number of 
positive nodes categories and extra-capsular extension.
This nomogram resulted in a C index of 0.67 and an AUC of 0.67 in the Australian 
dataset. When examined only in stage IIIB patients or IIIC patients separately, the 
AUC was 0.64 and 0.65 respectively. In the validation cohort, this nomogram had an 
AUC of 0.66 and a C index at 0.62. The clinical significance of the nomogram was 
again assessed using calibration curves comparing predicted 5 year survival prob-
abilities with observed probabilities in this validation dataset (Figure 2). Similarly, 
the AUC when considering only stage IIIB or only stage IIIC patients was 0.61 and 
0.63 respectively.
diSCuSSioN
Accurate predictors of melanoma outcome are needed for stage III melanoma 
patients undergoing lymph node dissection to orient management. In this study, 
we established and validated nomograms for predicting recurrence at 2 years or 
figure 2: Calibration plots for 5- year melanoma-specific survival predictive performance in 
validation cohort.
Figure 1: Calibration plots for 5- year melanoma-specific survival predictive performance in validation 
cohort. 
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melanoma-specific death. In a prospective cohort, we first conducted a failure-time 
multivariate analysis that identified some of the key predictive factors important 
in stage III melanoma. Formulas based on an adjusted combination of these fac-
tors were then used to generate nomograms that increased in value linearly with 
two-year recurrence and death. Each of these nomograms incorporated additional 
characteristics such as extracapsular extension beyond criteria already present in the 
AJCC staging system. They were able to classify patient outcome within each AJCC 
subclass and their predictive value was also validated in a second prospective cohort 
from The Netherlands.
Previous studies have described prognostic factors of stage III progression. In their 
study of 441 patients with macrometastases, Balch et al, reported that age, ulceration, 
anatomic site, and number of tumor-bearing lymph nodes independently predicted 
survival5. In Cox proportional hazard models, only number of nodes and age were 
independent predictors. None of the primary tumour attributes played an important 
role as predictors of survival5. The present study of the larger Australian cohort of 
stage IIIB and IIIC melanoma patients, reproduced these findings for age, num-
ber of invaded nodes and anatomic site. Similar results were also obtained in our 
confirmation cohort8. The reproducibility of these factors across multiple cohorts 
including ours suggests the generalizability of our study sample. We also considered 
additional parameters not reported by Balch et al, such as extracapsular extension. 
The prognostic significance of extracapsular extension has been previously reported 
and proved essential in terms of predictive value in our nomogram for both recur-
rence and death4, 8, 14.
A major strength of this study is the use of a validation cohort8. Similar to ours, 
this cohort was composed of patients treated in a tertiary referral centre and, in many 
aspects, they shared general characteristics of our cohort, though on average, Dutch 
patients were older, had more advanced Stage III disease and consequently the 
recurrence rate was overall higher. Lack of staging with FDG-PET in the Netherlands 
patients might play a role in the differences in outcome observed between both 
cohorts15. However, the ability of the nomogram to accurately classify Dutch patients 
into distinct prognostic groups despite the outcome differences demonstrates its 
robustness.
For patients with stage III metastatic melanoma there are no clear adjuvant 
therapeutic options after surgery3. Interferon alpha may be used but its benefit is 
limited; postoperative radiotherapy may reduce local recurrence in high risk stage III 
patients16, 17. In our study, 90% of recurrences were systemic and therefore unlikely 
to be affected by radiotherapy. Others have used immunotherapy also with mod-
est benefits18, 19. Clinical trials of adjuvant regimens where therapy is applied to all 
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stage III patients regardless of their risk of progression or response may fail due 
to inclusion of patients unlikely to progress and therefore unlikely to benefit from 
the intervention, reducing the potential difference between treated and untreated 
groups. They will be nevertheless exposed to the toxicity of the therapy. An impor-
tant clinical application of a nomogram for stage III patients may be the capacity to 
analyse therapeutic responses of subgroups stratified according to the nomogram 
bands as described here. An example is interferon therapy where the benefit has 
been shown to be maximal for patients with lower tumour burden20, 21.
In conclusion, we have developed and validated mathematical models to predict 
outcome in stage IIIB and IIIC melanoma patients undergoing LND. The models 
included prognostic factors additional to the number of positive nodes described 
in the AJCC staging system. Such models have not been applied to this subgroup 
of patients previously and may add value beyond existing staging tools for patients 
with lymph node metastases. Nomograms described here could become a tool for 
routine use in a clinical setting for the management of patients with stage IIIB and 
stage IIIC melanoma or in a research setting for better stratification in clinical trials.
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SuPPLeMeNTARy TAbLeS
Supplemental Table 1. Nomogram ranges and associated numbers of patients, recurrences and two-
year recurrence rates for Stage IIIB and Stage IIIC patients in the Australian cohort.
Stage IIIB Stage IIIC
Range Recurrences/total Two year 
recurrence rate
Recurrences/total Two year recurrence 
rate
≤ 0.2 16/89 21.8 9/33 35.9
0.3 – 0.6 16/57 37.9 13/35 45.8
0.7 17/53 43.8 16/32 63.6
0.8 – 1.2 28/50 69.7 28/58 58.5
13 – 1.4 3/6 50.0 11/19 82.6
≥ 1.5 2/2 100.0 39/60 76.6
Total 82/257 39.2 116/237 59.1
For the stage IIIB sub-group the AUC and C-index were 0.68 and 0.67 respectively; for the stage IIIC 
sub-group, 0.64 and 0.64 respectively.
Supplemental Table 2. Nomogram ranges and associated numbers of patients, recurrences and two-
year recurrence rates for Stage IIIB and Stage IIIC patients in the Netherlands cohort.
For the stage IIIB sub-group the AUC and C-index were 0.57 and 0.54 respectively; for the stage IIIC 
sub-group, 0.64 and 0.58 respectively.
Stage IIIB Stage IIIC
Range Recurrences/total Two year 
recurrence rate
Recurrences/total Two year 
recurrence rate
≤ 0.2 36/77 51.8 4/6 77.8
0.3 – 0.6 44/66 68.9 12/21 63.0
0.7 12/18 69.7 7/10 75.0
0.8 – 1.2 17/29 64.9 28/39 75.2
13 – 1.4 1/1 100 8/13 72.8
≥ 1.5 1/1 100 43/50 88.3
Total 111/192 61.0 102/139 77.6
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AbSTRACT
Management of patients with clinically detectable lymph node metastasis to the 
groin is by ilioinguinal or combined superficial and deep groin dissection (CGD) 
according to most literature, but in practice superficial groin dissection only (SGD) is 
still performed in some centers. The aim of this study was to evaluate the experience 
in CGD vs. SGD patients in our center.
Between 1991 and 2009, 121 therapeutic CGD and 48 SGD were performed in 169 
melanoma patients with palpable groin metastases at our institute. Median follow-up 
was 20 and, for survivors, 45 months.
In this heterogeneous group of patients, overall (OS) and disease-free survival, 
local control rates and morbidity rates were not significantly different between CGD 
and SGD patients, however CGD patients had a trend towards more chronic lymph-
edema. Superficial lymph node ratio, the number of positive superficial lymph nodes 
and the presence of deep nodes were prognostic factors for survival. CGD patients 
with involved deep lymph nodes (24.8%) had estimated 5-year OS of 12% compared 
with 40% with no involved deep lymph nodes (p=0.001). Preoperative computed 
tomography (CT) scan had a high negative predictive value of 91% for the detection 
of pelvic nodal involvement.
This study demonstrated that survival and local control do not differ for patients 
with palpable groin metastases treated by CGD or SGD. Patients without pathologi-
cal iliac nodes on CT might safely undergo SGD, while CGD might be reserved for 
patients with multiple positive nodes in the SGD and/or positive deep nodes on CT 
scan.
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iNTRoduCTioN
Management of patients with clinically detectable lymph node metastasis to the groin 
consists of ilioinguinal or combined superficial and deep groin dissection (CGD) 
according to most literature.1-7 Some surgeons are willing to do so only when there 
are multiple positive nodes in the groin or when there is evidence of pelvic nodal 
involvement on the basis of imaging information.8 In practice, a solely inguinal or 
superficial groin dissection (SGD) is still being performed in some cases and/or 
centers. The potential survival or local control benefit of extensive surgery remains 
controversial in the absence of randomized data.
Prognosis and outcome of patients after a CGD is believed to correlate with the 
biology of the disease rather than with the extent of the operation.4, 8-11 It is advocated 
that CGD should be performed when there is clinically gross involvement of the 
groin, when there are clinically detectable deep lymph nodes, when Cloquet’s node 
is histologically positive or when pelvic computed tomography (CT) demonstrates 
pelvic lymphadenopathy.12
The aim of this study is to evaluate the experience in patients with clinically 
evident metastatic melanoma to the groin who underwent CGD versus SGD only. 
Postoperative morbidity, regional recurrence, preoperative CT scan, and disease-free 
and overall survival were analyzed. The necessity of removal of the deep iliac and 
obturator lymph nodes as well as prognostic factors for survival in patients with 
metastatic melanoma to the groin were evaluated.
PATieNTS ANd MeThodS
Patients
Patients in this study presented with clinically detectable metastases to the groin at 
the Erasmus University Medical Center – Daniel den Hoed Cancer Center, Rotterdam, 
the Netherlands. Patients were selected for therapeutic ilioinguinal or combined 
superficial and deep groin dissection (CGD) or for inguinal or superficial groin 
dissection (SGD). All patients underwent the operation within 2 months of detec-
tion of palpable metastasis. Patients who underwent sentinel lymph node biopsy 
were excluded. All patients’ characteristics, tumor characteristics, postoperative 
morbidities, regional recurrence patterns and imaging procedures (preoperative 
CT scanning) were collected and sorted in a database for this retrospective single 
institution study. Postoperative morbidities were collected from patient’s charts and 
divided into two categories; short-term morbidities, e.g. wound infection or necrosis, 
seroma, and long-term morbidities, e.g. chronic lymphedema. Chronic lymphedema 
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was recorded if moderate or severe swelling was present for more than 6 weeks 
postoperatively and the patient required therapy. Adjuvant radiotherapy was given 
to 16 (9.5%) patients and they were treated with doses between 15 and 80 Gy.
Surgical procedure
Four coauthors performed the majority of lymph node dissections assessed for this 
study (J.H. de W., A.N. van G., A.M.M.E., and C.V.). In general, patients with palpable 
inguinal nodes underwent CGD. Indication for SGD was based on surgeon or patient 
preference. Patients with significant (cardiopulmonary) co-morbidities and absence 
of preoperative radiological and/or clinical suspicion for involved deep lymph nodes 
underwent SGD. SGD was performed via a transverse inguinal incision and involved 
complete dissection of lymph nodes from the inguinofemoral content to the apex of 
the femoral triangle where the long saphenous vein joins the femoral vein. Sartorius 
muscle transposition to cover and protect femoral vessels was selectively performed 
when adjuvant radiotherapy was to be expected and/or patient’s skin was at risk. 
When a CGD was performed, an additional incision was made approximately 3 to 5 
centimeters above the line of the inguinal ligament. CGD included dissection of the 
inguinofemoral and external iliac nodes up to the common iliac artery (if necessary 
up to the aortic bifurcation) and dissection of the obturator nodes.
Statistics
Disease free survival (DFS) was calculated from the operation date of the lymph 
node dissection to the date of first recurrence at any site. Overall survival (OS) was 
calculated from the operation date of the lymph node dissection to the date of death 
due to any cause.
Different statistical methods were assessed when appropriate. The chi-square 
test, Fisher’s exact test and Mann-Whitney test were assessed to investigate differ-
ences in clinicopathological features, the predictive value of the number of involved 
superficial nodes for deep lymph node involvement, postoperative morbidities and 
regional recurrence patterns in CGD and SGD patients. The log-rank test and the 
Kaplan-Meier method were assessed for survival analysis and the search for prog-
nostic factors in CGD patients, SGD patients, and the total group of patients. All 
calculations were performed with STATA version 10.1 and 11.1 (StataCorp LP, College 
Station, TX, USA).
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Table 1 – Clinicopathological factors
Combined deep and 
superficial Groin 
Dissections (n=121)
n (%)
Superficial Groin 
Dissections (n=48)
n (%)
P-value*
Gender
Female 70 (57.9) 32 (66.7)
Male 51 (42.2) 16 (33.3) 0.303
Age (years)
≤ 50 47 (38.8) 11 (22.9)
> 50 74 (61.2) 37 (77.1) 0.072
Site of primary
Leg 78 (78.8) 37 (92.5)
Trunk 21 (21.2) 3 (7.5) 0.080
Missing 22 8
Breslow thickness (mm)
≤ 2.00 52 (57.1) 14 (38.9)
2.01 - ≤ 4.00 23 (25.3) 10 (27.8)
> 4.00 16 (17.6) 12 (33.3) 0.099
Missing 30 12
Clark level
II-III 26 (32.1) 9 (30)
IV 48 (59.3) 19 (63.3)
V 7 (8.6) 2 (6.7) 0.907
Missing 40 18
Ulceration
Absent 89 (73.6) 34 (70.8)
Present 32 (26.5) 14 (29.2) 0.706
Extranodal invasion
Absent 33 (48.5) 14 (51.9)
Present 35 (51.5) 13 (48.2) 0.823
Missing 53 21
Largest diameter of positive superficial 
node (cm)
< 3 21 (29.2) 11 (50.0)
≥ 3 51 (70.8) 11 (50.0)
Missing 50 26 0.002
No. positive superficial nodes
1 57 (47.1) 26 (54.2)
2 – 3 35 (28.9) 14 (29.2)
> 3 29 (24.0) 8 (16.7) 0.553
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ReSuLTS
Cgd vs. Sgd
This study included 121 patients (70 women and 51 men) who underwent a thera-
peutic combined superficial and deep dissection (CGD) and 48 patients (32 women 
and 16 men) who underwent a therapeutic superficial dissection (SGD) for palpable 
melanoma metastases to the groin. Surgeries were performed between 1991 and 
2009 at the Erasmus University Medical Center – Daniel den Hoed Cancer Center, 
Rotterdam, the Netherlands. Median follow-up time was 20 months for all patients 
and 45 months for all survivors (both, range 1 – 202 months). Median age at time of 
surgery was 54 (range 21 – 87) years at time of surgery. CGD patients had signifi-
cantly more patients with large superficial nodes than SGD patients (p=0.002), more 
harvested superficial lymph nodes (p<0.001) and lower superficial lymph node ratio 
(p=0.0004). (Table 1)
Preoperative diagnosis
Patients were clinically diagnosed by computed tomography (CT), fine-needle as-
piration cytology (FNAC) and/or ultrasound. All SGD patients were diagnosed with 
superficial lymph node involvement only. Of all CGD patients, 24 (19.8%) were 
diagnosed with superficial and deep lymph node involvement and 97 (80.2%) were 
diagnosed with only superficial lymph node involvement.
Table 1 (continued)
Combined deep and 
superficial Groin 
Dissections (n=121)
n (%)
Superficial Groin 
Dissections (n=48)
n (%)
P-value*
No. harvested superficial nodes
Median (IQR) 15 (12-22) 8 (5-14) < 0.001
Superficial lymph node ratio (%)
Median (IQR) 11 (6-25) 20 (10-50) 0.0004
≤ 10 54 (45.4) 12 (25.0)
10 – ≤ 25 37 (31.1) 18 (37.5)
> 25 28 (23.5) 18 (37.5) 0.035
Missing 2 0
Positive deep lymph nodes
Absent 91 (75.2) 48 (100.0)
Present 30 (24.8) 0 (0.0) -
Adjuvant radiotherapy 11 (9.1) 5 (10.4) 0.776
IQR = Interquartile range
* P-values are calculated with the Fisher exact test, Chi-square test and Mann-Whitney test.
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Preoperative CT scans could be retrieved in 61 of 121 CGD. Of the 61 radiographi-
cally evaluated CGD patients, 44 (62.1%) were diagnosed with only superficial lymph 
node involvement, of which 40 were histologically confirmed by the pathologist 
(negative predictive value for pelvic involvement 91%). Positive predictive value for 
pelvic metastases was 59%, sensitivity was 71%, and specificity was 85%. (Table 2)
Postoperative morbidity
Median hospital stay was 6 (range 3 – 27) days in patients with CGD and 6 (range 
2 – 32) days in patients with SGD. There were no statistically significant differences 
in postoperative morbidities between CGD and CGD patients (all p>0.05), although 
Table 2 – CT accuracy for pelvic lymph node involvement in CGD patients
CT pelvic + CT pelvic - Total
Histology Pelvic + 10 4 14
Histology Pelvic - 7 40 47
Total 17 44 61
Sensitivity = 10/14 = 71.4%
Specificity = 40/47 = 85.1%
Positive predictive value = 10/17 = 58.8%
Negative predictive value = 40/44 = 90.9%
CT= Computed Tomography, CGD = Combined deep and superficial Groin Dissection
Table 3 – Post-operative morbidity en regional recurrence rates
Type of morbidities Combined deep and 
superficial Groin 
Dissections (n=121)
n (%)
Superficial Groin 
Dissections (n=48)
n (%)
P-value†
Overall 77 (63.6) 24 (50.0) 0.119
Short-term* 60 (49.6) 19 (39.6) 0.305
Long-term** 32 (26.5) 8 (16.7) 0.229
Wound infection and/or necrosis 30 (24.8) 13 (27.1) 0.845
Chronic lymphedema 31 (25.6) 7 (14.6) 0.154
Type of recurrence
Median time to recurrence 7.6 6.0 0.677
Regional superficial and deep 
lymph node recurrence
19 (15.7) 10 (20.8) 0.498
Of which:
Pelvic lymph node recurrence
12 (9.9) 5 (10.4) 1.000
*Short term morbidities include wound infection and/or necrosis, seroma, post operative bleeding, 
urinary tract infection, pulmonary embolism or thrombosis and transient nerve damage.
**Long term morbidities include chronic lymphedema, urinary tract damage, permanent nerve 
damage and loss of function
† P-values are calculated with the Mann-Whitney test, Fisher’s exact test and Chi-square test.
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there was a trend towards more chronic lymphedema in the CGD group (25.6% vs. 
14.6%, p=0.154). (Table 3)
Recurrence
There was no statistical difference in disease-free survival time or time to regional 
relapse between SGD and CGD patients, with overall recurrence rate of 73% (90/121) 
and 74% (35/48), respectively. At time of last follow-up, 81 of 121 patients (67%) in 
the CGD group and 31 of 48 patients (65%) in the SGD group were dead. Regional 
recurrence rates were more common in SGD than in CGD patients, i.e., 21% and 
16% (p=0.498), and pelvic recurrence rates were 10% in both groups of patients 
(p=1.000). Median time to first recurrence was 7.6 (range 1 – 96) months for CGD 
patients and 6.0 (range 1 – 42) months for SGD patients (p=0.677). (Table 3)
Survival analysis
Disease-free (DFS) and overall survival (OS) in CGD patients were not better than 
in SGD patients (p=0.722 and p=0.647, respectively)). (Figure 1C-D) Comparison of 
DFS and OS of CGD patients who only had superficial nodes involved with SGD 
patients also showed no significant difference (p=0.421 and p=0.217, respectively).
Five-year estimated DFS and OS rates for patients who underwent SGD were 
15.7% and 28.7%, respectively. Five-year estimated DFS and OS rates for patients 
who underwent CGD were 18.3% and 33.0% respectively. (Figure 1C-D)
On univariate analysis of prognostic factors in the total number of patients 
(n=169), the number of positive superficial nodes (1, 2 – 3, ≥ 4) were significant 
prognostic factors for DFS [≥ 4 nodes only; hazard ratio (HR) = 1.85; 95% confidence 
interval (CI) 1.21 – 2.84; p=0.005] and OS (HR=1.60; 95%CI 1.03 – 2.51; p=0.038 and 
HR=2.36; 95%CI 1.50 – 3.71; p=0.0005) as well as superficial lymph node ratio for 
DFS (HR=2.33; 95%CI 1.25 – 4.34; p=0.008) and OS (HR=3.16; 95%CI 1.68 – 5.94; 
p<0.001). Presence of involved deep lymph nodes was a prognostic factor for OS 
(HR=1.95; 95%CI 1.24 – 3.07; p=0.004).
On univariate analysis of prognostic factors in SGD patients only, the largest 
diameter of the positive lymph node was significant for OS (HR=3.10; 95%CI 1.07 
– 8.98; p=0.037), while analysis in CGD patients revealed superficial lymph node 
ratio, more than 3 positive superficial nodes as well as the presence of involved 
deep lymph nodes as poor prognostic factors for OS (HR=5.90; 95%CI 2.21 – 15.76; 
p<0.001, HR=2.29; 95%CI 1.34 – 3.91; p=0.002 and HR=2.25; 95%CI 1.38 – 3.66; 
p=0.001, respectively) and DFS (HR=4.64; 95%CI 1.70 – 12.65; p=0.003, HR =1.96; 
95%CI 1.19 – 3.22; p=0.008 and HR=1.61; 95%CI 1.02 – 2.55; p=0.041, respectively). 
(Table 4)
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Five-year estimated DFS and OS rates for positive deep lymph nodes were 9.1% 
and 12.5%, respectively, compared with 5-year estimated DFS and OS rates for posi-
tive superficial lymph nodes only in CGD patients of 21.5% and 39.7%. (Figure 1A) 
Five-year estimated DFS rates for the number of positive superficial lymph nodes 
was 23.7% for 1 involved node, 12.0% for 2 – 3 and 11.2% for ≥ 4 involved nodes. 
Five-year estimated OS rates for the number of positive superficial lymph nodes 
was 42.6% for 1 involved node, 25.8% for 2 – 3 and 17.1% for ≥ 4 involved nodes. 
(Figure 1B)
figure 1A: Overall survival – Positive deep 
lymph nodes
figure 1b: Overall survival – Number of positive 
superficial lymph nodes
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diSCuSSioN
Survival in patients with palpable metastatic melanoma to the groin is poor. In the 
literature, estimated 5-year overall survival (OS) rates vary from 20 to 40%.8, 11, 13 In 
our series of 169 patients with palpable nodes in the groin, 5-year estimated OS 
rates were 33% for CGD and 29% for SGD respectively. Also 5-year DFS rates were 
Table 4 – Cox regression univariate analysis of overall and disease-free survival for prognostic factors 
in CGD and SGD patients, and the total group of patients.
Combined deep and 
superficial Groin 
Dissections (n=121)
Superficial Groin 
Dissections (n=48)
All Groin Dissections 
(n=169)
Disease Free Survival*
HR 95%CI P HR 95%CI P HR 95%CI P
Largest diameter of superficial node (cm)
< 3 1   1   1   
≥ 3 1.69 0.90-3.17 0.100 2.48 0.91-6.80 0.077 1.82 1.08-3.07 0.024 
No. of positive superficial nodes
1 1   1   1   
2-3 1.53 0.93-2.51 0.092 1.29 0.63-2.66 0.494 1.40 0.93-2.11 0.103 
≥4 1.96 1.19-3.22 0.008 1.85 0.77-4.41 0.167 1.85 1.21-2.84 0.005 
Superficial lymph node ratio 4.64 1.70-12.65 0.003 1.64 0.66-4.08 0.283 2.33 1.25-4.34 0.008
Positive deep nodes
Absent 1      1   
Present 1.61 1.02-2.55 0.041   N/A† 1.48 0.96-2.28 0.075 
Overall Survival*
Largest diameter of superficial node (cm)
< 3 1   1   1   
≥ 3 1.43 0.74-2.77 0.292 3.10 1.07-8.98 0.037 1.72 0.99-3.00 0.055 
No. of positive superficial nodes
1 1   1   1   
2-3 1.66 0.96-2.87 0.071 1.48 0.69-3.17 0.316 1.60 1.03-2.51 0.038 
≥4 2.29 1.34-3.91 0.002 2.44 0.99-6.01 0.052 2.36 1.50-3.71 0.0005 
Superficial lymph node ratio 5.90 2.21-15.76 <0.001 2.27 0.88-5.88 0.091 3.16 1.68-5.94 <0.001
Positive deep nodes
Absent 1      1   
Present 2.25 1.38-3.66 0.001   N/A† 1.95 1.24-3.07 0.004 
N/A= Not Applicable, CGD= Combined deep and superficial groin dissection, SGD= superficial groin 
dissections
*the following variables did not have any prognostic significance in all groups: gender, age, site of 
primary, Breslow thickness, Clark level, ulceration and extra nodal invasion.
† Variable not assessable due to no presence of positive deep nodes
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virtually identical, i.e.,18% for CGD and 16% for SGD. Patients with CGD with posi-
tive deep nodes have the poorest prognosis with OS ranging in the literature from 
6 to 34%.7-8, 10, 14-16 (Table 5) In our institute, patients with CGD and positive deep 
nodes have estimated 5-year OS and DFS rates of 12% and 9%. In contrast, for CGD 
patients without deep nodal involvement, we observed 40% and 22%, respectively. 
There were differences between the CGD and SGD patients. CGD patients had a sig-
nificantly larger size of involved superficial lymph nodes than SGD patients. (Table 
1) Moreover, 25% of CGD patients had involved deep lymph nodes, while there was 
no suspicion and no diagnosis of deep nodal involvement in SGD patients. CGD 
patients had unfavorable preoperative prognosis, which is apparent since selection 
Table 5 – Overview of literature describing survival rates in patients with positive deep nodes to the 
groin diagnosed after therapeutic combined deep and superficial lymph node dissection only
Institute Reference Year Study period Median 
follow-up
(months)
No. patients with 
positive pelvic nodes
(% of total)
5-year OS
(%)
NCI/ALH Jonk 24 *
Strobbe 7
1999 1961-1995 18 71 (20) 24
UCLA Finck 14 1982 1970-1980 23 24 (29) 17
MSKCC Coit 10
Mann 8
1989
1999
1974-1984
1985-1994
86**
40
10 (7)
21 (19)
6
±35
RPCI Karakousis ‡
2-3, 15, 25
1996 1977-1993 ±46 48 (NR) 34
UE Meyer 13 2002 1978-1997 20 23 (31) 21
MLUHW Kretschmer 16 2001 1983-1994 68** 24 (35) 6
RMH Hughes 11 2000 1984-1998 19 29 (40) 19
MDACC Badgwell 26 2007 1990-2001 90 55 (51)† 42†
DDHCC Recent study 2010 1991-2009 20 30 (25) 12
OS= Overall Survival, NR= Not reported; NCI/ALH = Netherlands Cancer Institute/Antoni van 
Leeuwenhoek Hospital, Amsterdam, the Netherlands; UCLA = University of California, Los Angeles, 
California, USA; MSKCC = Memorial Sloan-Kettering Cancer Center, New York City, New York, USA; 
RPCI = Roswell Park Cancer Institute, Buffalo, New York, USA;
UE= University of Erlangen, Erlangen, Germany; MLU HW = Martin-Luther-Universitat Halle-
Wittenberg, Halle, Germany
RMH= Melanoma and Sarcome Unit, Royal Marsden Hospital, London, UK; MDACC = M.D. Anderson 
Cancer Center, Houston, Texas, USA; DDHCC = Erasmus Medical Center - Daniel Den Hoed Cancer 
Center, Rotterdam, the Netherlands
*The 23 patients (5 year overall survival 32%) reported by Jonk et al. in 1989 are included in the 
study performed by Strobbe et al.
**The median survival shown is for the patients who survived only. The median follow-up for the entire 
group is not reported
‡ The patients described in the three earlier reports (1986 and two reports in 1994) of Karakousis et 
al. are included in the 1996 study
† The patients in this study underwent any type of lymph node dissection and not only therapeutic 
lymph node dissections
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for the extent of surgery was based on comorbidities and the suspicion of involve-
ment of deep lymph nodes. However, during CGD, more superficial nodes were 
harvested and the number of positive superficial nodes was not different, resulting 
in a significant lower superficial lymph node ratio. (Table 1) Lower superficial lymph 
node ratio is a good prognostic factor for survival.17-19
Based on surgery only, CGD patients were expected to have favorable prognosis. 
In this study, the outcome of CGD patients was virtually identical to that of SGD 
patients. (Figure 1C-D) Even comparison of patients with superficial involved nodes 
only showed no difference, indicating that the extent of groin surgery does not 
influence outcome (data not shown; p=0.217). Also in other studies, it has been 
demonstrated that the extent of groin surgery, regardless of the presence or absence 
of deep lymph node involvement in CGD patients, has no effect on survival.8, 10, 16
Preoperative CT was performed in 61 of 121 patients who underwent CGD. Posi-
tive predictive value (PPV) of CT scanning was only 59% in our experience, whilst 
the negative predictive value (NPV) was fairly good at 91%. Sensitivity was 71% and 
specificity 85% in our group of patients. (Table 2) Allen et al. found different results 
with PPV of 100%, NPV of 86%, specificity of 100% and sensitivity of 60%, stating CT 
scanning was not reliable as a tool for preoperatively assessing pelvic lymph node 
involvement.4 However, both studies show that a CT-based decision on whether or 
not to perform a CGD could be correctly made in 9 out of 10 patients. Thus, CT 
scan may be used as a tool in the decision on whether or not to remove the deep 
lymph nodes.
Morbidity rates in the present study are divided into short- and long-term morbidi-
ties. Under-estimation of events in the morbidity data could have occurred due to 
the retrospective gathering of the data from medical records. However, comparison 
of the two groups of patients in this study remains valid since this presumed under-
estimation arose in both groups. Neither short- nor long-term morbidities were 
significantly lower in SGD than in CGD patients, being 39.6% versus 49.6% (p=0.305) 
and 16.7% versus 26.5% (p=0.229), respectively. (Table 3) The most debilitating 
morbidity is chronic lymphedema, which is difficult to define. Some authors have 
used measurements to define this, whilst others have opted to define chronic lymph-
edema as edema requiring intervention. Also debated is the minimum period of 
edema to define it as chronic, which we did when moderate or severe swelling was 
present (more than) 6 weeks after surgery and required treatment. In any case, it is a 
widely feared and unpleasant complication.20-22 There was a trend towards increased 
chronic lymphedema in patients after a CGD (25.6%) than in patients after a SGD 
(14.6%), yet this difference was not statistically significant (p=0.154). This difference 
was not the result of an imbalance of additional radiotherapy to the groin, as 10% 
of SGD patients received radiotherapy versus 9% of CGD patients (p=0.776). The 
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assessment of one large or two small incisions for CGD has no influence on the rate 
of lymphedema as well.23 Other reports also indicate that lymphedema rates after 
CGD (range 23 – 55%) are greater than after SGD (range 7% - 29%) albeit not always 
statistically significant.8, 11, 20, 22 Faries et al. recently reported the difference in lymph-
edema rates between immediate and delayed lymph node dissection. In these data 
of the Multicenter Selective Lymphadenectomy Trial (MSLT) I, lymphedema rates for 
SGD patients were 21.4% when undergoing immediate dissection and 22.6% when 
undergoing delayed dissection (p=0.9), while CGD patients had higher lymphedema 
rates of 36.4% for immediate dissection and 34.2% for delayed dissection (p=0.89).22 
Unfortunately, p-values for the difference in lymph edema between SGD and CGD 
patients were not provided.22
Regarding loco-regional control in the iloinguinal region, we found no differences 
between CGD and SGD, as regional recurrence rates were similar. (Table 3) The 
frequency of pelvic recurrences was equal in both groups. Possible causes for this 
counterintuitive observation could be the small sample size, patient selection, i.e., 
SGD patients having occult pelvic disease at time of surgery, and/or the overall 
worse prognosis of both groups of patients compared with literature. Patients might 
die of distant visceral metastases before pelvic recurrence has been developed. Our 
results are in line with other reports in the literature. Coit et al. reported similar nodal 
recurrence rates for SGD and CGD patients, while Singletary et al. reported relatively 
more nodal recurrence in SGD patients, but attributed that to the extent of tumor 
burden rather than the extent of surgery.10, 27
Our group of patients has worse survival compared to the literature; for example, 
Balch et al. reported 5-year OS rates of 50% for N1b, 45% for N2b and 40% for N3 
patients in the 2009 AJCC melanoma staging system analysis.28 Patients from our 
center showed (in that same order) 5-year OS rates of 43%, 26%, and 17%. Because 
of our relatively small study population compared with the enormous AJCC data-
bases of > 30.000 patients, a single event will have a greater impact on the estimate 
survival rates in Kaplan-Meier analysis, because the number at risk is smaller. Due 
to our relatively short median follow-up, we underestimate our long-term survival. 
Moreover, all patients were operated at the Erasmus University Medical Center – 
Daniel den Hoed Cancer Center, a tertiary center in the Netherlands for such cases. 
This implies that a negative selection bias is most likely. More advanced cases might 
lead to worse survival.
As well as the superficial lymph node ratio, the number of positive superficial nodes 
was a consistent prognostic variable for OS and DFS. (Table 4) This is consistent with 
the outcome after analysis of stage III melanoma patients by the AJCC.28-29 With an 
increasing number of positive superficial lymph nodes, the chance of involvement 
of the deep lymph nodes increased. No patients with 1 involved superficial node 
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showed additional positivity in the pelvic area, while this applied to 32% of patients 
with 2 – 3 involved superficial lymph nodes and to 66% of patients with ≥ 4 involved 
superficial lymph nodes. A decision on the extent of surgery might be made on 
the number of involved superficial lymph nodes. A scenario based on our results 
of preoperative CT scanning and the number of involved superficial lymph nodes 
could be considered. When preoperative CT is negative for involvement in the pelvic 
region and only one superficial lymph node is involved, SGD might be performed. 
When, after pathological analyses of the SGD specimen, more than one involved 
superficial lymph node is found, additional dissection of the pelvic region could be 
considered. CGD is performed in case of suspicion of multiple positive superficial 
lymph nodes and/or positive deep lymph nodes.
We acknowledge that this study is retrospective and has short follow-up time. 
We selected patients who underwent only therapeutic groin dissection for palpable 
disease and excluded patients who underwent elective lymph node dissection or 
sentinel node biopsy. The consequence was that our clean cohort of melanoma 
patients underwent surgery in a period of time (1991-2009) with evolving practice 
and imaging. Before bringing this scenario into clinical practice, results similar to 
those of the present study should be reported by other retrospective studies or a 
randomized controlled trial.
In conclusion, the poor outcome in melanoma patients with palpable nodal 
disease in the groin after CGD was equal after SGD in our series and in many 
other reports in the literature. Patients without overt iliac nodes on CT might safely 
undergo SGD and be spared the greater morbidity of CGD. CGD might be reserved 
for patients with multiple positive nodes in the SGD and/or positive nodes on CT 
scan. A prospective randomized controlled trial is the only study that can overcome 
the classical drawbacks of this and other retrospective studies.
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AbSTRACT
The aim of this study was to evaluate the incidence and outcome of melanoma of 
unknown primary site (MUP) after therapeutic lymph node dissection (TLND) of 
palpable nodal melanoma metastases. Disease-free (DFS) and overall survival (OS) 
time of MUP patients were analyzed and compared to patients undergoing a TLND 
for known primary melanomas (MKP).
This single institution retrospective study analyzed 342 consecutive patients who 
were treated with 415 TLNDs for palpable nodal disease from 1982 to 2009. Univari-
ate and multivariate analyses included: MUP versus MKP, gender, Breslow thickness, 
ulceration of primary tumor, site of primary tumor, site of dissection, extracapsular 
extension (ECE), number of collected nodes, number of positive nodes and the node 
positive ratio.
A total of 47 MUP were identified in 342 patients (13.7%). In univariate analysis, a 
trend was seen towards better survival for MUP patients compared to MKP patients 
having 5-year OS rates of 40% and 27%, respectively (p=0.06). Multivariate analysis 
for OS showed two highly significant factors associated with worse prognosis: ex-
tracapsular extension and N3 status (both p < 0.001). Two factors were associated 
with a significant better prognosis: MUP (p = 0.03) and a neck dissection (p = 0.04).
Patients with MUP showed a significant better OS compared to patients with 
melanoma metastases from known primary tumors. Presence of extracapsular exten-
sion and an increased number of positive nodes are statistically significantly negative 
prognostic factors for OS. The absence of a primary melanoma in stage III melanoma 
patients does not preclude surgery.
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iNTRoduCTioN
First presentation of palpable nodal disease in melanoma patients still occurs in 
spite of early recognition programs leading to a decrease in Breslow thickness.1 
Approximately 4% to 9% of all patients presenting with melanoma are diagnosed 
with palpable nodal disease, i.e. stage III disease.2-3 Patients with clinically detected 
and histologically confirmed nodal melanoma metastases with no identification of 
a primary site are diagnosed as patients with melanoma of unknown primary site 
(MUP). In 8% to 20% of all therapeutic lymph node dissections (TLND) for regional 
metastatic melanoma, no primary tumor can be found.4-5 Possible explanations for 
the absence of a primary tumor are spontaneous regression, unidentified primary 
melanoma, previous excision of what was considered a benign lesion or a malignant 
transformation of an ectopic nodal melanocyte.4, 6 Whether patients with MUP have 
better or worse prognosis than patients with melanoma of known primary site (MKP) 
presented with nodal metastases is uncertain. Some studies suggest an improved 
survival for patients with MUP compared to MKP, whereas others report similar 
survival or even worse survival for MUP patients.3-5, 7
The aim of this study was to evaluate the incidence and outcome of MUP patients 
after TLND for palpable nodal disease compared to patients undergoing a TLND 
for palpable nodal disease with a known primary tumor. Disease-free (DFS) and 
overall survival (OS) were analyzed to identify prognostic factors for all patients who 
underwent TLND.
PATieNTS ANd MeThodS
Patients in this retrospective study were all treated with therapeutic lymph node 
dissection (TLND) for palpable nodal disease between 1982 and 2009 at the Erasmus 
University Medical Center - Daniel den Hoed Cancer Center in Rotterdam, the Neth-
erlands. In 342 melanoma patients, a total of 415 TLNDs were performed. Patients 
who were treated with a lymph node dissection (LND) because of a positive sentinel 
node, patients who underwent LND with an isolated limb perfusion and patients 
who underwent elective LND were excluded.
There was no history of a primary melanoma and no primary tumor could be 
located in 47 of 342 patients (13.7%). The control group was formed by 295 patients 
(86.3%) with a known primary tumor. The diagnosis of unknown primary melanoma 
(MUP) consisted of histologically confirmed nodal metastatic melanoma and the 
absence of a primary tumor, confirmed after thorough examination of the skin and 
unusual primary sites such as urogenital, nasopahryngeal, or ocular.
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All patient, primary and metastatic tumor characteristics were prospectively col-
lected and sorted in a data base. Clinically detectable nodal disease and the absence 
of visceral metastases was radiographically confirmed by either ultrasonography of 
the lymph node fields and/or the liver, a chest X-ray, a cerebral MRI or a computed 
tomography scan of the thorax and abdomen.
Surgical technique
Four co-authors performed the majority of lymph node dissections assessed for this 
study (A.N.V.G., J.H.D.W., A.M.M.E. and C.V.) Ilio-inguinal dissections or deep groin 
dissections included dissection of the femoral-inguinal and external iliac nodes up 
to the common iliac artery (if necessary up to the aorta bifurcation) and dissection 
of the obturator nodes. Ilio-inguinal dissections were performed using one long 
vertical incision in the early stage of the study period. Two separate incisions 
were used in a later stage. Sartorius muscle transposition to cover and protect the 
femoral vessels was selectively performed when adjuvant radiotherapy was to be 
expected and/or patient’s skin was at risk. An axillary lymphadenectomy comprised 
dissection for levels I-III. The modified radical neck consists of dissection of level 
I-V with preservation of the spinal accessory muscle, internal jugular vein and 
sternocleidomastoid muscle. Radical neck dissections were only performed if last 
mentioned structures were involved in the tumor process. In all patients vacuum 
drains were placed operatively and removed postoperatively if they produced less 
than 100 ml in 24 hours. Postoperatively the treatment protocol of all patients 
consisted of daily wound inspections. No pre-, peri- or post-operative antibiotic 
prophylaxis was routinely given. Ilio-inguinal dissection patients were ordered 3 
days of bed rest postoperatively, after which they would be mobilized with the use 
of a support stocking. Patients received low molecule weight heparin during im-
mobilization. The number and type of complications and duration of hospitalization 
were recorded.
Adjuvant therapy
In the later years of this study, several patients participated in the EORTC 18 951, 
18 952 or 18 991 trials. The EORTC 18 951 trial found no clinically relevant activity 
for adding interleukine-2 (IL-2) to a chemo-immunotherapy combination of dacar-
bazine, cisplatin and interferon (IF)-α 2b.8 The EORTC 18 952 trial evaluated the 
effects of adjuvant therapy with intermediate doses of IF-α 2b, and did not show 
a significant survival benefit for patients in the treatment group.9 The EORTC 18 
991 trial evaluated the role of long-term treatment with pegylated IF and found a 
significant sustained effect on recurrence-free survival.10 Seven of 47 (14.9%) MUP 
patients and 46 of 295 (15.6%) of MKP patients participated in these trials.
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Adjuvant radiotherapy was considered if narrow resection margins, excessive 
nodal involvement, i.e. more than three positive lymph nodes, extracapsular exten-
sion or simultaneous in-transit, subcutaneous or skin metastases in the operation 
area were present.
Statistical analysis
All descriptive and survival analyses were performed assessing the 342 patients. 
The Fisher exact test, chi-square test and Mann-Whitney U test were executed to 
determine the differences between MUP and MKP patients. Disease-Free Survival 
(DFS) was calculated from the first dissection date to the date of first recurrence. 
Overall Survival (OS) time was calculated from the dissection date to date of death. 
Patients without such an event at their last follow-up were censored at that time. 
Estimates were made according to the Kaplan Meier method and compared with 
the log rank score. The following factors were evaluated with a univariate Cox 
regression analysis: age, gender, MUP, location of the affected lymph node basin, the 
number of tumor positive lymph nodes, node-positive ratio (N-ratio; total affected 
lymph nodes / total harvested nodes), extracapsular extension (ECE) and adjuvant 
radiotherapy. The number of positive lymph nodes was defined by the AJCC 2009 
classification, i.e. N1 (one positive lymph node), N2 (two or three positive lymph 
nodes) and N3 (more than three positive lymph nodes). Multivariate analysis us-
ing Cox’s proportional hazards regression model was performed with all variables 
reaching a significance level of 10% in the univariate models. A stepwise backward 
algorithm was used at a level of 5% significance to exclude factors. All statistical 
analyses were performed using SPSS software (SPSS PASW 17.0.2).
ReSuLTS
A total of 342 patients were treated with therapeutic lymph node dissection (TLND). 
A melanoma of unknown primary (MUP) was diagnosed in 47 (13.7%) patients and 
295 patients (86.3%) had a known primary tumor (MKP). Two or more dissections 
were performed in 59 patients making the total number of dissections 415. The 
following types of dissections were performed: inguinal (13%), iliacal (5%), ilio-
inguinal (35%), axillary (20%) and neck (28%).
Characteristics
Patient, tumor and lymph node characteristics are summarized in Table 1. Age char-
acteristics were very similar for MUP (median 56, interquartile range (IQR) 44 – 66 
years) and MKP (median 56, IQR 46 – 68 years) patients (p=0.75). Gender was not 
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Table 1 – Baseline characteristics of patient, primary and metastatic melanoma for patients with a 
known primary site (MKP, n=295) and patients with an unknown primary site (MUP, n=47)
Characteristic MKP MUP p-value*
N % N %
Gender
Male 149 50.5 27 57.4
Female 146 49.5 20 42.6 0.38
Age
Median (IQR) 56 (44 – 66) 56 (46 – 68) 0.75
Site of primary
Head/neck 61 20.7 - -
Trunk 88 29.8 - -
Extremity 141 47.8 - -
Other 5 1.7 - - N/A
Breslow thickness
T1 35 11.9 - -
T2 80 27.1 - -
T3 72 24.4 - -
T4 75 25.4 - -
Missing 33 11.2 - - N/A
Histology
NM 89 30.2 - -
SSM 64 21.7 - -
Other 17 5.8 - -
Missing 125 42.4 - - N/A
Cark level
II 13 4.4 - -
III 69 23.4 - -
IV 115 39.0 - -
V 34 11.5 - -
Missing 64 21.7 - - N/A
Ulceration
Absent 217 73.6 - -
Present 78 26.4 - - N/A
Site of TLND
Inguinal 39 13.2 5 10.6
Iliacal 15 5.1 1 2.1
Ilio-inguinal 103 34.9 17 36.2
Axillary 58 19.7 10 21.3
Neck 80 27.1 14 29.8 0.89
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significantly different between the MKP group (50% male) and MUP group (57% 
male) (p=0.38). The site and the extent of the lymph node dissection performed was 
not significantly different between both groups (all p>0.05). Adjuvant radiotherapy 
was given in 17.6% of MKP patients and 29.8% of MUP patients (p=0.07). The mean 
and median follow-up for the entire population was 36 and 19 months respectively 
(IQR 9 – 43). The mean and median follow-up for MUP was 40 and 24 months (IQR 
14 – 49) against 35 and 19 months for MKP (IQR 8 – 42), respectively.
Complications
Of all patients, 44.4% experienced at least one complication during follow-up. Most 
frequent complications were wound infection and/or skin necrosis (17.8%), seroma 
(16.9%) and chronic lymph edema (12.3%). For patients who underwent an inguinal 
Table 1 (continued)
Characteristic MKP MUP p-value*
N % N %
Nr. of harvested nodes
Median (IQR) 16 (11 – 26) 17 (12 – 28) 0.55
Nr. of positive nodes
Median (IQR) 2 (1 – 4) 1 (1 – 7) 0.71
AJCC staging
N1 124 42.0 24 51.1
N2 86 29.2 6 12.8
N3 70 23.7 14 29.8
Missing 15 5.8 3 6.4 0.07
LN ratio (%) 0.38
Median (IQR) 11.6 (6.3 – 26.3)  8.2 (4.8 – 32.3) 
ECE
no 205 69.5 29 61.7
yes 90 31.5 18 38.3 0.31
Adjuvant radiotherapy
no 243 82.4 33 70.2
yes 52 17.6 14 29.8 0.07
Nr. of TLND performed
1 295 81.7 47 87.0
> 1 66 18.3 7 13.0 0.88
MKP = Melanoma of known primary site; MUP = Melanoma of unknown primary site; IQR = 
Interquartile Range
NM = Nodular melanoma; SSM = Superficial spreading melanoma; TLND = Therapeutic Lymph Node 
Dissection; LN = Lymph Node; ECE = extra capsular extension; N/A = Not applicable
*p-values are calculated using the Fisher exact test, Chi-square test or Mann-Whitney U test
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LND, 59.1% experienced at least one complication, while at least one complication 
was found in 37.5% of patients who underwent an iliacal LND, in 65.0% of patients 
who underwent an ilio-inguinal LND, in 26.5% of patients who underwent an axillary 
dissection and in 25.5% of patients who underwent a neck dissection. Chronic lymph 
edema was present in 11.4% of patients who underwent an inguinal LND, in 31.3% of 
patients who underwent an iliacal LND, in 24.2% of patients who underwent an ilio-
inguinal LND and in 1.5% and 2.1% of patients who underwent an axillary and neck 
LND, respectively. MUP patients had at least one complication in 55.3% and chronic 
lymph edema was present in 12.5%. MKP patients had at least one complication in 
55.6% and chronic lymph edema was present in 12.8%.
The median duration of hospitalization was 5 days (IQR 3 – 8 days) for both MUP 
and MKP patients (p=0.484).
Survival
Univariate analyses demonstrated that the following factors significantly impacted 
disease free survival (DFS): site of dissection, number of positive nodes, node posi-
tive ratio, ECE. (Table 2) Multivariate analyses for DFS showed three significant prog-
Table 2 – Univariate analyses of prognostic factors for disease free survival and overall survival
Variable
DFS OS
HR 95% CI p-value HR 95% CI p-value
Gender
Female 1 1
Male 1.03 0.80 – 1.33 0.81 1.22 0.94 – 1.59 0.13
Age
≤50 1 1
>50 0.94 0.73 – 1.21 0.63 1.01 0.77 – 1.32 0.94
Site of primary
extremity 1 1
head/neck 0.77 0.53 – 1.11 0.16 0.81 0.55 – 1.18 0.26
trunk 1.34 0.99 – 1.82 0.06 1.30 0.95 – 1.78 0.11
other 0.54 0.22 – 2.20 0.54 0.49 0.11 – 1.97 0.31
unknown 0.73 0.63 – 1.38 0.73 0.70 0.45 – 1.08 0.10
MUP
No 1 1
Yes 0.92 0.64 – 1.31 0.63 0.68 0.45 – 1.03 0.07
Breslow
T1 1 1
T2 1.37 0.85 – 2.21 0.20 1.54 0.91 – 2.63 0.11
T3 1.78 1.10 – 2.89 0.02 1.80 1.05 – 3.07 0.03
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Table 2 (continued)
Variable
DFS OS
HR 95% CI p-value HR 95% CI p-value
T4 1.18 0.72 – 1.94 0.51 1.62 0.95 – 2.76 0.08
MUP 1.21 0.72 – 2.06 0.47 1.08 0.59 – 1.97 0.81
Histology
SSM 1 1
NM 1.07 0.74 – 1.55 0.73 1.10 0.75 – 1.61 0.64
MUP 0.91 0.59 – 1.41 0.68 0.71 0.44 – 1.15 0.16
Other 0.70 0.36 – 1.39 0.31 0.94 0.49 – 1.82 0.85
Clark level
II 1 1
III 0.88 0.46 – 1.69 0.70 1.16 0.55 – 2.45 0.70
IV 0.96 0.51 – 1.80 0.90 1.11 0.54 – 2.29 0.78
V 0.85 0.41 – 1.73 0.64 1.12 0.51 – 2.51 0.77
MUP 0.83 0.42 – 1.64 0.60 0.79 0.36 – 1.74 0.55
Ulceration
Absent 1 1
Present 1.21 0.90 – 1.63 0.2 1.48 1.10 – 1.99 0.01
Site of TLND
inguinal 1 1
iliacal 0.97 0.47 – 1.98 0.93 0.96 0.49 – 1.87 0.90
ilio-inguinal 0.76 0.50 – 1.14 0.18 0.71 0.47 – 1.07 0.10
axillary 1.14 0.73 – 1.76 0.57 1.06 0.68 – 1.67 0.78
neck 0.63 0.41 – 0.97 0.04 0.61 0.39 – 0.94 0.03
Nr of harvested nodes 1.00 0.99 – 1.01 0.54 1.00 0.99 – 1.01 0.65
AJCC staging
N1 1 1
N2 1.34 0.98 – 2.50 0.07 1.33 0.96 – 1.84 0.09
N3 1.90 1.39 – 2.58 <0.001 1.97 1.43 – 2.72 <0.001
LN ratio 2.35 1.51 – 3.64 <0.001 2.83 1.80 – 4.45 <0.001
ECE
Absent 1 1
Present 1.60 1.23 – 2.08 <0.001 1.83 1.39 – 2.40 <0.001
Adjuvant radiotherapy
No 1 1
Yes 1.13 0.83 – 1.53 0.45 1.18 0.85 – 1.63 0.33
DFS = Disease free survival; OS = Overall survival; HR = hazard ratio; MKP = melanoma of known 
primary site; MUP = melanoma of unknown primary site; SSM = superficial spreading melanoma; NM 
= nodular melanoma; TLND = Therapeutic Lymph Node Dissection; LN = Lymph node; ECE = Extra 
capsular extension
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nostic factors: N2 (p = 0.04), N3 (p <0.001) and ECE (p = 0.004). (Table 3) Gender, 
age, the number of harvested lymph nodes, primary site, Clark level, histology of 
the primary, MUP and adjuvant radiotherapy were not significant. Hazard ratios and 
p-values of all analyzed factors are summarized in table 2 and 3.
As for overall survival (OS), ulceration, site of dissection, node positive ratio, 
number of positive nodes, ECE and MUP were significant prognostic factors. (Table 
2) Ulceration was not known for MUP patients and not included in multivariate 
analyses. Multivariate analysis for OS revealed two highly significant factors associ-
ated with worse prognosis: the presence of extracapsular extension (ECE) and N3 
status (both p < 0.001). Two factors were associated with significant better prognosis: 
MUP (p = 0.03) and neck dissections (p = 0.04). (Table 3)
The estimated 5-year DFS rates for extracapsular extension (ECE) were an esti-
mated 12% when present and 26% when absent (p <0.001). For nodal status, 5-year 
DFS rates were 31%, 17% and 9% for the respective N1, N2 and N3 categories (p < 
0.001). The five-year DFS rate for MKP patients was 21%, while the five-year DFS rate 
for MUP patients was 25% (p=0.619).
Table 3 – Multivariate analyses of prognostic factors in all patients (n=342) for disease free survival 
and overall survival
Disease Free Survival
Variable N HR 95% CI P
AJCC staging N1 148 1
N2 92 1.40 1.02 – 1.93 0.04
N3 84 2.08 1.47 – 2.94 <0.001
ECE No 234 1
Yes 108 1.57 1.16 – 2.12 0.004
Overall Survival
Variable N HR 95% CI P
ECE No 285 1
Yes 130 1.69 1.25 – 2.28 0.001
MUP No 47 1
Yes 295 0.62 0.40 – 0.96 0.03
AJCC staging N1 148 1
N2 92 1.28 0.92 – 1.79 0.15
N3 84 1.80 1.28 – 2.52 0.001
Dissection type Inguinal 44 1
Axillary 68 0.74 0.47 – 1.16 0.19
Neck 94 0.61 0.38 – 0.97 0.04
AJCC = American Joint Committee of Cancer; ECE = extracapsular extension; HR = Hazard ratio; CI = 
Confidence Interval; MUP = Melanoma of Unknown Primary
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Absence of ECE demonstrated a 5-year OS of 36% compared to 15% when present 
(p < 0.001). (Figure 1A) The estimated 5-year OS rates for the different categories 
of nodal status (N1, N2 and N3) were 36%, 30% and 16% respectively (p < 0.001). 
(Figure 1B) The 5-year estimated Kaplan-Meier OS rate for MUP vs. MKP showed a 
trend towards a better survival for MUP at 43% vs. 27% for MKP, respectively (p = 
0.06). (Figure 1C)
figure 1A: Overall Survival – Extracapsular 
extension
figure 1b: Overall survival – number of positive 
lymph nodes according to AJCC system
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diSCuSSioN
In this retrospective study, 342 melanoma patients treated with a total of 415 thera-
peutic lymph node dissections (TLND) for palpable lymph nodes metastases were 
analyzed. Outcome of melanoma patients with an unknown primary site (MUP) were 
compared with patients with a known site of the primary melanoma lesion (MKP). 
After multivariate analysis, a significant overall survival (OS) benefit was found for 
patients with MUP over MKP patients. Five-year OS rates were 43% for MUP patients 
and 27% for MKP patients (p = 0.03).
Cormier et al. demonstrated a significant survival benefit for 71 MUP patients 
in a multivariate Cox proportional hazard model when adjusted for nodal status, 
dissection site, age, gender and adjuvant therapy as well (p = 0.006). The 5-year OS 
rates were 55% and 42% for MUP vs. MKP respectively, with a median follow-up 
of 92 months.5 Lee et al. demonstrated similar results with 5-year OS rates of 55% 
for MUP patients (N = 262) and 44% for MKP patients (N = 1309), with a median 
follow up of 36 months. Again MUP was identified as a significant prognostic factor 
in multivariate analysis (p = 0.0001).4 Where previous mentioned studies revealed a 
small increased 5-year OS rate compared to our results, Chang et al.3 reported similar 
5-year OS rates for both groups; 46% for MUP and 49% for MKP.
All the above-mentioned studies demonstrated higher 5-year OS rates for MKP 
(42% - 49%) compared to our results (27%). No significant differences were found 
in patient and tumor characteristics between all studies.3-5 A reason for the worse 
survival of MKP patients in the present study might be the short median follow-up. 
Moreover, a tertiary referral center might perform surgery in patients with more 
advanced cases, which might lead to worse survival.
A possible hypothesis for the survival benefit seen in MUP patients is an endog-
enous immune response,11 which also might have caused regression of the primary 
lesion. Interleukin-2 (IL-2) and interferon-α (IFN-α), have shown some therapeutic 
benefit, supposedly by enhancing antitumor immune responses.10, 12 In a small study 
Moschos et al. treated twenty stage IIIB and IIIC patients with neoadjuvant high-dose 
interferon-alfa-2b. Three were diagnosed with MUP and demonstrated no evidence 
of disease after 7, 9 and 10 months respectively.13 Furthermore, cytoreductive surgery 
(complete metastatectomy) revealed a long-term clinical benefit that depended on 
the host’s immune response to a surgical reduction in tumor burden.14 Causes for 
the effectiveness of these therapies in MUP patients might be the favorable patients’ 
immune system. Unfortunately, no specific data is available to prove a difference 
between survival of MUP and MKP patients receiving any form of immunotherapy.
The rate of MUP in patients treated with TLND for palpable nodal disease was 
13.7% in our institute (47/342). This is in line with other studies. In the study per-
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formed by Rutkowski et al., the rate was 12.8%.15 Lee et al. demonstrated a MUP rate 
of 16.7%, while the study performed by Cormier et al. had a MUP rate of 13.2%.4-5
Lymph node status and ECE are important significant prognostic factors for OS, 
which has been demonstrated in several studies.4, 15-18 A previous study from our 
group demonstrated that ECE was the most important prognostic factor for OS after 
TLND.16 A recent MUP study by Rutkowski et al also revealed ECE and lymph node 
status as significant factors for OS.15 Balch et al. found several significant prog-
nostic factors for stage III melanoma such as nodal micrometastases, number of 
tumor-containing lymph nodes, Breslow thickness, patient age, ulceration, site of the 
primary and primary mitotic rate. Unfortunately MUP and ECE were not analyzed 
in their study.17 Disease of patients with metastatic melanoma from an unknown 
primary site, arising in lymph nodes, skin, or subcutaneous tissues, was clarified to 
be categorized as stage III rather than stage IV.19
The fact that patients treated with neck dissections had a survival benefit versus 
inguinal dissections is counter-intuitive, since head/neck melanomas are associated 
with worse prognosis.2, 17, 20 It may be a chance finding as the minimal significant 
difference (p = 0.04) could be explained by the small sample size, the difference in 
age (median 54 vs. 62 years) and percentage of ECE (24.4% vs. 37.1%).
Comparing MUP patients with MKP patients stratified by Breslow thickness as T1, 
T2, T3 and T4 showed increased hazard ratio’s for T2 (HR = 1.54), T3 (HR = 1.80) and 
T4 (HR = 1.62) versus a T1 tumor. MUP patients showed nearly the same hazard ratio 
(HR = 1.08) as patients with T1 tumors at univariate analysis. Increasing Clark level 
was of little significance for OS, as did the MUP patients with unknown Clark scores. 
Patients with ulcerated primaries had significant worse OS (p = 0.01) compared to 
the unknown group. Also MUP patients have a survival benefit compared to patients 
with a primary tumor located on an extremity or trunk. It was previously suggested 
that MUP patients had a worse prognosis compared to patients with known primary 
tumors.3 These data suggest at least that MUP is not a significant negative prognostic 
factor compared to some stage III melanoma patients with known primary tumor 
characteristics.
A recent study in the Netherlands by Koomen et al. demonstrated that the in-
cidence of non-cutaneous melanoma is very rare.21 Therefore the value of naso-
pharyngeal examination is doubtful and could be ignored when a patient presents 
with a palpable lymph node without a known primary tumor. A thorough physical 
examination in order to locate a primary tumor is still recommended. Also close 
examination of the skin of the drainage area of the metastatic lymph node could be 
considered in order to indentify a regressive primary lesion.22
In conclusion, this study showed the presence of ECE, an increased number of 
positive nodes and patients with MKP as significantly negative prognostic factors 
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for OS. Patients with melanoma of an unknown primary site showed a significantly 
better OS after multivariate analysis compared to patients with melanoma metastases 
from known primary tumors. Melanoma patients with palpable nodal disease and an 
unknown primary melanoma should be classified as stage III disease. The absence 
of a primary melanoma in stage III melanoma patients does not preclude surgery.
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AbSTRACT
Several reports in the literature suggest a difference in outcome between mela-
noma patients with an unknown primary (MUP) and a known primary (MKP) with 
macroscopic (clinically palpable) nodal disease. The purpose of this study was to 
compare the outcomes for MUP and MKP patients following therapeutic lymph node 
dissection (TLND) for macroscopic nodal disease.
From a large, prospective, single institution database the details of melanoma 
patients who first presented with macroscopic nodal disease and underwent TLND 
between 1971 and 2010 were extracted and analyzed.
There were 287 MUP patients and 264 MKP patients who fulfilled the study 
selection criteria. MUP patients had better disease-free, distant metastasis-free 
and melanoma-specific survival after their TLND than MKP patients (all p<0.001). 
Extranodal melanoma extension, >3 positive lymph nodes and administration of 
adjuvant radiotherapy were all independent predictors of reduced disease-free and 
melanoma-specific survival (all p<0.05). MUP patients also had a better prognosis 
than MKP patients whose primary melanoma had regression (p=0.001).
The occurrence and improved outcome of MUP patients may be due to immune-
induced total regression of the primary tumor and better immunological prevention 
or control of distant metastatic disease. Alternatively, in some MUP patients, mela-
noma may not be metastatic but may originate de novo from naevus cells in lymph 
nodes, with the more favorable prognosis attributable to their primary nodal origin 
and complete surgical resection.
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iNTRoduCTioN
In most patients with metastatic melanoma there is a known primary tumor site.1 
However, 2-5% of all melanoma patients with metastatic disease have an unknown 
primary site (MUP)2-9. MUP has been defined as histologically confirmed subcutane-
ous, nodal or visceral metastatic melanoma with no evidence or history of a cutane-
ous or non-cutaneous primary melanoma. Explanations for the existence of MUP 
include an unidentified primary melanoma, spontaneous regression of a primary 
melanoma after it has metastasized, or melanoma arising de novo from ectopic 
melanocytes located within lymph nodes (such as intranodal naevus cells).2,10-12
The most common site of first recurrence in melanoma patients with a known 
primary (MKP) is in the regional lymph node (LN) field.1,13 Of melanoma patients 
presenting with macroscopic nodal disease, 13-17% have no evidence of a syn-
chronous primary tumour after thorough examination, and no history of a previous 
primary melanoma.1,14-17
Several reports in the literature suggest a difference in outcome between MUP 
and MKP patients. Dasgupta and colleagues published the first report on MUP in 
1963. In their study survival was similar in MUP patients and MKP patients.5 Since 
then, several further reports have also suggested an equivalent outcome for MUP 
and MKP patients.4,6-8,12,17,18 However, others have reported that MUP patients have 
a worse outcome.4,19 Yet other studies suggest that the prognosis of MUP patients is 
better than that of MKP patients.2,14-16
Two previously reported retrospective studies from our institution demonstrated 
better survival for MUP patients with Stage IV disease than for MKP patients with 
equivalent disease.23,24 The aim of the current study was to compare the outcome for 
MUP patients undergoing a therapeutic lymph node dissection (TLND) for macro-
scopic nodal disease (AJCC stage IIIB or IIIC) with that of MKP patients diagnosed 
and treated similarly. Another objective was to assess the prognostic significance of 
primary tumor regression in the MKP cohort.
MeThodS
For this retrospective, single institution study, data were extracted from the pro-
spectively collected Melanoma Institute Australia (MIA) database, and patients who 
had undergone a TLND for macroscopic (clinically palpable) nodal disease at MIA 
between 1971 and 2010 were identified in the following manner: In the study period 
26,825 patients with a single known primary melanoma were treated at MIA, and 
1162 who had metastatic disease from an unknown primary site. Only patients within 
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these two groups who had stage III disease at the time of their initial presentation 
were selected for the study (n=1969). Patients who were classified as having stage 
III disease on the basis of a positive sentinel node biopsy were then excluded 
(n=758), as well as patients who underwent an elective lymph node dissection and 
were found to have one or more positive nodes (n=204). Finally, patients were 
excluded if they had local recurrence or in transit metastasis simultaneously with 
macroscopic nodal disease (n = 456). The data retrieved for each patient included 
patient demographics, primary tumor characteristics, nodal metastatic tumor details, 
and surgery, follow-up and survival information.
Patients
After excluding patients according to the criteria described above, 551 melanoma 
patients who underwent TLND at MIA after presenting with macroscopic disease 
in regional lymph nodes between 1971 and 2010 were identified. Eighty-nine pa-
tients (16%) underwent TLND before 1990 and the remainder after this time. A 
single primary melanoma had been diagnosed in 264 patients (47.8%), while 287 
patients (52.5%) underwent TLND for nodal melanoma from an unknown primary 
site (MUP). Patients were diagnosed with MUP when the palpable nodal melanoma 
was histologically confirmed and there was no history of a synchronous or meta-
chronous primary tumor, and after thorough examination of the skin and potential 
non-cutaneous primary melanoma sites.
diagnosis and surgery
All MKP patients underwent wide local excision and regional LN dissection at MIA at 
the time of presentation with clinical lymph node involvement (n=264). The diagnosis 
of metastatic melanoma in regional lymph nodes was usually confirmed preopera-
tively by fine needle biopsy25,26, and the absence of distant disease was demonstrated 
radiographically using a variety of imaging techniques including ultrasonography 
of lymph node fields and/or the liver, chest X-ray, computed tomography, positron 
emission tomography, and/or magnetic resonance imaging.
Six co-authors performed the majority of the lymph node dissections included in 
this study (A.J.S., M.J.Q., R.P.M.S., K.F.S., J.R.S. and J.F.T.). The quality of their TLND 
surgery, as reflected by lymph node retrieval parameters, has been documented in 
a prior publication.27 MIA-affiliated pathologists at the Royal Prince Alfred Hospital, 
Sydney undertook the histopathological assessment of all surgical specimens.
Statistics
Statistical analyses were performed with SPSS 17.0 software (SPSS PASW Inc. 
Chicago, IL). Variables were coded for statistical analysis as mentioned in table 1. 
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Table 1 Patient, tumor and lymph node dissection data for MUP and MKP patients
MUP patients
n (%)
287 (52.2)
MKP patients
n (%)
264 (47.8)
p*
Gender
Female 83 (28.9) 79 (29.9)
Male 204 (71.1) 185 (70.1) 0.852
Age (yr)
Mean±SD 53.6±0.97 57.3±1.02 0.008
≤ 56 153 (53.3) 117 (44.3)
> 56 134 (46.7) 147 (55.7) 0.041
Primary site
Extremity - 111 (42.9)
Trunk - 82 (31.7)
Head & Neck - 66 (25.5)
Missing - 5 -
Thickness (mm)
Median (IQR) - 3.95 (2.22-6.08) -
≤ 1.00 / T1 - 20 (8.1)
> 1.00 – ≤ 2.00 / T2 - 32 (12.9)
> 2.00 – ≤ 4.00 / T3 - 81 (32.7)
> 4.00 / T4 - 115 (46.4) -
Missing - 16
Tumour mitotic rate (/mm2)
Median (IQR) - 6 (3-13) -
Clark level
II - 12 (5.3)
III - 37 (16.3)
IV - 125 (55.1)
V - 53 (23.3) -
Missing - 37
Histologic subtype
SSM - 37 (18.9)
NM - 117 (59.7)
Other - 42 (21.4) -
Missing - 68
Ulceration
Absent - 92 (41.3)
Present - 131 (58.7) -
Missing 41
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Fisher’s exact, Chi-square and Mann-Whitney U tests were used to calculate p-values 
for differences between MUP and MKP patients. For univariate survival analysis, 
Kaplan-Meier curves and log rank tests were assessed. A Cox proportional hazards 
model using backward stepwise selection was performed for multivariate analyses. 
Table 1 (continued)
MUP patients
n (%)
287 (52.2)
MKP patients
n (%)
264 (47.8)
p*
Regression
Absent - 79 (48.2)
Present - 85 (52.2) -
Missing - 100
Site of LND
Neck 74 (25.9) 71 (27.1)
Axilla 133 (46.5) 96 (36.6)
Groin 70 (24.5) 81 (30.9)
Other 9 (3.1) 14 (5.3) 0.075
Missing 1 2
Nr. of harvested nodes
Median (IQR) 21 (12-31) 18 (12-28) 0.210
Nr. of positive nodes
Median (IQR) 1 (1-3) 2 (1-3) 0.047
1 159 (57.0) 127 (48.8)
2-3 69 (24.7) 76 (29.2)
>3 51 (18.3) 57 (21.9) 0.166
Missing 8 4
Lymph node ratio (%)
Median (IQR) 8 (5-19) 11 (5-26) 0.021
≤ 10 157 (57.7) 125 (49.6)
10 - ≤ 25 67 (24.6) 63 (25.0)
> 25 48 (17.6) 64 (25.4) 0.071
Missing 15 12
Extracapsular extension
Absent 221 (77.0) 199 (75.4)
Present 66 (23.0) 65 (24.6) 0.689
Adjuvant Radiotherapy
No 208 (72.5) 195 (73.9)
Yes 79 (27.5) 69 (26.1) 0.773
MUP = Melanoma with Unknown Primary; MKP = Melanoma with Known Primary; SSM = Superficial 
Spreading Melanoma; NM = Nodular Melanoma; IQR = Inter Quartile Range
* P-values were calculated using the Fisher exact test, Chi-square test or Mann-Whitney U test.
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Disease-free survival (DFS) was measured from the date of LN dissection to the date 
of any first recurrence. Distant metastasis-free survival (DMFS) was measured from 
the date of LN dissection to the date of first distant recurrence. Melanoma-specific 
survival (MSS) was measured from the date of LN dissection to the date of death 
from melanoma. Patients without such an event were censored at the time of last 
follow-up.
ReSuLTS
Of the 551 patients who presented with macroscopic nodal disease, 26% had a neck 
dissection, 42% had an axillary dissection, 28% had a groin dissection and 4% had 
a dissection of another LN field (e.g. epitrochlear or popliteal). Mean and median 
follow-up times for MUP patients were 5.1 and 3.3 (interquartile range (IQR) 1.1 – 
7.6) years, respectively. Mean and median follow-up times for MKP patients were 3.8 
and 1.4 (IQR 0.7 – 4.6) years, respectively. There was no change in the incidence of 
the diagnosis of MUP over the study period.
differences between patient populations
Significant differences were present between MUP and MKP patients (Table 1). The 
mean ages were 53.6 (standard deviation (SD) ±0.97) years for MUP patients and 
57.3 (SD ±1.02) years for MKP patients (p=0.008). The median number of positive 
nodes was significantly higher in MKP patients (p=0.047) as well as the positive LN 
ratio (p=0.021). The administration of adjuvant radiotherapy was not significantly 
different between the two groups, with 27.5% of MUP patients and 26.1% of MKP 
patients receiving radiotherapy postoperatively (p=0.773).
Survival analyses
In univariate analyses for all patients, the following were significant prognostic fac-
tors for reduced DFS: known primary melanoma, greater number of positive LNs, 
higher positive LN ratio, extracapsular tumor extension (ECE) and administration 
of adjuvant post-operative radiotherapy (all p<0.05) (Table 2). After multivariate 
analyses for DFS, significant adverse prognostic factors for survival were: known pri-
mary melanoma (p<0.001), ECE (p=0.010), administration of adjuvant radiotherapy 
(p<0.001) and the presence of >3 positive nodes (p<0.001) (Table 3). MKP was a 
significant adverse prognostic factor for DMFS in univariate analysis (p<0.001).
In univariate analyses significant adverse prognostic factors for MSS were: MKP, 
older age, increased number of positive LNs, increased positive LN ratio, ECE, and 
administration of adjuvant radiotherapy (Table 2). After multivariate analyses, the 
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following factors remained significant: MKP (p<0.001), older age (p=0.023), ECE 
(p<0.001), administration of adjuvant radiotherapy (p<0.001) and > 3 positive nodes 
(p<0.001) (Table 3).
For DFS and MSS, positive LN ratio was not assessed in the multivariate model 
due to correlation with the number of positive nodes. When positive LN ratio was 
Table 2 – Univariate analysis of prognostic factors in all patients
Variable Disease-Free Survival Melanoma-Specific Survival
HR 95% CI P* HR 95% CI P*
Known primary
Absent Ref Ref
Present 1.88 1.46 – 2.42 < 0.001* 2.25 1.70 – 2.98 < 0.001*
Gender
Female Ref Ref
Male 0.90 0.68 – 1.18 NS 1.06 0.78 – 1.43 NS
Age (yr)
Mean±SD 1.00 1.00 – 1.01 NS 1.01 1.01 – 1.02 0.002
Site of LND
Neck Ref Ref
Axilla 0.77 0.56 – 1.05 NS 1.01 0.71 – 1.44 NS
Groin 1.06 0.77 – 1.47 NS 1.06 0.73 – 1.54 NS
Nr. of harvested nodes
Median (IQR) 1.00 0.99 – 1.01 NS 1.01 1.00 – 1.02 NS
Nr. of positive nodes
Median (IQR) 1.05 1.03 – 1.07 < 0.001 1.06 1.03 – 1.08 < 0.001
1 Ref Ref
2-3 1.34 0.99 – 1.82 NS 1.43 1.02 – 1.99 0.036
> 3 2.40 1.76 – 3.26 < 0.001 2.39 1.71 – 3.35 < 0.001
Lymph node ratio (%)
Median (IQR) 1.93 1.17 – 3.19 0.010 2.02 1.19 – 3.43 0.009
≤ 10 Ref Ref
10 - ≤ 25 1.52 1.12 – 2.06 0.007 1.30 0.93 – 1.84 NS
> 25 1.88 1.37 – 2.60 < 0.001 2.10 1.50 – 2.95 < 0.001
Extracapsular extension
Absent Ref Ref
Present 1.44 1.07 – 1.92 0.015 1.93 1.42 – 2.63 < 0.001
Adjuvant Radiotherapy
No Ref Ref
Yes 2.10 1.60 – 2.76 < 0.001 2.28 1.72 – 3.02 < 0.001
HR = Hazard Ratio, CI = Confidence Interval, IQR = Interquartile range, NS = Non significant, Ref = 
Reference
*P-values are calculated using the log rank test
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included in the multivariate model (in place of the number of positive nodes) it was 
not a significant predictor of DFS (p=0.920) or OS (p=0.753).
Five-year cumulative DFS in the absence and presence of ECE was 51.4% and 
36.2% respectively (p=0.015), while 5-year cumulative MSS in the absence and pres-
ence of ECE were 62.4% and 37.3% respectively (p<0.001) (Figure 1A). Five-year MSS 
according to the number of positive nodes were 64.8% for 1 positive node, 54.9% 
for 2 or 3 positive nodes and 38.7% for > 3 positive nodes (p<0.001) (Figure 1B).
Table 3 – Multivariate Cox’s hazard regression analysis of prognostic factors in all patients
Variable Disease-Free Survival Melanoma-Specific Survival
HR 95% CI P* HR 95% CI P*
Known primary
Absent Ref Ref
Present 1.91 1.48 – 2.47 < 0.001* 2.35 1.77 – 3.13 < 0.001*
Age (per yr) NS** 1.01 1.00 – 1.02 0.023
Nr. of positive nodes
1 Ref Ref
2-3 1.22 0.90 – 1.66 NS 1.26 0.90 – 1.76 NS
> 3 1.84 1.34 – 2.54 < 0.001 1.90 1.34 – 2.71 < 0.001
Extracapsular extension
Absent Ref Ref
Present 1.44 1.07 – 1.92 0.015 1.56 1.13 – 2.15 0.007
Adjuvant Radiotherapy
No Ref Ref
Yes 2.10 1.60 – 2.76 < 0.001 1.89 1.40 – 2.55 < 0.001
HR = Hazard Ratio, CI = Confidence Interval, NS = not significant, Ref = Reference
*P-values are calculated using the log rank test
**Not significant in univariate analysis
figure 1 – Melanoma-specific survival of melanoma patients for A) extracapsular extension and B) 
the number of positive nodes
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The 5-year cumulative DFS for MUP patients was 56.3% and for MKP patients it 
was 37.7% (p<0.001) (Figure 2A). The 5-year cumulative DMFS was 66.1% and 48.6% 
for MUP and MKP patients, respectively (p<0.001) (Figure 2B). For MSS, 5-year cu-
mulative survival was 68.3% for MUP patients and 44.7% for MKP patients (p<0.001) 
(Figure 2C). When MKP patients were stratified for regression of the primary mela-
noma, the 5-year MSS was 50.4% for patients with regression and 35.9% for patients 
with no regression of the primary (p=0.083) (Figure 2D).
diSCuSSioN
This retrospective, single institution study reports what is, to the best of our knowl-
edge, the largest series of MUP patients who have undergone TLND for macroscopic 
nodal disease. It demonstrated that after TLND, patients with a MUP have better DFS, 
DMFS and MSS than patients with a MKP (Table 3, Figure 2A-C). The presence of 
figure 2 – A) Disease-free survival, B) Distant metastasis-free survival and C) Melanoma-specific 
survival for unknown versus known primary melanoma, and D) Melanoma-specific survival for 
unknown primary versus known primary with regression versus known primary without regression
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ECE, >3 positive LNs and the administration of adjuvant radiotherapy were all inde-
pendent prognostic factors for reduced DFS and MSS (Table 3, Figure 1A-B). MUP 
patients also had a better prognosis than MKP patients with a primary melanoma 
that showed regression. MKP patients with a primary melanoma associated with 
regression had a clear trend towards better MSS than MKP patients with a primary 
without regression but this was not statistically significant (Figure 2D).
There were some differences between the MUP and the MKP patients. MKP pa-
tients were significantly older (p=0.008) and had a higher positive LN ratio (p=0.021) 
and a greater number of involved nodes (p=0.047). A higher positive LN ratio was 
correlated with worse survival (Table 2).28,29 Even when these differences were 
accounted for in multivariate survival analysis, MUP patients continued to have a 
significantly better outcome (Table 3).
Administration of adjuvant radiotherapy was a significant independent prognostic 
factor for adverse DFS and MSS (Table 2-3). This is counter-intuitive, but probably 
reflects selection bias. Adjuvant radiotherapy was administered to 42.7% of patients 
with ECE compared to 21.9% of patients with no ECE (p<0.001). Thus patients with 
more advanced disease were selected for adjuvant radiotherapy, which is the most 
likely explanation of their worse outcome.
The significantly better overall outcome after TLND for stage III MUP patients 
compared to MKP patients in this study is in line with some other studies reported in 
recent years.14-16 In Table 4, results of the largest and most recent studies addressing 
the outcome for MUP patients are presented. All studies demonstrated higher sur-
vival rates for MUP patients compared to MKP patients, although this was not always 
statistically significant. The study performed by Lee et al., containing the largest 
number of MUP patients reported prior to the present study, produced results that 
were similar to ours, with MUP patients having a better outcome than MKP patients.15
Several theories have been proposed to explain the occurrence of MUP.2,14,15,30,31 
Firstly, it is possible that a primary melanoma could exist but remain unidentified. 
Whenever a MUP is suspected, a thorough physical examination is recommended. 
However, a detailed search for a non-cutaneous primary melanoma, e.g. involv-
ing colonoscopy, ophthalmic and nasopharyngeal examination, is not routinely 
performed at our institution since the incidence of non-cutaneous melanomas is 
extremely low.32,33 A second possibility is that an excised melanoma could have 
been misdiagnosed as a benign naevus. These two possibilities can be excluded 
by performing thorough and careful physical and pathological examinations and 
reviewing the histopathology of any previously biopsied pigmented lesions.
A third possible explanation is that a melanoma may arise de novo within a LN 
from ectopic nodal naevus cells. In a report by Shenoy et al, a single axillary LN 
containing melanoma and naevus cells was described, with an apparent transition 
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from benign naevus cells to dysplastic naevus cells to melanoma cells. It was sug-
gested that this provided evidence that the melanoma had arisen primarily in the 
LN.30 Our finding of fewer tumor-positive LNs in MUP patients gives some support to 
this hypothesis, i.e., a primary nodal melanoma may have a lesser ability to spread to 
other LNs because it is at an earlier phase in its acquisition of a metastatic phenotype 
Table 4 – Published series reporting the outcome after lymph node dissection for stage III melanoma 
patients with an unknown primary and a known primary
Reference
(year)
Groups Nr. of 
patients
5-year 
DFS
p†† 5-year
OS
p††
Present study*
(2011)
MUP 287 56% 68%
MKP 264 38% <0.001 45% <0.001
Prens16
(2011)
MUP 47 25% 43%
MKP 292 21% 0.619 27% 0.06**
Rutkowski17
(2010)
MUP 59 44% 41%
MKP 400 28% 0.09 36% 0.45
MUP† 59 44% 41%
MKP† 57 29% 0.29 39% 0.14
Lee15
(2008)
MUP 262 NR 55%
MKP 1309 NR N/A 44% 0.0021**
MUP† 221 47% 58%
MKP† 221 35% 0.066 40% 0.0006
Cormier14
(2006)
MUP 71 43% 55%
MKP 466 30% 0.14** 42% 0.04**
Schlagenhauff6
(1997)
MUP 37 NR 50%
MKP NR NR N/A 36% 0.14
Anbari9
(1997)
MUP 20 NR 57%‡ 19%‡
MKP 46 NR N/A 0.008
Norman18
(1992)
MUP 18 NR NR
MKP 38 NR 0.15 NR 0.96
Wong4
(1987)
MUP 188 NR 46%
MKP 387 NR N/A 37% 0.10
DFS = Disease Free Survival; OS = Overall Survival; MUP = Melanoma with Unknown Primary; MKP = 
Melanoma with Known Primary; NR = Not Reported; N/A = Not Applicable
* Melanoma Specific Survival has been reported
† Matched paired analysis
†† log rank tests were used to calculate p-values
‡ 4-year overall survival rates have been reported
**After multivariate analysis, Prens et al. reached p=0.03 (hazard ratio 0.62 for having MUP in 
OS), Lee et al. reached p=0.0001 (hazard ratio of 1.51 for having MKP in OS) and Cormier et al. 
demonstrated p=0.006 (hazard ratio of 0.61 for having MUP in OS) and p=0.057 (hazard ratio of 
0.73 for having MUP in DFS).
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at the time it is detected clinically than is a nodal metastatic tumor from a cutaneous 
primary.
A fourth theory for the occurrence of MUP, probably the most frequently dis-
cussed in the literature, hypothesises that an endogenous immune response results 
in complete spontaneous regression of the primary tumor, which is therefore un-
recognised.3,15,31,35 Spontaneous tumor regression has been noted amongst others 
cancers, but is most well-described in melanoma.36 Regression of the primary tumor 
does not seem to be associated with a more favorable prognosis, although this 
remains controversial.31,37,38 In the present study, 52.2% of MKP patients had partial 
regression of their primary. The outcome for MKP patients in whom regression of the 
primary was identified was better than the outcome for MKP patients with no primary 
melanoma regression, although this did not reach statistical significance (p=0.084). 
Both groups had a significantly worse outcome than MUP patients (p<0.05) (Figure 
2D). This finding indicates that primary tumor regression might be correlated with 
a better prognosis. Immune-induced regression of a primary melanoma (after it has 
given rise to a nodal metastasis) could be the cause of a better outcome for MUP 
patients as a consequence of the immune response also being directed against any 
metastatic tumour.39
The rate of MUP in patients presenting with clinically palpable nodal disease and 
treated with TLND in our institution was 52.5% (247/551). This is substantially higher 
than in previous studies, which have reported MUP rates of 12.8 – 16.7% (Table 
4).14-17 However, in contrast to many prior reports, the selection criteria were much 
more restrictive in the current study, and only patients whose initial presentation 
was with palpable LN disease were included. The MKP patients were only included 
when they had a single primary melanoma, and underwent both their wide excision 
and TLND for palpable disease at the time of their initial presentation to Melanoma 
Institute Australia. This might also be a factor contributing to the higher five-year 
survival rates for MKP patients compared to those reported in the literature (Table 
4). However, when all melanoma patients who underwent TLND at MIA between 
1970 and 2010 were considered, the MUP rate was similar to the rates reported in 
the literature (i.e. 13.4%).
In conclusion, this large retrospective study demonstrated that MUP patients with 
macroscopic disease in LNs had a better outcome after TLND than MKP patients with 
equivalent disease at the time of presentation. Possible factors that might contribute 
to the improved survival in MUP patients include a more active tumor-directed im-
mune response against the tumor (manifest by complete regression of the primary 
tumor) in some cases, and de novo origin of the melanoma within a LN in other 
cases. ECE, >3 positive LNs and adjuvant radiotherapy were factors associated with 
a worse prognosis. Our results suggest that all patients presenting with macroscopic 
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melanoma in a LN and no evidence of metastatic melanoma elsewhere should be 
treated as patients with stage III disease, with curative intent, even when there is no 
known primary melanoma.
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This thesis is divided in three parts. Part i describes the management and prognosis 
of stage I – II melanoma patients. Part ii and iii describes the management and 
prognosis of stage III patients separated in, respectively, patients with micrometasta-
ses and patients with macrometastases.
In chapter 2 of part i the management and outcome are evaluated of nearly 
6000 patients with a single primary melanoma treated with wide local excision at 
the Melanoma Institute Australia (MIA), Sydney, Australia. Of these patients treated 
between 1992 and 2008, approximately 50% underwent sentinel node biopsy (SNB) 
and 50% did not undergo SNB, but were observed (OBS). After univariate analysis, 
patients with intermediate thickness melanoma (T2 – T3; > 1.0 – 4.0 mm) had 
significantly better outcome when undergoing SNB. After correcting for baseline 
differences that occurred between both groups in multivariate analyses, SNB pa-
tients had improved disease free survival (DFS), but no better distant metastasis 
free (DMFS) and melanoma specific survival (MSS) in patients with any primary 
thickness.
In chapter 3, the lymphatic drainage pattern of melanoma is addressed. All 
patients treated at the MIA between 1993 and 2010 with melanoma on the ear were 
included in this study. The specific location of 111 primary tumors, classified accord-
ing to the embryologically-derived anatomical subunits of the ear, were correlated 
with their mapped 281 sentinel nodes (SNs) identified by lymphoscintigraphy (LS). 
The helical rim was the location with highest prevalence (55.0%), followed by the 
lobule (24.3%). In conclusion, lymphatic drainage of the ear has no predictive pat-
tern and there is no drainage to the contralateral neck. Most commonly drainage is 
to cervical level II (36.4%) and the preauricular and postauricular LN fields. LS can 
accurately identify the lymphatic drainage pattern and is essential for accurate SN 
identification and reliable SNB.
Part ii of this thesis starts with chapter 4 reporting on a study regarding 421 SNB 
patients treated at the Erasmus University Medical Centre – Daniel den Hoed Cancer 
Centre. The 121 (28.7%) SN positive patients were stratified for SN tumor burden 
according to the Rotterdam criteria (largest diameter of the largest lesion < 0.1 mm, 
0.1 – 1.0 mm and > 1.0 mm). Besides the high identification rate of SN metastases by 
the EORTC MG SN pathology work-up protocol, the protocol identified a high rate 
of minimal tumor burden, i.e. 18% (22/121), as well. These patients with Rotterdam 
criteria < 0.1 mm had an estimated 5-year overall survival (OS) rate of 91% and a 
non-sentinel node (NSN) positivity rate in the specimen of the completion lymph 
node dissection (CLND) of 0%. This was not significantly different from the outcome 
of SN negative patients.
In chapter 5, the outcome of SN positive patients is analyzed in a multicenter 
setting. Nine EORTC MG centers combined their data into the largest number of 
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SN positive patients in the world. Between 1993 and 2008, 1080 melanoma patients 
were diagnosed with SN tumor burden. The Rotterdam criteria and Dewar criteria 
(subcapsular vs. non-subcapsular metastases) were determined. Patients with Rot-
terdam criteria < 0.1 mm had an estimated 5-year OS rate of 91% and NSN positivity 
of 9%. The so-called Rotterdam Dewar Combined (RDC) criteria identified patients 
with metastases < 0.1 mm located subcapsularly having an estimated 5- and 10-year 
MSS rate of 95% and NSN positivity of 2%. Long-term follow-up is necessary, since 
median follow-up was 3 years. However, in absence of results of prospective trials, 
the latter group might be classified as SN negative patients, therefore possibly not 
indicated for an immediate CLND.
The aim of the study presented in chapter 6 was to validate the results of chapter 
5 by adding data of an Australian center and a European center. Moreover, tumor 
penetrative depth (TPD) was added as a SN tumor burden parameter. After classify-
ing the added SN positive patients for the different SN tumor burden parameters in 
an equivalent matter, outcome was analyzed for the total cohort (n=1539) and for 
each of the eleven centers individually. The maximum tumor size, the intranodal 
location and the TPD provided prognostic and predictive information in the total 
cohort, but their prognostic significance varied considerably between the different 
centers. Differences could have been occurred due to differences in SN detection, 
removal and examination techniques such as the number and location of SN slides 
to be cut, but also due to sample size limitations or patient characteristic differences.
Until now, all SN positive patients analyzed in part ii underwent immediate 
CLND. Patients with minimal SN tumor burden (< 0.1 mm, especially when located 
subcapsularly), however, have very good prognosis and might not be indicated for 
CLND. Thus, the question remains: what if these patients do not undergo CLND? 
In chapter 7, 61 SN positive patients without CLND with a median follow-up of 4 
years are analyzed. This group is compared to 1113 SN positive patients with CLND, 
all from ten EORTC MG centers. Performing CLND did not significantly influence 
MSS, however, patients without CLND had more favorable prognostic factors. After 
performing matched pair analysis, CLND did not demonstrate a therapeutic benefit 
as well. In patients with minimal SN tumor burden, outcome was significantly better 
in patients with TPD ≤ 0.3 mm with CLND compared to patients without CLND. 
Patients with micrometastases < 0.1 mm and/or located subcapsularly with CLND 
had no significantly better MSS than the same group without CLND. These latter two 
results should be considered with great caution due to the small sample sizes of the 
subgroups and due to the retrospective setting with probable selection bias.
Part iii describes the management and outcome of melanoma patients with 
macrometastases in the lymph nodes. When palpable lymph nodes are present a 
therapeutic lymph node dissection (TLND) is indicated. Despite proper management, 
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survival can vary substantially due to the presence or absence of prognostic risk 
factors. In chapter 8, a mathematical model, i.e. nomogram, has been developed 
to predict recurrence within 2 years after TLND in a cohort of 504 patients from 
Brisbane, Australia. The nomogram included the following independent predictors 
of 2-year recurrence: number of positive lymph nodes, extracapsular extension, 
nodular histopathological subtype and post-operative seroma. The predictive value 
of the nomogram was successfully validated in a cohort of 331 patients from Rot-
terdam, the Netherlands.
Chapter 9 of this thesis evaluates the therapeutic surgical management of patients 
with clinically detectable nodal metastases to the groin. At the Erasmus University 
Medical Centre – Daniel den Hoed Cancer Centre, 121 patients underwent an ilio-
inguinal or combined superficial and deep groin lymph node dissection (CGD) and 
48 patients underwent an inguinal or superficial groin lymph node dissection (SGD). 
Survival and local control did not differ for patients with palpable groin metastases 
treated by CGD or SGD. Morbidity rates were not significantly different between 
both groups as well, although CGD patients had a trend towards more chronic 
lymphedema. Preoperative computed tomography (CT) could accurately identify a 
negative deep lymph node field with 91%. Patients without pathological iliac nodes 
on CT might safely undergo SGD, while patients with multiple positive nodes or 
positive deep nodes on CT might be indicated for CGD.
Chapter 10 and 11 evaluate the outcome of patients with melanoma of unknown 
primary (MUP). In chapter 10, an entire cohort analysis of a single center is de-
scribed, while in chapter 11 restrictive inclusion criteria were assessed to include 
MUP and MKP patients from a single center for analyses. In the study described in 
chapter 10, patients who underwent a therapeutic lymph node dissection (TLND) 
for clinically detectable disease at the Erasmus University Medical Centre – Daniel 
den Hoed Cancer Centre were included. Between 1982 and 2009, 47 (13.7%) MUP 
patients and 295 patients with a known primary melanoma (MKP) were treated with 
TLND. After multivariate analysis, patients with MUP demonstrated a significantly 
better OS than MKP patients. Extracapsular extension and an increased number of 
positive nodes are significantly associated with worse prognosis.
In chapter 11, the outcome of 287 MUP patients who were treated between 
1971 and 2010 was analyzed. The control group consisted of 264 MKP patients who 
were treated in the same time frame with wide local excision for a single primary 
melanoma and TLND for nodal metastases and had their follow-up at the MIA. 
MUP patients had improved DFS, DMFS and MSS over MKP patients. Extracapsular 
extension, an increased number of positive nodes and adjuvant radiotherapy were 
independent prognostic factors for MSS. MKP patients whose primary was in regres-
sion had a trend towards improved survival compared to those without regression of 
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the primary. Explanations of the significantly improved outcome of MUP patients in 
chapter 10 and 11 may be an endogenous immune response resulting in regression 
of the primary or that melanoma cells arise de novo within a lymph node.
CoNCLuSioNS
Chapter 2: Melanoma patients who underwent wide local excision and sentinel 
node biopsy had improved disease free survival, but no improved distant metastasis 
free and melanoma specific survival over patients who underwent wide local exci-
sion only.
Chapter 3: Lymphatic drainage of the ear has no predictive pattern. Drainage to 
the contralateral neck did not occur. Lymphoscintigraphy is essential to accurately 
identify the sentinel node.
Chapter 4: SN negative patients had significantly improved survival over sentinel 
node positive patients. The Rotterdam criteria significantly stratify patients for over-
all survival. Patients with < 0.1 mm SN metastases (18% of sentinel node positive 
patients) had five-year overall survival of 90% which is comparable to the survival 
of sentinel node negative patients and significantly improved survival over patients 
with 0.1-1.0 mm and > 1.0 mm SN metastases.
Chapter 5: Patients with metastases < 0.1 mm located subcapsularly in the sentinel 
node had 5- and 10-year melanoma specific survival of 95% and non-sentinel node 
positivity of 2%. These patients might be spared the additional completion lymph 
node dissection.
Chapter 6: The maximum sentinel node tumor size, the intranodal location and 
tumor penetrative depth provided prognostic information for melanoma specific 
survival and predictive information for non-sentinel node status after completion 
lymph node dissection.
Chapter 7: Completion lymph node dissection did not demonstrate to have a thera-
peutic benefit, especially in patients with minimal sentinel node tumor burden.
Chapter 8: A nomogram with independent predictive factors of 2-years recurrence, 
i.e. number of positive lymph nodes, extracapsular extension, nodular histopatho-
logical subtype and post-operative seroma, was developed and validated for patients 
with palpable metastases who underwent therapeutic lymph node dissection.
Chapter 9: Survival and local control did not differ for patients with palpable groin 
metastases treated by combined superficial and deep groin dissection or superficial 
only groin dissection. Patients with a single superficial positive node and preopera-
tive negative deep nodes on CT scan should undergo superficial groin dissection 
only.
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Chapter 10: Patients with melanoma of unknown primary had improved survival 
over patients with a known primary melanoma. Extracapsular extension and an in-
creased number of positive nodes are significantly associated with worse prognosis.
Chapter 11: Patients with melanoma of unknown primary had improved disease 
free, distant metastasis free and melanoma specific survival over patients with a 
known primary. Regression of a primary demonstrated a trend towards improved 
survival.
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Dit proefschrift is verdeeld in drie delen. deel i beschrijft het beleid en de prognose 
van stadium I – II melanoompatiënten. deel ii en iii beschrijven het beleid en de 
prognose van stadium III patiënten in, respectievelijk, patiënten met micrometastasen 
(niet-palpabel en gedetecteerd door middel van schildwachtklier (SWK) procedure) 
en patiënten met macrometastasen (palpabele ziekte).
In hoofdstuk 2 van deel i zijn het beleid en de prognose beschreven van bijna 
6000 patiënten waarbij het primair melanoom is verwijderd door middel van chirur-
gische excisie in het Melanoma Institute Australia (MIA) te Sydney, Australië. Van 
deze patiënten die behandeld zijn tussen 1992 en 2008 heeft ongeveer 50% een 
SWK procedure ondergaan. De andere 50% is geobserveerd gedurende follow-up 
(OBS). Na univariate analyse was de overleving voor patiënten met een gemiddelde 
tumordikte (T2 - T3; > 1.0 – 4.0 mm) significant beter voor diegene die een SWK 
procedure hebben ondergaan. Nadat in mulitvariate analyse gecorrigeerd was voor 
de significante verschillen tussen de SWK en de OBS groep, hadden patiënten in de 
SWK groep een verbeterde ziektevrije overleving, maar geen betere afstandsmetasta-
se-vrije overleving of melanoom-specifieke overleving.
In hoofdstuk 3 wordt het lymfedrainage patroon van het melanoom beschre-
ven. Alle patiënten behandeld in het MIA tussen 1993 en 2010 met een melanoom 
op het oor werden in deze studie geïncludeerd. De specifieke locaties van 111 
primaire tumoren, geclassificeerd volgens de embryologisch afgeleide anatomische 
localisaties van het oor, werden gecorreleerd met de 281 SWK-en geïdentificeerd 
door middel van lymfoscintigrafie (LS). De helix was de locatie met de hoogste 
prevalentie (55.0%), gevolgd door de oorlel (24.3%). Het patroon van lymfedrainage 
van het oor was niet te voorspellen. Er werd geen drainage naar de contralaterale 
hals gezien. Metastasering vindt meestal plaats naar het cervicale niveau II (36.4%) 
en naar de preauriculaire en postauriculaire lymfeklierregio’s. LS kan nauwkeurig het 
drainagepatroon identificeren en is essentieel voor nauwkeurige SWK identificatie 
en een betrouwbare SWK procedure.
deel ii van dit proefschrift begint met hoofdstuk 4. In deze studie zijn 421 
SWK patiënten geïncludeerd die behandeld zijn in de Erasmus Medisch Cen-
trum – Daniel den Hoed kliniek te Rotterdam. Het percentage SWK positieve 
patienten was hoog (28.7%). De tumorgrootte van de 121 (28.7%) SWK-positieve 
patiënten is geanalyseerd en de patiënten zijn ingedeeld volgens de Rotterdam 
criteria (grootste diameter van de grootste laesie <0.1 mm, 0.1 – 1.0 mm en > 
1.0 mm). Binnen de SWK-positieve groep heeft het SWK pathologie protocol 
van de EORTC melanoomgroep een hoog percentage patiënten met minimale 
tumorgrootte (Rotterdam criteria <0.1 mm) geïdentificeerd van 18% (22/121). Deze 
patiënten hebben een geschatte 5-jaars overleving van 91% en een percentage 
niet-schildwachtklier (NSWK) positieve patienten na completerende lymfeklierdis-
Stijn BW.indd   229 04-Dec-13   13:33:04 PM
230 Chapter 13
sectie (CLKD) van 0%. Deze prognose is niet significant verschillend van die van 
SWK-negatieve patiënten.
In hoofdstuk 5 wordt de prognose van SWK-positieve patiënten geanalyseerd in 
een multicentrische setting. Negen centra binnen de EORTC melanoomgroep voeg-
den hun gegevens samen. Tussen 1993 en 2008 werden 1080 melanoompatiënten 
gediagnosticeerd met tumor in de SWK. De Rotterdam criteria en Dewar criteria 
(subcapsulair versus niet-subcapsulair gelegen metastasen) werden bepaald voor 
elke SWK metastase. Patiënten met Rotterdam criteria < 0.1 mm hadden een geschatte 
5-jaars overleving van 91% en NSWK-positiviteit na CLKD van 9%. De zogenaamde 
Rotterdam-Dewar gecombineerde (RDC) criteria identificeerden bij patiënten met 
< 0.1 mm subcapsulair gelegen metastase een geschatte 5- en 10-jaars melanoom-
specifieke overleving van 95% en NSWK-positiviteit van 2%. Lange-termijn follow-up 
is noodzakelijk omdat de mediane follow-up 3 jaar was. Deze laatste groep met 
minimale tumorgrootte heeft een overleving die niet lijkt te verschillen van die van 
SWK-negatieve patiënten. Een aanvullende operatie, een CLKD, met hoge morbidi-
teit zoals chronisch lymfoedeem zou deze patiënten bespaard kunnen blijven.
Het doel van de studie die beschreven is in hoofdstuk 6 was het valideren van 
de studie in hoofdstuk 5. Patiënten die behandeld zijn in twee andere centra en 
een nieuwe variabele werden meegenomen in de analyse. De penetratiediepte van 
de tumor in de SWK (TPD) werd toegevoegd als een SWK tumor karakteristiek. De 
totale cohort (n=1593) werd geanalyseerd alsmede ieder van de elf centra apart. 
De maximale grootte van de tumor, de locatie en de TPD hadden allen een prog-
nostische waarde voor overleving en een voorspellende waarde voor additionele 
lymfekliermetastasen na CLKD in de totale cohort. Hun prognostische betekenis ver-
schilde echter aanzienlijk tussen de verschillende centra. Verschillen in de prognose 
zouden het gevolg kunnen zijn van verschillen in de SWK detectie, verwijdering en 
onderzoekstechnieken zoals het aantal en de locatie van de gesneden SWK coupes. 
Het zou ook een gevolg kunnen zijn van verschillen in de samenstelling van de 
groepen met betrekking tot aantallen en patient kenmerken.
In alle voorgaande hoofdstukken in deel ii zijn alle SWK positieve patiënten ge-
analyseerd die een CLKD hebben ondergaan. Patiënten met minimale SWK metastase 
(< 0.1 mm, vooral wanneer subcapsulair gelegen) hebben een zeer goede prognose. 
Gezien het feit dat deze patiënten een additionele CLKD hebben ondergaan blijft 
de vraag: wat als deze patiënten geen CLKD hadden ondergaan? In hoofdstuk 7 
zijn 61 SWK positieve patiënten die geen CLKD hebben ondergaan, geanalyseerd. 
De mediane follow-up was 4 jaar. Deze groep werd vergeleken met 1113 SWK 
positieve patiënten met aanvullende CLKD. Alle patiënten waren behandeld in tien 
EORTC MG centra. Na analyse bleek er geen significant betere overleving te zijn na 
het uitvoeren van een CLKD. Patiënten zonder additionele chirurgie hadden echter 
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meer gunstige prognostische factoren zoals kleinere metastasen. Na het uitvoeren 
van een matched pair analyse van twee groepen met 61 patiënten met vergelijkbare 
prognostische factoren werd een therapeutisch voordeel van een CLKD ook niet 
aangetoond.
deel iii beschrijft het management en de prognose van melanoompatiënten met 
(palpabele, klinisch detecteerbare) macrometastases in de lymfeklieren. In hoofd-
stuk 8 zijn nomogrammen gecreëerd en gevalideerd. De cohort groep bestond uit 
504 patiënten uit Brisbane, Australie met palpabele (klinisch detecteerbare) macro-
metastasen die een therapeutische lymfeklierdissectie (TLKD) hebben ondergaan. 
De primaire uitkomstmaten waren de recidiefkans en de overleving binnen 2 jaar na 
TLKD. Het aantal positieve lymfeklieren en extranodale groei waren onafhankelijk 
significante factoren voor een recidief binnen 2 jaar en voor de 2-jaars overleving. 
Histologisch nodulair type melanoom en postoperatieve seroomvorming waren ad-
ditionele onafhankelijke significante factoren voor een recidief binnen 2 jaar en leef-
tijd was dat voor de 2-jaars overleving. Het nomogram werd succesvol gevalideerd 
in een vergelijkbare groep van 331 patiënten uit Rotterdam, Nederland.
hoofdstuk 9 van dit proefschrift heeft de chirurgische behandeling van patiënten 
met klinisch aantoonbaar nodale metastasen naar de lies geevalueerd. In het Eras-
mus Universitair Medisch Centrum / de Daniel den Hoed kliniek ondergingen 121 
patiënten een ilioinguinale lymfeklierdissectie (LKD) en ondergingen 48 patiënten 
een inguinale LKD. Overleving en lokale controle verschilden niet in beide groepen. 
De postoperatieve morbiditeit was niet significant verschillend tussen beide groepen, 
hoewel ilioinguinale LKD patiënten een trend naar meer chronische lymfoedeem 
lieten zien. Preoperatieve computertomografie (CT) kon een negatieve iliacale 
lymfeklier nauwkeurig identificeren in 91% van de patiënten met een ilioinguinale 
LKD. Patiënten zonder pathologische iliacale lymfeklieren op CT zouden veilig een 
inguinale LKD kunnen ondergaan, terwijl patiënten met meerdere positieve klieren 
of positieve iliacale klieren op CT een ilioinguinale LKD kunnen ondergaan.
in hoofdstuk 10 en 11 zijn studies behandeld die patiënten met melanoom 
met een onbekende primaire tumor (MUP) hebben onderzocht. De overleving tus-
sen deze groep patiënten en patiënten met een bekend primair melanom (MKP) 
werd vergeleken. In hoofdstuk 10 werd een totale cohort analyse van een enkel 
centrum beschreven, terwijl in hoofdstuk 11 strikte inclusiecriteria werden gebruikt 
om MUP en MKP patiënten te selecteren voor een nauwkeurigere analyse. In de 
studie beschreven in hoofdstuk 10 waren alle patiënten die een TLKD voor klinisch 
detecteerbare ziekte in de Erasmus Universitair Medisch Centrum – Daniel den Hoed 
kliniek inbegrepen. Tussen 1982 en 2009 werden 47 (13.7%) MUP patiënten en 
295 MKP patiënten behandeld met een TLKD. Na multivariate analyse bleek dat 
patiënten met MUP een significant betere overleving hadden dan MKP patiënten. 
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Extranodale groei en positieve klieren waren significant geassocieerd met een slech-
tere prognose.
In hoofdstuk 11 is de studie besproken waar 287 MUP patiënten zijn geana-
lyseerd die tussen 1971 en 2010 met een TLKD zijn behandeld in het Melanoma 
Institute Australia (MIA) in Sydney, Australië. De controlegroep bestond uit 264 
MKP patiënten die behandeld werden in hetzelfde tijdsbestek met radicale excisie 
van een enkel primair melanoom, TLKD voor macrometastasen en follow-up in 
het MIA hadden. MUP patiënten hadden een significant verlengde ziekte-vrije en 
afstandsmetastase-vrije periode en een significant verbeterde algehele overleving 
vergeleken met MKP patiënten. Extranodale groei, het aantal positieve klieren en 
adjuvante radiotherapie waren onafhankelijke prognostische factoren voor slechtere 
prognose. MKP patiënten bij wie de primaire tumor in regressie was hadden een niet 
significante, maar verbeterde overleving in vergelijking met mensen zonder regressie 
van de primaire tumor. Een verklaring voor de aanzienlijk verbeterde overleving 
voor MUP patiënten in hoofdstuk 10 en 11 zou een endogene immuunrespons 
kunnen zijn welke resulteert in regressie van het primaire melanoom. Tevens zou 
het kunnen zijn dat de melanoomcellen de novo ontstaan binnen een lymfeklier.
CoNCLuSieS
hoofdstuk 2: Melanoompatiënten die een schildwachtklier procedure hebben on-
dergaan hadden een verbeterde ziektevrije overleving, maar geen verlengde periode 
tot afstandsmetastasen en geen verbeterde ziektespecifieke overleving.
hoofdstuk 3: Lymfedrainage van melanoom van het oor heeft geen voorspellend 
patroon van metastasering. Metastasering naar de contralaterale hals trad niet op. 
Lymfoscintigrafie is essentieel om de schildwachtklier nauwkeurig te identificeren.
hoofdstuk 4: Schildwachtklier negatieve patiënten hadden significant betere over-
leving dan schildwachtklier positieve patiënten. De Rotterdam criteria stratificeren 
patiënten significant voor algemene overleving. Patiënten met <0.1 mm schildwacht-
klier metastasen (18% van de schildwachtklier positieve patiënten) hadden een vijf-
jaars overleving van 90% wat vergelijkbaar is met de prognose van schildwachtklier 
negatieve patiënten en significant beter dan patiënten met 0.1-1.0 mm en > 1.0 mm 
metastasen.
hoofdstuk 5: Patiënten met < 0.1 mm metastase subcapsulair gelegen in de 
schildwachtklier hadden 5- en 10-jaar ziekte-specifieke overleving van 95% en een 
niet-schildwachtklier positiviteit in het completerende lymfeklierdissectie preparaat 
van 2%. Deze patiënten zouden een aanvullende completerende lymfeklierdissectie 
bespaard kunnen blijven.
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hoofdstuk 6: De maximale grootte van de schildwachtklier, de intranodale locatie 
en de tumor penetratiediepte zijn prognostisch onafhankelijke factoren voor ziekte 
specifieke overleving en hebben een voorspellende waarde voor niet-schildwacht-
klier metastasen.
hoofdstuk 7: Completerende lymfeklierdissectie bij schildwachtklier positieve 
patiënten had geen therapeutisch effect, vooral bij patiënten met minimale schild-
wachtklier metastase.
hoofdstuk 8: Nomogrammen met risicofactoren voor het voorspellen van een 
recidief binnen 2 jaar en de 2-jaars overleving na therapeutische lymfeklierdissectie 
in verband met palpabele lymfeklieren werden verwezenlijkt. De nomogrammen 
bestonden uit de volgende factoren: Het aantal positieve lymfeklieren, extranodale 
groei, een nodulaire melanoom, postoperatieve seroomvorming en leeftijd.
hoofdstuk 9: Overleving en lokale controle waren niet verschillend voor patiënten 
met palpabele inguinale lymfeklieren behandeld met ilioinguinale lymfeklierdissectie 
of alleen inguinale lymfeklierdissectie. Patiënten met een enkele inguinale metastase 
in de lymfeklier en preoperatieve negatieve iliacale klieren op CT-scan zouden een 
inguinale lymfeklierdissectie kunnen ondergaan.
hoofdstuk 10: Patiënten met melanoom van een onbekende primaire tumor hadden 
een significante betere overleving dan patiënten met een bekend primair melanoom. 
Extranodale groei en het aantal positieve lymfeklieren was significant geassocieerd 
met een slechtere prognose.
hoofdstuk 11: Patiënten met melanoom van onbekende primaire origine hadden 
een verlengde ziektevrije en afstandsmetastase vrije periode en een verbeterde ziek-
tespecifieke overleving. Regressie van de primaire tumor toonde een niet significant 
verbeterde overleving.
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SeNTiNeL Node bioPSy
Twenty years after its introduction, SNB is standardized in cancer centers worldwide 
for staging in melanoma patients. According to analyses from the Surveillance, Epi-
demiology and End-Result (SEER) database, only 53% of eligible patients had under-
gone SNB between 2004 and 2008 in the United States.1 SNB is highly recommended 
for patients with intermediate-thickness melanoma (T2 and T3; Breslow thickness of 
1 to 4 mm) at any anatomic site.2 (Chapter 2) For patients with thick melanomas (T4; 
Breslow thickness > 4 mm), the use of SNB is accepted as staging purpose and to 
facilitate regional control, although the risk of occult distant metastases is present.2, 3 
For patients with thin melanomas (T1; Breslow thickness < 1 mm), SNB is more 
controversial. Most claim that SNB should only be offered to those with risk factors 
such as ulceration or mitotic rate ≥ 1/mm and melanoma > 0.75 mm thick.2, 4
The SN status is the most prognostic factor for melanoma specific survival.5, 6 In 
approximately 20%, patients are diagnosed with a positive SN which implies that 
their prognosis decreases significantly. SN negative patients have 5-year MSS rates 
of approximately 90%.5, 6 Heterogeneous groups of SN positive patients have 5-year 
MSS rates ranging from over 50% to around 75%.7, 8 In most guidelines, patients with 
proven melanoma metastases in one or more SNs should undergo an “early” comple-
tion lymph node dissection (CLND), sparing the patients without SN metastases 
the additional surgery.2 According to analyses from the National Cancer Data Base, 
only 50% of 2942 SN positive patients treated in 2004 and 2005 in the United States 
underwent CLND.9
Multicenter Selective Lymphadenectomy Trial – 1 (MSLT-1)
The MSLT-1 is the only randomized controlled trial (RCT) to date, which randomized 
primary melanoma patients (60:40) for SNB, followed by early CLND when SN posi-
tive, or for nodal observation (OBS), followed by therapeutic lymph node dissection 
(TLND) when regional nodal relapse. Between January 1994 and March 2002, 2001 
patients with primary melanoma ≥ 1.00 mm or having Clark level IV or V were 
randomized. The study completion date was June 2012, 10 years after the last patient 
accrual. Interim-results on the primary outcome measure are published in 2006, on 
morbidity in the nodal metastases group in 2010 and on surgery in stage IV patients 
in 2012. Final results and results on the total cohort have not been published or 
presented (yet). An overview and minor update of both MSLTs has been published 
in 2012, but did not report on the primary end-point (melanoma-specific survival) 
for the original cohort.10
Only patients with melanomas 1.2 – 3.5 mm in thickness were selected for the 
interim-analysis in 2006, because “statistical modeling indicated that the timing of 
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CLND probably affects survival among patients within this range”. The primary end-
point, i.e. prolonged melanoma-specific survival (MSS) for SNB patients compared 
to nodal observation, has not been reached. In the nodal metastases subgroups, SN 
positive patients who underwent CLND had improved survival over OBS patients 
with nodal relapse who underwent TLND (p=0.004). A survival benefit is only seen 
in a subgroup of a subgroup of the primary aim group. The SN hypothesis that 
SNB will detect occult metastases, which will eventually all progress to aggressive 
regional or distant disease, is tested in the interim-analyses. After 5 years the rate 
of nodal metastases between the SNB group (15.6% + 3.8% = 19.4%) and the OBS 
group (16.1%) has a difference of 3.3%. A similar percentage of 2.8% has been 
detected in chapter 2 of this thesis (follow-up of 3.5 years). Longer follow-up will 
identify more patients with nodal metastases or these patients have very low volume 
metastases that never will progress to clinically detectable disease. Several reports 
in this thesis have identified this possible SN “false-positive” group. In contrast, the 
recent update of MSLT-1 provided by Dr. Morton describes an equivalent incidence 
of nodal metastases in both groups after 8 until 10 years of follow-up. For patients 
with intermediate thickness melanomas, the incidence of nodal metastasis was 19.8% 
in the SNB group compared to 20.5% in the OBS group.10 An additional 3.9% of the 
OBS group in MSLT-1 had recurrence in the regional nodal field between follow-up 
years 5 to 8. It will remain unclear if these percentages also apply for the total study 
cohort, since these data are not (yet) presented. At the same time, some SN positive 
patients might not have developed clinically relevant lymph node metastases, but 
might have succumbed to distant metastases prior to this.
Moreover, pathology work-up and analysis play a very important role in deter-
mining these percentages and can skew these results. A more extensive pathology 
protocol and different analysis of SN tumor burden might detect more clinically 
insignificant SN metastases.11 A higher SN positivity rate will be detected which has 
been demonstrated in chapter 4.6, 12 Follow-up of studies in the present thesis should 
be expanded by several years to support these results.
In the two decades MSLT-1 was running, the field of melanoma has changed 
significantly. Imaging techniques, e.g. PET-CT scans and ultrasound(US)-guided fine-
needle aspiration cytology (FNAC), have improved. New therapeutic agents have 
become available. SN melanoma experts gained more experiences, especially on the 
field of pathology. This all will make the final results of MSLT-1 not easy to interpret 
into the new reality of everyday practice.
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SeNTiNeL Node PAThoLogy PRoToCoL
After the surgical procedure of removing SNs, the SNs are sent to the pathology 
department for pathological examination. Pathology work-up protocols are different 
worldwide and no standard approach for the SNs has been adopted. Substantial 
differences in identifying, removing and analyzing SNs exist between different can-
cer centers. Agreement on the SN pathology work-up protocol is an issue highly 
discussed in recent years.6, 13, 14 In a very recent survey of 142 academic institutions 
in the United States on the histopathological evaluation of SNs, 32 (28%) institutions 
responded to the questionnaire. Twenty-six (81%) institutions had a protocol for 
SN examination. Nine (28%) centers cut the SN in half (bivalve), whereas 59% cut 
the SN at even intervals without specifically commenting about any orientation to 
the hilum. The number of levels cut varied from 1 to 8. Histologic protocols varied 
vastly among institutions.15 In general, three protocols are being assessed according 
to literature. Cochran et al. of the John Wayne Cancer Institute developed a proto-
col.16 The European Organisation for Research and Treatment of Cancer (EORTC) 
Melanoma Group uses the protocol developed by Cook et al.17 The Melanoma 
Institute Australia handles a protocol formed by Scolyer et al, which is adapted by 
the Cochran protocol.18
There are differences between the protocols, i.e. where the sections in the SN are 
cut, how many sections are cut and how large the interval between sections is. It 
is unclear what the influence is of the different approaches, but they evidently will 
lead to differences in decision making during daily clinical practice. Some bivalve 
through the hilum, some through the longest axis and others cut sections at random. 
Some suggest that most metastases are located near the hilum, while others state that 
evenly sized melanoma metastases are located throughout the nodes, so sectioning 
either in the central area or in the peripheral area does not matter.13 Another issue is 
the number of sections cut from each halve or part of the SN. In general, according 
to the EORTC MG protocol by Cook, 12 sections should be cut from each SN, which 
is more sections than other protocols recommend.17, 18 More extensive sectioning 
and examination of SNs increases detection rate of SN metastases from 14% up to 
almost 30%.6, 12, 17, 19-22 Moreover, it increases the detection rate of submicrometasta-
ses.6 Sectioning more than 50 μm could miss submicrometastases, since sometimes 
submicrometastases are smaller than 50 μm.17 Experience tells us that every extra 
section cut from an SN may reveal that a very small deposit is in fact much larger.13, 20 
Patients with minimal SN tumor burden will in some cases show to have more ad-
vanced disease than was previously shown. At the same time, negative patients will 
become upstaged to minimal SN tumor burden patients. When cutting more, more 
clinically irrelevant metastases will appear.11 Complete sectioning would lead to high 
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detection rates, but at the same time this will cost much more time for sectioning and 
analyses of these sections, which in turn is a financially costly matter.14 In conclusion, 
pathology work-up is not performed equivalent over different centers in the world, 
which could be an important cause in the differences in prognostic significance of 
the SN tumor burden parameters.
PAThoLogy SLide ANALySiS
In the last decade, numerous studies identified several different factors in melanoma 
patients with SN tumor burden predicting the risk of death and/or the risk of ad-
ditional non-sentinel node (NSN) involvement.6, 7, 23-46 Most often assessed are the 
microanatomic location,7, 25, 26, 43, 44, the tumor penetrative depth (TPD)31, 40, 43 and 
tumor size as maximum diameter of the largest lesion6, 24, 26-28, 33, 35, 40-43, 47. All were 
predictors for survival, NSN involvement or both.
Van Akkooi et al. on behalf of the EORTC MG pointed out how to specifically 
report the anatomic location and the maximum size of SN metastasis.48 Murali et 
al. made guidelines for assessment of the SN and its metastasis.49 Both parties rec-
ommend a practical methodology. The tumor penetrative depth is defined as the 
maximum distance of melanoma cells from the interior margin of the respective SN 
capsule.31, 50 A subcapsular metastasis is defined as the location of all lesions in the 
SN strictly confined to the subcapsular sinus or the paratrabecular and not tattered 
or irregularly shaped.25, 48 The maximum size of the metastasis is defined as the 
measurement of the largest diameter of only the largest deposit with no interruption 
by lymphocytes.32, 48
When clinical decision making, for instance to undergo a CLND or observation, 
is based on the assessment of the above mentioned micromorphometric parameters, 
there is an absolute need for agreement between observers. Murali et al. calculated 
the interobserver agreement on measurement of quantitative and qualitative SN tu-
mor burden parameters.49 Quantitative parameters as the maximum size of the largest 
deposit and TPD had an excellent degree of agreement, while a qualitative param-
eter as the location of deposits in the SN had a moderate degree of agreement.49 
TPD, classified according to the S-classification, provides important prognostic and 
predictive information and assesses both size and location of the SN metastases, 
as well as the RDC criteria does31, 38, 43 There are, however, differences present. For 
example, a patient with a large subcapsular lesion which is 1.4 mm in diameter 
could have a minimal TPD, i.e. < 0.3 mm (S1), and thus be addressed to the group 
of patients with the best prognosis. At the same time a very small lesion, which is 
located somewhere far from a capsule, could be seen as an S3 classification (most 
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aggressive disease), when this might be far less.48 These two examples clarify that the 
TPD classified according to Starz et al. does not always correctly reflect the location 
of the SN metastases, while the RDC-criteria does reflect both factors on all lesions. 
TPD and the S-classification should be included in addition to the Dewar criteria, 
Rotterdam criteria and Rotterdam-Dewar Combined (RDC) criteria in forthcoming 
analyses of SN positive patients.
PRogNoSTiC heTeRogeNeiTy of SeNTiNeL Node PoSiTiVe PATieNTS
Outcome of SN positive patients is determined by the predictive value for non-
sentinel node (NSN) status in the CLND specimen and the prognostic value for 
survival. The group of SN positive patients is a heterogeneous group of patients with 
survival rates ranging from approximately 30% to over 90% in various subgroups.51 
Patients with high volume SN tumor burden have significant worse outcome than 
patients with low volume tumor burden.5, 25, 31, 32, 42, 43, 51 A meta-analysis performed by 
Nagaraja et al. demonstrated the heterogeneity of SN positive patients in the likeli-
hood of NSN metastases with 12 significantly different predictive factors.52 SNB has 
implemented in the TNM staging system since a decade.53 The American Joint Com-
mittee on Cancer (AJCC) Melanoma Staging Committee anticipated that microscopic 
tumor burden will be included in the analysis for the eight edition of the Cancer 
Staging Manual.54, 55
Subgroups are defined by micromorphometric parameters and their classification. 
The anatomic location is most efficiently divided into subcapsular located versus 
non-subcapsular located metastases according to the Dewar criteria.25 Subcapsular 
metastases represent approximately 20-30% of SN positive patients and have better 
outcome than non-subcapsular metastases.25, 26, 35, 39, 43, 56, 57 TPD beneath the SN cap-
sule is classified according to Starz et al. in S1 (≤ 0.3 mm), S2 (> 0.3 – ≤ 1.0 mm) and 
S3 (> 1.0 mm) metastases.31 Patients with S1 metastases are about 30% of SN positive 
patients and have improved survival over patients with S2 and, subsequently, S3 
metastases.31, 38, 39, 43, 50, 56-59 The maximum size is classified according to the Rotterdam 
criteria, i.e. < 0.1 mm, 0.1 – 1.0 mm and > 1.0 mm metastases.32 Patients with < 0.1 
mm represent around 10-15% of SN positive patients and have better outcome than 
patients with 0.1 – 1.0 mm and > 1.0 mm metastases.6, 12, 26, 32, 38, 41-43 Several studies 
using other cut-off points (0.5, 1.0 and/or 2.0 mm) for subgroups of maximum 
size demonstrated a significant influence on survival as well.35, 39, 56, 60, 61 In the only 
meta-analysis performed in the field of SN tumor burden, patients with < 0.1 mm 
metastases had the lowest odds ratio for having NSN metastases. The parameter 
was devoid for heterogeneity.52 In chapter six the location and the maximum size 
Stijn BW.indd   241 04-Dec-13   13:33:06 PM
242 Chapter 14
in the SN were combined into the RDC (Rotterdam Dewar combined) criteria. The 
S-classification also represents the size and location, however, not the maximum 
size in any direction. Patients with < 0.1 mm metastases located subcapsularly only 
represented 6% of SN positive patients and had excellent survival, i.e. 5- and 10-year 
MSS rates of 95%, compared to the other subgroups.26 (Chapter 5) A maximum SN tu-
mor size > 1mm separated a cohort of SN positive patients into two equivalent sized 
groups and was the most consistent independent predictor of NSN positivity and 
poorer DFS and MSS in individual centers, and in the combined cohort. (Chapter 6)
Several studies demonstrated that patients with minimal SN tumor burden had 
excellent survival equivalent to the survival of SN negative patients.6, 26, 32, 38, 42, 58 Few 
studies statistically compared the outcomes of SN negative patients and patients with 
minimal SN tumor burden (Table 1).6, 38, 62, 63 When comparing SN negative patients to 
SN positive patients with < 0.1 mm metastases, no significant differences were identi-
fied for DFS and MSS. Meier et al. performed analyses on 697 melanoma patients in 
their institute with a median follow-up of 5 years.38 There was no significant differ-
ence in disease free (DFS) (p=0.183) and overall survival (OS) (p=0.400) between SN 
negative patients (n=480) and SN positive patients with Rotterdam criteria < 0.1 mm 
(n=85). Meier et al. also reported that the additional parameters of tumor penetrative 
depth (TPD) and capsular involvement had no impact on prognosis in patients 
with Rotterdam criteria < 0.1 mm. The proposed group by Meier et al. with the best 
Author
(year)
Group of 
patients
No. of 
patients
Median 
follow-
up
(mo)
Median
Breslow
Thickness
(mm)
Ulceration
(%)
Disease Free 
survival
Melanoma 
Specific Survival
5-yr
DFS 
rates 
(%)
P HR 5-yr
MSS 
rate 
(%)
P HR
Van der 
Ploeg 6
(2010) † 
SN negative 300 55 2.00 21.7 82% 0.902 N/A 90% 0.762 N/A
< 0.1 mm 22* 66 1.90 31.8 80% 91% 
Meier 38
(2010) 
SN negative 480 45.5** 1.70 19.4 ± 85% ± 90%
< 0.1 mm 85* N/A N/A ± 78% 0.183 N/A ± 86% 0.400 N/A 
Scheri 62
(2007) 
SN negative 1168 57** 1.20 15.5 89% 94%
< 0.2 mm 57* 1.70 14 74% 0.0008 N/A 89% 0.02 N/A 
Ollila 63
(2009) 
SN negative 488 26** 1.1 16 83% N/A
< 0.1 mm 33*  2.1 24 78% 0.048 N/A N/A 0.40 N/A 
CLND = early Completion Lymphadenectomy after a positive SNB, N/A = Not Available
* Scheri et al: 5 of 57 patients did not undergo CLND, Ollila et al: 3 of 22 patients did not undergo 
CLND, Meier et al: 42 of 217 SN positive patients did not undergo CLND, 22 due to minimal SN tumor 
burden, van der Ploeg et al: 7 of 22 patients did not undergo CLND
** The median follow-up of the total number of patients included in the study has only been provided
† Additional analyses after publication have been performed by authors
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outcome was the Hannover scoring system group 1. This group consisted only of 
patients with Rotterdam criteria < 0.1 mm.38
The above mentioned results are confirmed by a study performed with the Rot-
terdam cohort.6 (Chapter 4) Some additional analyses have been performed for a 
reply to Satzger et al.64 SN negative patients from the Rotterdam cohort (n=298) had 
a median follow-up of 4.6 years and median Breslow thickness of 2.0 mm, while 
patients with Rotterdam criteria < 0.1 mm (n=23) had 5.5 years follow-up and 1.9 
mm thick melanoma, respectively. SN negative patients did not have a significantly 
different DFS (p=0.902) and OS (p=0.762) compared to patients with < 0.1 mm SN 
metastases.6
Others feel that patients with isolated tumor cells (ITC) cannot be compared to 
SN negative patients.62, 63, 65 Scheri et al. revealed that < 0.2 mm metastases cannot 
be considered as SN negative.62 Scheri et al., compared outcome of patients with 
SN metastases ≤ 0.2 mm (n=57) to SN negative patients (n=1168).62 With a median 
follow-up time of 4.8 years, improved DFS (p=0.0008) and OS (p=0.02) were dem-
onstrated for SN negative patients. However, the SN negative group had a median 
Breslow thickness of 1.20 mm, which is less than a normal SN negative population, 
e.g. the MSLT-I trial (1.80 mm) patients, and significantly less than patients with SN 
tumor burden < 0.2 mm (1.70 mm) in their study. Thus, it does not seem that this is 
a true reflection of the outcome of SN negative patients, from most cohorts and has 
lead to a survival rate of 94%, which is much higher than reported by other studies 
in the literature.62 Furthermore, When changing the minimal cut-off from 0.1 to 
0.2 mm, five-year MSS rates decrease significantly from over 90% to approximately 
80%.26 Murali et al. demonstrated that 20 patients with < 0.1 mm metastases cannot 
be safely regarded as SN negative. When extra sections were cut from the SNs, 
patients were upstaged and had worse survival.65 Murali et al, however, introduced a 
new bias, as SN negative patients were not upstaged. In theory, when extra sections 
are also cut from the group of SN negative patients, the “true” patients with < 0.1 
mm metastases might be identified. With a non-extensive SN pathology work-up 
protocol, patients with ITC’s or < 0.1 mm metastases might not be safely regarded 
as clinically irrelevant and/or SN negative. With an extensive SN pathology work-up 
protocol, < 0.1 mm metastases might be clinically irrelevant.
As well as differences in pathology work-up and protocols, differences in any part 
of the SNB technique, e.g. nuclear medicine and surgery, can affect the accuracy of 
SNB.66 Chapter 6 demonstrated that several parameters of SN tumor burden provided 
important prognostic information, but had prognostic variability between different 
centers. It will be difficult to overcome all differences, but consensus on pathol-
ogy work-up and analyses might have great impact on treatment of patients who 
underwent SNB.
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MANAgeMeNT of SeNTiNeL Node PoSiTiVe PATieNTS
In most cancer centers, standard treatment for all SN positive patients is CLND. 
However, Bilimoria and colleagues demonstrated, surprisingly, that only 50% of 
patients with melanoma diagnosed with a positive SN in 2004 and 2005 in the USA 
underwent CLND. 24 After conducting a worldwide web-based survey on opinions 
about CLND of melanoma surgeons, Pasquali et al demonstrated that 91.8% of 193 
surgeons recommend CLND in patients with a positive SN. Decision-making is based 
on patient comorbidities and SN tumor burden.67 Henderson already stated that it 
is a logical and necessary progression to explore whether it is possible to define 
the subgroups of SN positive patients who will and who will not benefit from a 
potentially morbid procedure as CLND.68 McMasters believes it is also appropriate 
to suggest that CLND sometimes should be avoided. However, he feels we should 
wait for randomized controlled trials, although he argues we would cure the same 
number of patients if we did not perform CLND.69
The therapeutic benefit of CLND is unknown and it attends with high morbid-
ity.70-73 Some have hypothesized that not all SN positive patients might be indicated 
for immediate “early” CLND.27, 32, 42, 58, 70 Others have reported that all SN positive 
patients should undergo CLND.39, 62, 69, 74, 75 No additional metastases are detected 
in approximately 80 per cent of patients undergoing CLND. Furthermore, CLND is 
associated with considerable greater morbidity than SNB alone71, 72, 76-79. Complication 
rates from 23% to 61% are reported after CLND with lymphedema, wound infection, 
haematoma/seroma formation and sensory nerve injury as most common complica-
tions.79, 80 Results from the Sunbelt Melanoma Trial demonstrated complication rates 
of 23 per cent after CLND and 5 per cent for patients who underwent SNB alone.79 In 
a study by de Vries et al investigating the quality of life, patients undergoing CLND 
had more problems than patients who underwent SNB alone.81
Some retrospective studies have reported on the outcomes of patients who did not 
undergo CLND (Table 2).58, 70, 73, 82 SN positive patients who did not undergo CLND 
had similar DFS and MSS as those with CLND. However, selection bias was evident in 
these nonrandomized retrospective studies, a problem highlighted by Henderson.68 
The study mentioned in chapter seven performed matched-pair analysis to overcome 
the selection bias. MSS was not significantly different between both groups consist-
ing of 61 patients with minimal SN tumor burden.82 Patients with high volume SN 
tumor burden seem to have more therapeutic benefit from undergoing CLND than 
patients with minimal SN tumor burden.82 Patients with low SN tumor burden could 
probably be spared the morbidity associated with CLND.52 The possible survival 
benefit of patients undergoing CLND could not only be limited to patients with high 
volume SN tumor burden. Patients with intermediate primary thickness melanoma 
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(> 1.00 – 4.00 mm) are most likely to have therapeutic benefit from undergoing 
CLND.83 Other significant predictive factors such as primary tumor thickness should 
be considered in the decision to perform CLND.60, 84
MuLTiCeNTeR SeLeCTiVe LyMPhAdeNeCToMy TRiAL – 2 (MSLT-2) ANd 
eoRTC 1208 STudy (MiNiTub)
Prospective trials are evidently the only studies that can overcome the drawbacks 
of above-mentioned nonrandomized retrospective studies. A randomized controlled 
trial, i.e. the Multicenter Selective Lymphadenectomy Trial-II (MSLT-II), is currently 
ongoing to investigate if all SN-positive patients have therapeutic benefit when CLND 
has been performed. Unfortunately, SN tumor burden is not taken into consideration. 
Chapters 4, 5, 6 and 7 of this thesis underline the strong prognostic impact of SN 
tumor burden on melanoma specific survival. Obvious benefit of the MSLT-2 is the 
fact that it is a randomized controlled trial. MSLT-II opened in 2005, the estimated 
Author
(year)
Group of 
patients
No. of 
patients
Median 
follow-
up
(mo)
Median
Breslow
Thickness
(mm)
Ulceration
(%)
Disease Free 
survival
Melanoma 
Specific Survival
5-yr
DFS 
rates 
(%)
P HR 5-yr
MSS 
rate 
(%)
P HR
Van der 
Ploeg 
IM* 58
(2009) 
No CLND 20 32 1.8 N/A 83% 
(3-yr)
100% 
(3-yr)
CLND 50 34 3.8 N/A 60% 
(3-yr) 
0.40 N/A 80% 
(3-yr) 
0.04 N/A 
Kingham 70
(2010) 
No CLND 42 32 3.5 62 ± 45% ± 68%
CLND 271 43 2.8 44 ± 40% 0.63 N/A ± 58% 0.26 N/A 
Wong 73
(2006) 
No CLND 134 20 2.60 32.8 80% 
(3-yr)
80% 
(3-yr)
CLND 164 36 2.85 50 88% 
(3-yr) 
0.07 N/A 74% 
(3-yr) 
0.65 N/A 
Van der 
Ploeg 
AP** 82
(2012) 
No CLND 61 48 2.50 45 66.0
CLND 1113 34 3.00 49.4 N/A N/A N/A 66.9 0.60 0.89 
No CLND 61 48 2.50 45    66.0   
CLND† 61 44 2.50 45 N/A N/A N/A 69.0 0.64 0.86 
CLND = early Completion Lymphadenectomy after a positive SNB, N/A = Not Available
* Patients without CLND consist of patients with tumor penetrative depth (TPD) ≤ 1.0 mm (SI and SII), 
while patients with CLND consist of patients with TPD > 1.0 mm (SIII).
** Patients without CLND had, amongst others, a median maximum SN tumor size of 0.40 mm, while 
patients with CLND had a median maximum SN tumor size of 1.40 mm.
† After matched-pair analysis, both groups had a median maximum SN tumor size of 0.40 mm.
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completion date is in 2022. A prospective single arm study by the EORTC Melanoma 
Group, the EORTC 1208 or “Minitub” study, is in process to examine if patients 
with minimal SN tumor burden are safely to undergo observation instead of CLND. 
Patients with minimal SN tumor burden are defined as patients with metastases ≤ 0.1 
mm anywhere or ≤ 0.4 mm subcapsularly located. We have to wait for preliminary 
results from both these studies to make evidence based clinical decisions regarding 
the management of patients. Based on the results of studies performed in a large 
multicenter international retrospective setting it might be safe to withhold CLND in 
SN positive patients with ≤ 0.1 mm metastases, especially when located subcapsu-
larly, when an extensive SN pathology work-up protocol is assessed. All other SN 
positive patients should undergo CLND.
MANAgeMeNT of PATieNTS wiTh MACRoSCoPiC (CLiNiCALLy 
deTeCTAbLe) diSeASe
Compared to the more heterogeneous range in 5-year survival of approximately 30 
to 90% in patients with nodal microscopic disease, patients with nodal macrome-
tastases have a narrower range of 5-year survival of around 30 to 50%.51 Chapter 10 
demonstrated that patients who underwent a neck dissection had a survival benefit 
over patients with inguinal dissection. This is counter-intuitive to head and neck mela-
nomas, which are associated with worse prognosis compared to truncal or extremity 
melanomas. A less predictive drainage pattern of the head and neck area might be one 
of the causes. (Chapter 3) At the same time, it might also reflect more rigorous patient 
selection in case a neck dissection is considered compared to other dissection types. 
To our best knowledge, only one study analyzed the differences between prognoses 
of different lymph node dissection sites. Results stated in chapter 10 were confirmed 
by Wevers et al; performing a neck dissection was an independent prognostic factor 
for improved MSS over other dissection sites.85 Earlier detection of palpable disease in 
the head and neck region might have an impact of the improved outcome.
In part two of the present thesis, it has been demonstrated that the number of 
positive nodes was the most important prognostic factor in patients with macrome-
tastases. Extracapsular extension, postoperative seroma, adjuvant radiotherapy and 
nodular histological subtype were other independent prognostic factors for survival. 
Analysis of the AJCC staging system committee demonstrated that outcome in pa-
tients with macrometastases (n=440) was not predicted by primary melanoma char-
acteristics.51 In the most recent years, the number of positive nodes divided by the 
number of excised nodes, i.e. the lymph node (LN) ratio, has gained in popularity. 
LN ratio is an independent prognostic factor for survival.86-88 Furthermore, it can be 
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used as a quality parameter. It has been suggested that removal of at least 15, 8 and 
6 lymph nodes per positive lymph node in, respectively, the neck, axilla and groin 
lymph node fields should maintain good surgical quality.89 More research needs to 
be performed to detect if LN ratio is a stronger predictor for survival than the number 
of positive nodes. In other types of cancer such as gastric cancer and colorectal 
cancer, LN ratio was an independent prognostic factor for survival as well.90, 91 The 
number of positive nodes was the most prognostic factor in a predictive tool, i.e. 
a nomogram, which has been created in chapter 8 to predict 2-year recurrence in 
patients with macroscopic disease who underwent TLND. A web-based predictive 
tool has been created for clinicians to predict overall outcome for early-stage mela-
noma patients (www.melanomaprognosis.org). Multiple independent predictors of 
survival for patients with stage III melanoma were assessed to calculate estimated 1-, 
2-, 5- and 10-year survival rates. The number of positive nodes remained the most 
important independent predictor of survival.
Before the era of SNB, most melanoma patients presented with macroscopic 
(clinically detectable) disease.92 Primary management of patients presenting with 
macroscopic disease and no presence of distant metastases has not changed. A 
therapeutic lymph node dissection (TLND) should be performed. Controversial 
is which level of dissection should be assessed, especially in the groin area. For 
micrometastases detected by SN, performing combined superficial (inguinal) and 
deep (iliac) lymph node dissection (CGD) is more controversial than for palpable 
macrometastatic disease. Deep lymph node involvement occurs in 15% of SN posi-
tive patients and in approximately 30% of patients with palpable disease.93 Spillane 
et al. state that all patients should be considered for CGD, especially when having 
palpable disease, due to high rates of pelvic disease.94 Of patients who underwent 
CGD, 39% had involved deep LNs (of which only 9.3% had surgery for a positive SN). 
Pelvic recurrence in patients who underwent superficial groin dissection (SGD) was 
only 6.7% (7 of 105). In chapter 9, this rate was 10%. Deep lymph node involvement 
was present in 25% of CGD patients. As mentioned in chapter nine and according 
to most literature, DFS and OS were not significantly different between performing 
SGD or CGD.95-97 No melanoma patients with one superficial positive node had 
positive deep lymph nodes and preoperative CT had a high negative predictive value 
for deep lymph nodal involvement. Patients with one positive palpable superficial 
groin lymph node can be advised to undergo superficial groin dissection. Thus, we 
hypothesize that the “watch and wait” approach for pelvic involvement is safe. There 
has never been a randomized controlled trial which compared CGD vs SGD for 
palpable disease. Prospective trials will provide more definite conclusions whether 
deep iliac nodal removal can be avoided in a specific subgroup of patients. Currently 
two studies are being set-up worldwide to examine this issue.
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Chapter 10 and 11 of the present study have similar results. Patients with mac-
rometastases who underwent TLND having an unknown primary melanoma (MUP) 
had improved survival over those with a known primary (MKP). This confirms the 
results of the largest study performed to date by Lee et al.28 Management of MUP 
patients continues to be similar to management of MKP patients. The improved DFS, 
DMFS and MSS and similar management underline the insignificance of rigorous 
searching for a primary melanoma when palpable disease is present.98 The cause of 
the improved outcome is unknown, however, regression of the primary or the de 
novo origin of melanoma cells in lymph nodes might play a role.
fuTuRe PeRSPeCTiVeS
Final results of the MSLT-1 are tanxiously o be awaited within the next year(s). A 
therapeutic benefit for all SNB patients will most probably not be identified. Patients 
with intermediate thickness melanoma (between 1 and 4 mm in Breslow thickness) 
might have therapeutic benefit from undergoing SNB. The therapeutic benefit of 
CLND for SN-positive patients is unknown. It will take 10 to 15 years for MSLT-2 and 
EORTC 1208 study to come up with final results and definitive answers to whether 
CLND has a therapeutic benefit and to whether some SN positive patients could 
safely be spared CLND. In the meantime the discussion will carry on and interim-
results are already highly awaited.
Compliance and agreement on a routine pathology work-up protocol is essential 
in this discussion. For example, an extensive pathology protocol will identify more 
clinically irrelevant micrometastases than a limited protocol. In future pathology 
slide analyses, we recommend that at least the maximum SN tumor size, the in-
tranodal location and tumor penetrative depth will be analyzed, though correctly 
measured, and will be classified according to the Rotterdam criteria, Dewar criteria 
and S-classification. SN tumor burden will become important for clinical decision-
making regarding future adjuvant medical (e.g. interferon-alpha, molecular-targeted 
strategies (BRAFi/MEKi) and/or immunotherapy (anti-CTLA-4 / anti-PD-1)) and/or 
surgical (e.g. CLND) therapy. Molecular profiling of primary melanomas might add 
new promising risk factors as lymphangiogenic biomarkers to currently used clinico-
pathological features. Imaging techniques as PET-CT scans and ultrasound-guided 
fine needle aspiration cytology (US-FNAC) have already and will shine new lights 
on SN management in the forthcoming years. Regarding macroscopic (clinically 
detectable) disease in the groin area, prospective trials are currently being set up to 
provide more definite conclusions on the necessity of iliac lymph node dissection.
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